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ABSTRACT 
 
Ligand-induced internalisation and subsequent downregulation of receptor tyrosine kinases 
(RTKs) serve to determine biological outputs of their signalling. Intrinsically kinase-deficient 
RTKs control a variety of biological responses, however, the mechanism of their downregulation 
is not well understood and its analysis is focused exclusively on the ErbB3 receptor.  
The Eph group of RTKs is represented by the EphA and EphB subclasses. Each bears one 
kinase-inactive member, EphA10 and EphB6, respectively, suggesting an important role for 
these molecules in the Eph signalling network. While EphB6 effects on cell behaviour have been 
assessed, the mechanism of its downregulation remains elusive. 
Our work reveals that EphB6 and its kinase-active relative, and signaling partner, EphB4, are 
downregulated in a similar manner in response to their common ligand, ephrin-B2. Following 
stimulation, both receptors are internalised through clathrin-coated pits and are degraded in 
lysosomes. Their targeting for lysosomal degradation relies on the activity of an early endosome 
regulator, the Rab5 GTPase, as this process is inhibited in the presence of a Rab5 dominant-
negative variant.   EphB6 also interacts with the Hsp90 chaperone and EphB6 downregulation is 
preceded by their rapid dissociation. Moreover, the inhibition of Hsp90 results in EphB6 
degradation, mimicking its ligand-induced downregulation. These processes appear to rely on 
overlapping mechanisms, since Hsp90 inhibition does not significantly enhance ligand-induced 
EphB6 elimination. 
Taken together, our observations define a novel mechanism for intrinsically kinase-deficient 
RTK downregulation and support an intriguing model, where Hsp90 dissociation acts as a trigger 
for ligand-induced receptor removal.  
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CHAPTER ONE  
REVIEW OF THE LITERATURE 
1.1. Introduction 
Molecular mechanisms controlling receptor downregulation that is assured by its 
internalisation, trafficking and eventually, proteolytic degradation, actively modulate the 
responses that cell-surface receptors generate following ligand stimulation, and have a 
profound influence on cell behaviour (Casaletto and McClatchey, 2012). Ligand-induced 
receptor internalisation is a multipurpose process that gates routes towards both receptor 
degradation and signal abrogation, as well as to efficient activation of certain signalling 
pathways, including the Ras-MAPK (mitogen-activated protein kinase) cascade (Haugh 
et al., 1999a).  In agreement, imbalanced downregulation of a number of receptor 
tyrosine kinases (RTKs) through stimulation-triggered internalisation and degradation has 
been linked to oncogenic transformation (Abella and Park, 2009; Casaletto and 
McClatchey, 2012; Mosesson et al., 2008).  
RTKs are single-pass transmembrane proteins that are involved in transducing 
signals from the exterior of the cell to the interior, and are essential to maintaining a 
proper relationship between the cell and its environment. Following binding to an 
extracellular ligand they become activated, resulting in the phosphorylation of targets 
within the cellular interior, allowing for the transmission of the signal from the outside to 
the inside of the cell. These signals generally lead to cell growth, proliferation, survival, 
movement, or apoptosis. The ligand-induced downregulation of many RTKs, including 
that of the EGFR (epidermal growth factor receptor) family (Roepstorff et al., 2008), 
IGF-IR (insulin-like growth factor receptor I)(Mao et al., 2011), and Met receptor 
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(Clague, 2011), have been described. However, despite the fact that the RTK family 
contains five intrinsically kinase-inactive members (Aasheim et al., 2005b; Gurniak and 
Berg, 1996; Katso et al., 1999; Mossie et al., 1995; Sierke et al., 1997) that are known to 
mediate important biological functions including T-cell regulation and aspects of 
embryonic development (Baselga and Swain, 2009; Clark et al., 2012; Truitt and 
Freywald, 2011), our current understanding of the mechanism of their ligand-induced 
downregulation is incomplete and is limited to reports focused exclusively on a member 
of the EGFR group, the ErbB3 receptor. Furthermore, the current reports on ErbB3 
downregulation are often contradictory, with some studies proposing that it is 
downregulation deficient, and differs from kinase-active ErbB receptors in the 
mechanistic aspects of its downregulation, while others studies suggest ErbB3 
downregulation proceeds efficiently and in much the same manner as what has been 
described for EGFR (Cao et al., 2007; Sak et al., 2013). Two of the five known kinase-
dead RTKs belong to the Eph group of RTKs, EphB6 and EphA10 (Truitt and Freywald, 
2011), and currently nothing is known of their downregulation. Of these, EphB6, in 
particular, is gaining increasing attention, as it not only plays an important role in normal 
biology (Wu and Luo, 2005), but also in malignancy, where EphB6 presence appears to 
act as a suppressor of invasive behavior in several solid tumor types including breast, 
lung, and skin cancers (Bailey and Kulesa, 2014; Bulk et al., 2012; Truitt et al., 2010). As 
ligand-induced receptor trafficking has been shown to have a profound impact on the 
responses generated following RTK activation (Andersson, 2012), it is important to 
understand the mechanisms underlying EphB6 downregulation, as these may play a role 
in mediating EphB6 effects. Furthermore, the observations of ErbB3 downregulation are 
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as of yet unclear, and it is unknown if they will be relevant to other kinase dead receptors, 
therefore understanding the mechanisms of EphB6 downregulation will bring some 
clarity to this area.  
 The following literature review will discuss RTKs, focusing in particular on the Eph 
receptor family, with an emphasis on EphB6. I will also review current understandings of 
the mechanisms used by cells to facilitate ligand-induced RTK and Eph downregulation, 
and briefly describe the mechanisms of ligand-induced downregulation of the only other 
kinase-dead receptor for which it has been explored, ErbB3.   
 
1.2. Receptor Tyrosine Kinases 
RTKs are essential in modulating a wide variety of cellular responses to external 
stimuli, including cell cycle, survival, differentiation, motility and metabolism (Schartl et 
al., 2015). To date, there are 58 described RTKs expressed in humans (Schartl et al., 
2015). In general, RTKs are monomeric cell-surface single-pass transmembrane proteins, 
however, the insulin receptor (IR/IGFR) family is an exception to this rule and consists of 
two extracellular α-subunits, and two transmembrane β-subunits, all connected through 
disulphide bonds (Lee and Pilch, 1994). RTKs possess an extracellular ligand-binding 
domain, and an intracellular domain with intrinsic kinase activity. There are several sub-
families of RTKs, grouped based on similarities within their extracellular domains, and 
the ligands for each RTK group tend to possess high levels of sequence similarity as well 
(Schartl et al., 2015).  Close to 20 groups of RTKs have been identified, including 
EGFRs  (ErbBs), platelet-derived growth factor receptors (PDGFRs), fibroblast growth 
factor receptors (FGFRs), and the Ephs (named from the erythropoietin-producing 
  O. Allonby 
 
 4 
hepatocellular carcinoma cell line they were first identified in)(Table 1.1)(Schartl et al., 
2015). Activation of these receptors generally requires ligand-induced dimerization  
 
  Table 1.1. RECEPTOR TYROSINE KINASES IN HUMANS. 
Family Name Number of members 
(humans) 
Receptor names 
EGF/ErbB 4 
EGFR/ErbB1/Her, 
ErbB2/Her2, 
ErbB3/Her3, 
ErbB4/Her4 
IR  & IGFR 3* IRA, IRB & IGFIR* 
NTRK 3 TRKA, TRKB, TRKC 
FGFR 4 FGFR1, FGFR2, FGFR3, FGFR4 
VEGFR 3 VEGFR1, VEGFR2, VEGFR3 
PDGFR 5 PDGFRa, PDGFRb, FMS, FLT3, KIT 
TAM 3 TYRO, AXL, MERTK 
DDR 2 Ddr1, ddr2 
Eph 15 
EphA1, EphA2, EphA3, 
EphA4, EphA5, EphA6, 
EphA7, EphA8, 
EphA10, EphB1, 
EphB2, EphB3, EphB4, 
EphB6 
Ror 2 Ror1, ror2 
Tie 2 Tie1, Tie2 
Met 2 Met, Mst1r 
Alk 2 Alk, Ltk 
Musk 1 Musk 
Ptk7 1 Ptk7 
Ret 1 Ret 
Ros 1 Ros 
Ryk 1 Ryk 
Nok 1 Styk1 
 
*As the receptor functions as a dimer of two chains, combinations between all three listed types are 
possible, eg. IRA/IGFIR or IRA/IRB. 
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between sub- family members, and their consequent cross-phosphorylation (Hubbard and 
Miller, 2007; Schlessinger, 2014). Subsequently, numerous signalling pathways are 
initiated, depending both on the RTK type, and on the characteristics of the expressing 
cell. The phosphorylated tyrosine residues of the activated receptors serve as docking 
sites for intracellular proteins containing Src homology 2 (SH2) domains, or 
phosphotyrosine-binding domains (PTB).  These proteins in turn may be phosphorylated 
by the activated receptors to facilitate downstream signalling, or may serve as scaffolds to 
assist in the formation of signalling complexes (Schlessinger, 2014). Major pathways 
activated by RTKs include the proliferative Ras/MAPK pathway (Zhang and Liu, 2002), 
and the phosphatidylinotsitol-3-kinase (PI3K)/Akt pathway that regulates cell survival  
(Song et al., 2005). 
 
1.3. Eph Receptors 
1.3.1. The Eph Receptor Family 
The eph gene was initially identified in the late 1980’s by Hirai et al. during a screen 
of the human genome for tyrosine kinase domains (Hirai et al., 1987). Today, sixteen Eph 
receptor tyrosine kinases have been described, including ten EphA (EphA1-EphA10) and 
six EphB receptors (EphB1-EphB6), and nearly all of them, with the exception of EphA9 
and EphB5, are expressed in humans (Pasquale, 2005). The classification of a receptor as 
either EphA or EphB is based predominantly on sequence similarities within the two sub-
classes, but also upon which type of ligand they bind to, the glycosylphosphatidylinositol 
anchored  (GPI-anchored) ephrin-A class, or the transmembrane ephrin-B class 
(Pasquale, 2005). Eph-ligand binding tends to be promiscuous within a class, where 
EphA receptors are able to bind to multiple ephrin-As, and EphBs to multiple ephrin-Bs, 
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but is generally restricted from cross-class interactions (Lisabeth et al., 2013). However, 
there are exceptions to this rule as EphA4 is able to bind to ephrin-B2 and ephrin-B3 
(Guo and Lesk, 2014), and EphB2 can be activated by ephrin-A5 (Himanen et al., 2004) 
(Figure 1.1).  
 
 
Figure 1.1 Eph receptor-ephrin interactions. 
Eph receptors bind promiscuously to ligands within their own class, but are generally 
restricted from cross-class interactions, save a few exceptions, as illustrated above. 
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1.3.2. Eph Structure 
The first crystal structure of an Eph receptor was described in 1998, and revealed 
important information on the topology of the EphB2 ligand binding domain, including 
probable regions responsible for ligand binding (Himanen et al., 1998). Since then, the 
entirety of the Eph receptor domain structures have been solved (Seiradake et al., 2010), 
and the current structural model for Eph receptors contains an extracellular ligand-
binding domain, a cysteine-rich domain (Seiradake et al., 2010), 2 fibronectin-type-III-
like repeats (Himanen, 2012), a hydrophobic transmembrane domain,  juxtamembrane 
domain, kinase domain, sterile alpha motif (SAM) domain (Stapleton et al., 1999), and 
Postsynaptic density 95-Discs large-Zonula occludentes-1 (PDZ)-binding motif (Hock et 
al., 1998) (Figure 1.2, 1.3). Each domain is able to contribute to specific functions, as 
described below. 
 
1.3.2.1. Ligand-binding domain 
The ligand-binding domain is a globular domain located at the N-terminus of the 
receptor. There are two regions of the ligand binding domain that participate in the 
interaction with ephrins, an external surface area that facilitates polar interactions 
between the two, and a high-affinity binding pocket that associates with the ligand 
through non-polar interactions (Himanen et al., 2001). Crystallography studies on the 
binding between EphB2-ephrin-B2 (Himanen et al., 2001), EphB4-ephrin-B2 (Chrencik 
et al., 2006), and EphA2-ephrin-A1 structure (Himanen et al., 2009) have provided some 
insight into the general observation that Eph receptors tend to only bind to either ephrin-
As or ephrin-Bs. Specifically, it appears that several residues involved in EphA-ephrin-A  
  O. Allonby 
 
 8 
 
 
Figure 1.2. Eph receptor structure.  
Eph receptors are single-pass transmembrane proteins, with an extracellular ligand-
binding domain and an intracellular kinase domain, and also possess several other 
domains involved in Eph-Eph interactions and associations with downstream signaling 
effectors, as shown. 
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Figure 1.3. Crystal structure of EphA4 ectodomain bound to ephrin-B3.  
EphA4 receptor is shown in green and orange, ephrin-B3 is shown in red ad blue. Note 
the interactions between the ligand-binding domains, cysteine-rich domains, as well as 
the fibronectin-type III domains. Crystal structure generated by Seiradake et al. 
(Seiradake et al., 2013). 
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or EphB-ephrin-B binding possess biochemically opposing characteristics in the 
corresponding residues of the other class. For example, in EphA2-ephrin-A2 interactions, 
there are non-polar interactions between a phenylalanine of ephrin-A2 and an alanine of 
EphA2, where the equivalent residues for ephrin-B2 and EphB4 are the polar residues 
asparagine and serine respectively (Himanen et al., 2009). The sizes of the amino-acid 
side chains in the Eph-ephrin interaction region also appear to play a significant role in 
determining class specificity, and it has been found that bulky-side chains may replace 
small ones, and vice versa, in corresponding residues within the binding regions between 
EphA and EphB receptors (Guo and Lesk, 2014). The binding between classes differs 
slightly as well, as EphB-ephrin-B binding is a dynamic process requiring shifts within 
the ligand-binding domain, whereas EphA-ephrin-A binding occurs in a more “lock-and-
key” fashion (Himanen et al., 2009) (Figure 1.4). Eph-ephrin dimers are formed by an 
ephrin binding to the high-affinity ligand-binding pocket of the ligand-binding domain, 
while the second, lower-affinity region, is able to interact with a second ephrin, and in 
this way promote the stable interaction between two ligand-bound Ephs (Himanen, 2012) 
(Figure 1.5). Eph receptors are also able to form higher order oligomers, where Eph-
ephrin tetramers combine to form larger complexes, and the propagation of oligomer 
formation following ligand-binding involves clustering of Eph receptors through 
interactions between their ligand-binding domains, as well as their cysteine-rich domains. 
Interestingly, following initial nucleation of clustering by ligand, Eph-Eph receptor  
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Figure 1.4. Crystal structures of ephrin-Eph binding for EphA and EphB receptors. 
 Crystal structure for EphA4-ephrin-A2 interaction was solved by Bowden et al. (Bowden 
et al., 2009). Crystal structure for EphB4-ephrin-B2 interaction was solved by Chrencik 
at al. (Chrencik et al., 2006). 
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Figure 1.5. Eph-ephrin tetramer formation.  
Eph receptors are able to interact with their ligands through both a high-affinity and low 
affinity binding interface, and this association brings Eph receptors together in a stable 
association with correct positioning for cross-phosphorylation.  Image adapted from 
Murai and Pasquale (Murai and Pasquale, 2003). Crystal structure of EphB2-ephrin-B2 
tetramer solved by Himanen et al. (Himanen et al., 2001). EphB2 is shown in green and 
orange, ephrin-B2 is shown in blue and red. 
 
 
interactions contributing to the higher order oligomers can occur in a ligand independent 
manner (Wimmer-Kleikamp et al., 2004). 
 
1.3.2.2. Cysteine-rich domain, Fibronectin-type III Like Domains, and the 
transmembrane helix 
Immediately following the ligand-binding domain is the cysteine-rich region (CRD) of 
the receptor that was recently identified to structurally form a Sushi domain and an EGF-
like   domain     (Seiradake et al., 2010).  This   region   provides an    interaction surface 
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between Eph receptors, and, as mentioned, appears to be important to ligand-induced 
receptor clustering (Himanen et al., 2010; Seiradake et al., 2010; Wimmer-Kleikamp et 
al., 2004).  
Following the CRD, and immediately preceding the transmembrane domain, all Eph 
receptors possess two fibronectin-type III domains (FN1 and FN2), structural repeats of 
around 90 amino acids often found in fibronectin, and some cell surface proteins (Pankov 
and Yamada, 2002). These domains have been observed to assist in stabilising Eph-Eph 
interactions (Nikolov et al., 2014), but also to interact with ephrins in cis (within the same 
cell membrane) (Carvalho et al., 2006; Seiradake et al., 2010). Functionally, Eph-ephrin 
cis interactions are proposed to regulate the ability of Eph receptors to bind to and be 
activated by ephrins in trans (Carvalho et al., 2006), thus acting as an inhibitory 
mechanism to Eph activation.  
The Eph receptor transmembrane domain is a short, hydrophobic alpha-helix 
(Bocharov et al., 2010), and aside from anchoring the receptor in the cell membrane, 
studies have also suggested that this region plays an important role in Eph-Eph 
interactions, stabilizing the receptor complex after ligand binding (Artemenko et al., 
2008). However, its role may be more complex still, as EphA2 transmembrane domains 
are able to form dimers even in the absence of ligand (Bocharov et al., 2010), and there is 
structural evidence indicating that ligand-binding alters the interaction between the two 
transmembrane domains. Functionally, this effect is proposed to assist in ensuring 
receptor activation, potentially by promoting proper relative kinase domain orientation 
(Bocharov et al., 2010; Sharonov et al., 2014). In agreement, mutations within this region 
that inhibit its ligand-induced structural changes reduce the level of Eph receptor 
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activation following ligand binding (Sharonov et al., 2014). While this observation is as 
of yet exclusive to EphA2, it is possible that the transmembrane domains of other Eph 
receptors function in a similar manner, especially as other Eph receptor transmembrane 
domains have also been observed to interact (Bocharov et al., 2008). 
 
1.3.2.3. Juxtamembrane domain 
The Eph receptor juxtamembrane domain plays an important regulatory role in Eph 
receptor signalling as well as in signal propagation. Structural and biochemical analysis 
of the Eph receptor juxtamembrane domain determined that it is important to 
autoinhibition of kinase activity (Binns et al., 2000; Wybenga-Groot et al., 2001). This 
region contains two invariant tyrosine residues within a highly conserved motif of ten 
amino acids, and mutation of these residues severely compromises the kinase activity of 
the receptor in response to ligand treatment (Binns et al., 2000).   When these residues are 
not phosphorylated, the conformation of the juxtamembrane domain is such that it 
disrupts the active site of the kinase domain, limiting its kinase activity, while these steric 
inhibitions are removed when the two regulatory tyrosines are phosphorylated (Wybenga-
Groot et al., 2001) (Figure 1.6). Once phosphorylated these residues also play a major 
role in signal propagation as they are able to interact with a wide range of potential signal 
propagators, including the regulatory subunit of PI3K, p85 (Pandey et al., 1994), the 
adaptor protein Nck (Stein et al., 1998), and Src family kinases (Zisch et al., 1998). 
 
1.3.2.4. Kinase domain 
The Eph receptor kinase domain shares its major structural features will all other 
members of the RTK family. It is a two lobed structure, having a smaller N-terminal lobe 
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relative to the C-terminal lobe, with the two regions joined by a short linker.  The kinase 
domain contains several highly conserved subdomains that are essential to its enzymatic 
activity, numbered I through XI, and within these there are key amino acids consistent 
between almost all tyrosine kinases, that are required for the kinase domain to function 
(Hanks et al., 1988; Hubbard and Till, 2000).  Examples  include  the  invariant  aspartic  
 
 
 
Figure 1.6. Auto-inhibition of the kinase domain.  
In the absence of ligand, the juxtamembrane sterically inhibits the kinase domain, 
limiting the accessibility of its active site to ATP and target substrates, through 
interactions with both the N- and C-terminal lobes. Following ligand binding two 
tyrosine residues in the juxtamembrane domain are phosphorylated, relieving the steric 
inhibition, and allowing for the phosphorylation of a tyrosine in the kinase-domain 
activation loop, fully activating the receptor. Image adapted from Hubbard (Hubbard, 
2004). 
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acid found in subdomain VI that is involved with ATP interactions, an invariant lysine 
residue, required for transfer of the phosphate group, located in subdomain II, and the 
consensus sequence Alanine-Proline-Glutamate in subdomain VIII (part of the activation 
loop), that is required for catalytic activity (Hanks et al., 1988). A more unique feature 
ofthe Eph receptor kinase domain is that it is auto-inhibited by the juxtamembrane 
domain, and also by the more classical example of kinase-domain steric inhibition, 
mediated by the kinase domain activation-loop, both of which inhibit ATP and substrate 
binding when in their unphosphorylated configurations (Wybenga-Groot et al., 2001). 
Phosphorylation of tyrosines within the Eph receptor’s activation loop, as well the two 
residues within the juxtamembrane domain, allow the kinase domain to assume a more 
“open” conformation, facilitating substrate binding and kinase activity (Binns et al., 
2000) (Figure 1.6).  
 
1.3.2.5. The SAM domain and PDZ-binding motif 
The crystal structure of the Eph SAM domain was solved during the early period of 
discovery, and revealed two potential self-interacting domains (Stapleton et al., 1999; 
Thanos et al., 1999). However, due to their observed low level of affinity, it is now 
believed that these domains are only weakly involved in stabilizing interactions between 
Eph receptors (Behlke et al., 2001). Rather, the primary function of SAM domains 
appears to be in assisting in signal propagation through the interaction with downstream 
effectors. Among these include the regulatory subunit of PI3K, p85, and the cytoskeletal 
regulator, Vav3 (Fang et al., 2008). The SAM domain has also been observed to interact 
with proteins that may affect receptor stability on the cell membrane (Kajiho et al., 2012; 
Kim et al., 2010). 
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The PDZ-binding motif interacts with downstream effectors containing a PDZ 
domain, including AF6 (Hock et al., 1998), a protein that associates with components of 
the actin cytoskeleton (Kooistra et al., 2007), as well as the to Ras family GTPases 
(guanine-triphosphatases) (Linnemann et al., 1999). Other examples of proteins that 
interact with the PDZ-binding motif include PICK1 (Protein interacting with C kinase 1) 
and Grip. Of these, PICK1 at least may help contribute to Eph receptor signaling, as it 
was observed to promote Eph receptor clustering (Torres et al., 1998). However, the 
biological relevance of the PDZ-binding motif is not yet fully clear, as at least one study 
shows this domain is dispensable for normal Eph biological activity (Dufour et al., 2006). 
 
1.3.3. Eph-Ephrin Binding and Receptor Activation 
Using crystallography, it has been determined that ligand binding to Eph receptors 
allows for the formation of stable Eph-ephrin dimers, and tetramers, (Himanen et al., 
2001), where at least two Ephs simultaneously interact with two ephrins to initiate the 
activating phosphorylation of the receptors (Himanen et al., 2001; Himanen et al., 2010; 
Janes et al., 2012). While Eph receptors are able to form transient interactions with each 
other through multiple domains in the absence of ligand (Himanen et al., 2010), Eph-
ephrin binding is believed to stabilize Eph receptor interactions, and allow for the 
initiation of Eph receptor oligomerisation following ligand interaction (Himanen et al., 
2001; Himanen et al., 2010; Seiradake et al., 2010), and to also maintain Eph receptors in 
an orientation that promotes their ability cross-phosphorylate and activate each other 
(Seiradake et al., 2010) (Figure 1.7 A&B). While Eph receptor dimers may be sufficient 
for Eph receptor signalling (Himanen et al., 2001), it  is now  believed that Eph receptors  
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Figure 1.7. Ligand induced Eph receptor oligomerisation. 
 A) In the absence of ligand Eph receptors exist as monomers, or as transient interaction 
partners. The unliganded Eph receptor interactions have been observed to take place 
between the cysteine-rich domain and the kinase domain, among others, and do not result 
in Eph-Eph spatial relationships that are favorable to cross-phosphorylation. B) Ligands 
expressed on an adjacent cell bind to Eph receptors, inducing stable Eph-Eph 
interactions, and orient the receptors such that they are able to cross-phosphorylate each 
other. C) Following ligand binding, higher order Eph receptor oligomerisation often takes 
place, including both ligand-interacting and unliganded receptors. 
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also form higher level complexes, containing homo- and/or heterologous interactions 
between Ephs (Janes et al., 2011; Seiradake et al., 2010; Wimmer-Kleikamp et al., 2004) 
(Figure 1.7 C). Due to the ability of Ephs to form heterologous interactions (Janes et al., 
2011), it is likely that the varying contributions of each receptor within a signalling 
complex allows for the fine-tuning of exact biological outputs. Some observations have 
even indicated that EphA and EphB receptors can interact with each other upon ligand 
activation of one or the other receptor class, and these cross-class interactions contribute 
to the overall signalling output (Janes et al., 2011).  
 
1.3.4. Eph Receptor Signalling 
Eph mediated effects are not restricted by the presence of ligand, and indeed, while 
many Eph receptor effects are ligand-initiated, others are strictly ligand independent. 
Through their active signalling, Eph receptors control a wide range of responses, 
including rearrangements of the actin cytoskeleton, cell attachment, repulsion, migration, 
proliferation and survival, in a variety of normal and malignant cell types (Pasquale, 
2005, 2010). The ability of Eph signalling to influence the actin cytoskeleton is essential 
to facilitating their effects on cell movement, attachment, and repulsion (Klein, 2012).  
Eph receptors are able to influence actin dynamics by multiple mechanisms, including the 
ability to modulate the Rho family of GTPases, a protein family that largely coordinates 
the extension or collapse of branches of the actin cytoskeleton (Hanna and El-Sibai, 
2013). Within this family, Rac1 is responsible for the formation of lamellipodia, Cdc42 is 
involved with filopodia formation, and RhoA has been implicated in the formation of 
stress  fibers  and  grown  cone  collapse (Kozma et al., 1997) (Figure 1.8). Eph receptors  
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Figure 1.8. Cytoskeletal arrangements are coordinated by the Rho family.  
Neural growth cones depend on Rho family GTPases to help coordinate the actin 
skeleton and promote outgrowth. Filopodia are long finger like extensions that form focal 
adhesions with the substrate, and bundled actin filaments that rely on Cdc42 for their 
formation provide structural strength. Lammelipodia are regions of high actin 
polymerization activity,  containing a network of branched actin that helps to push the 
leading edge of a cell forward, and depend on the activity of Rac1 for this process. In 
contrast, RhoA activity can lead to a disassembly of the actin structures in the growth 
cone and lead to growth cone collapse, an important process in the targeting of neuronal 
axons to their correct targets. Figure adapted from Pak et al. (Pak et al., 2008). 
 
influence Rho GTPases, increasing or decreasing their activity, often acting through 
members of the Dbl family of guanine exchange factors (GEFs), ephexins (Shamah et al., 
2001). For example, activation of EphA4 results in the phosphorylation of ephexin1, 
enhancing its activity towards RhoA in relation to Cdc42 and Rac1. This relative increase 
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in active RhoA compared to Rac1 and Cdc42 promotes growth cone collapse and 
retraction (Sahin et al., 2005) (Figure 1.8). Additionally, separate studies have indicated 
that ephrin initiated EphA4 signalling leads to Rac1 inactivation through a mechanism 
dependent on  α-chimerin, a GTPase activating protein (GAP) for Rac1, providing a 
further Eph induced mechanism that shifts the balance in Rho family activities (Iwasato 
et al., 2007). In contrast to EphA4 signalling, EphB2 activation leads to the ubiquitination 
and degradation of ephexin5, inhibiting RhoA activity, and promoting growth cone 
extension and synapse formation (Margolis et al., 2010). Eph receptors are known to 
influence the cytoskeleton in the absence of ligand as well, as EphA2 interacts with 
ephexin4 independently of ligand-interaction, promoting the downstream activation of 
RhoG and recruitment of Rac GEFs, ELMO2 (Engulfment And Cell Motility 2) and 
Dock4. This allows for an increase in active Rac within the cell, and overall leads to 
enhanced breast cancer cell motility (Hiramoto-Yamaki et al., 2010). 
In parallel to this, EphB3 activation is able to attenuate cell movement by directly 
reducing Akt activity (Li et al., 2012).  In addition to the cyto-protective signalling Akt 
participates in, it is also able to regulate cell motility through several means, including 
altering cytoskeleton dynamics by phosphorylating the actin-interacting protein Girdin 
(Enomoto et al., 2005), modulation of intergrin recycling (Li et al., 2005), as well as 
other mechanisms (Jiang et al., 2009). EphB3 inhibits these activities by instigating the 
PP2A (protein phosphatase 2A)/RACK1 (Receptor for activated C kinase 1) dependent 
dephosphorylation of Akt, resulting in reduced cell motility (Li et al., 2012). EphA2 cross 
talk with Akt has also been found to modulate cell motlitlity, as it has been observed that 
in the absence of EphA2 ligand, active Akt phosphorylates Serine-897 of EphA2, and this 
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serves to promote cytoskeleton rearrangements and cell movement. In contrast to this, 
ligand-induced EphA2 kinase activity was found to actively block cell motility by 
inhibition of PI3K/Akt signaling and dephosphorylation of EphA2 Serine-897 (Miao et 
al., 2009). In contrast, some active Eph receptors have the ability to promote Akt 
signalling, as EphB receptor activation of the PI3K/Akt pathway has been observed in the 
spinal chords of mice, and is believed to be involved in nociception (pain perception) (Yu 
et al., 2012). Furthermore, our group has made observations in malignant T-cells, where 
activation of Akt by EphB receptors prevents Fas-induced apoptosis (Maddigan et al., 
2011).  
One mechanism utilized by Eph receptors to influence cell-cell adhesion is through 
the modulation of other cell surface proteins, including cadherins. Cadherins are involved 
in the formation of stable connections between cells, and are a crucial component of 
adherins junctions (Maitre and Heisenberg, 2013). In Xenopus embryos, activation of Eph 
receptors was shown to negatively regulate cadherin mediated cell-cell adhesion 
(Winning et al., 1996), which may be an important mechanism to facilitate Eph receptor 
mediated cell-cell repulsion, and in agreement, in a human cell line, Eph expression was 
found to reduce expression of cadherin17 (Bhushan et al., 2014). In contrast, in some 
situations, Eph receptors may also utilise cadherins to promote enhanced adhesion, as a 
separate group found that in a colorectal cancer cell line, DLD1, Eph activation led to an 
increased targeting of cadherin to the cell surface, and that this was important to the 
correct execution of Eph receptor effects (Cortina et al., 2007). 
Not only do Eph receptors play key roles in regulating cell movement and 
attachment, they also act to promote or inhibit proliferation. As mentioned, activation of 
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the Ras/MAPK pathway frequently results in cellular proliferation, and EphA2 activation 
has been observed to inhibit Ras/MAPK signalling in multiple cell types, including 
prostate epithelial cells. Here, ephrin-A activated EphA2 is able to reduce overall levels 
of MAPK phosphorylation, and also attenuates EGF and PDGF enhancement of 
Ras/MAPK signalling (Miao et al., 2001). Ligand activation of EphA2 inhibits MAPK 
signaling in myoblasts as well, where it alters the output of IGF induced signals by 
reducing activation of the Ras/MAPK pathway through the activation of p120RasGAP 
(GTPase activating protein) (Minami et al., 2011). In contrast, EphA2 activation does not 
inhibit the IGF induced activation of the PI3K/Akt pathway, and this shift in overall 
signaling output was observed to enhance myoblast differentiation (Minami et al., 2011). 
Signalling appears to be cell-type dependent, as treatment of PC3, a PTEN (phosphatase 
and tensin homolog) deficient prostate cancer cell line with high levels of constitutive 
Akt activation, with an EphA2 ligand was observed to decrease both Erk1/2 and Akt 
phosphorylation (Yang et al., 2011). Furthermore, EphB4 appears to be able to activate, 
or inactivate the Ras/MAPK pathway depending on the cell type, as it has been observed 
to promote proliferation through MAPK activation in the breast cancer cell line, MCF7 
(Michigan Cancer Foundation-7), but to inhibit growth and suppress Ras/MAPK 
signaling in the endothelial cell line, HUVEC (Human Umbilical Vein Endothelial Cells) 
(Xiao et al., 2012). Likewise, ephrin-B1-activated EphB2 decreases MAPK 
phosphorylation in glioma cell lines, by activating R-Ras, a Ras family member that does 
not initiate the MAPK signaling cascade (Hancock, 2003; Nakada et al., 2005; Self et al., 
2001), while EphB2 signalling increases Ras and Erk2 phosphorylation in the colon 
carcinoma cell line, DLD1 (Riedl et al., 2005). In mice neuroepithelial cells, EphA3 and 
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EphA4 increase MAPK activity in response to ephrin-A1 treatment, but in a Ras 
independent manner, suggesting that non-classical activation of the MAPK signaling 
cascade can be initiated by Eph receptors as well (Aoki et al., 2004). 
Eph receptors may also play a role in signalling pathways critical to regulating 
differentiation, as there are increasing observations of interactions between Eph 
activation and Wnt signalling. For example, EphA2 has been shown to contribute to the 
ephithelial-mesenchymal transition (EMT) in gastric cancer cells by enhancing activation 
of the Wnt/β-Catenin pathway (Huang et al., 2014). EphB6, on the other hand, may act to 
suppress EMT, as its expression was shown to reduce nuclear β-catenin, and to reduce β-
catenin transcriptional activity (Toosi et al., In Revision), and this may contribute the less 
invasive phenotype observed when EphB6 is present (Truitt et al., 2010). 
 
1.3.5. Eph Receptor Biological Functions 
1.3.5.1. Ephs in embryogenesis 
In agreement with the wide range of signalling pathways influenced by Eph 
receptors, they are actively involved in multiple biological processes. During embryo 
development Eph-ephrin interactions play crucial roles in segregation of tissues (Klein, 
2012). The first observations of Eph mediated tissue separation came from studies of 
rhombomere segregation in the mouse embryo. Rhombomeres are sequential segments 
located in the developing hindbrain that ultimately give rise to the pons, cerebellum, and 
medulla (Gray et al., 2005). In the developing embryo, Eph receptors and their ligands 
are alternately expressed in sequential rhombomere segments (Becker et al., 1994; 
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Bergemann et al., 1995; Gilardi-Hebenstreit et al., 1992) (Figure 1.9), and experiments in 
the zebrafish  have  demonstrated  the  ability  of  active  Eph  and  ephrin  signalling  to  
 
 
 
 
Figure 1.9. Rhombomere segregation in the developing embryonic brain.  
Eph receptors and their ligands are alternately expressed in odd (Ephs) or even (ephrins) 
numbered rhombomeres (r1-r7), are essential to the formation of boundaries between the 
segments. Figure adapted from McNeill (McNeill, 2000). 
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determine the preferential sorting of cells into either odd, or evenly numbered 
rhombomeres (Xu et al., 1999). Further support for the important role of Eph receptors in 
rhombomere segregation comes from observations that rhombomere formation and 
segregation is severely impaired when Eph expression is eliminated (Cooke et al., 2005).  
It is now understood that Eph receptors play a major role in development of the 
nervous system, and are involved in various aspects of the process. Eph receptors are 
essential to mediating the correct migration of neural crest cells, an embryonic cell group 
that gives rise to the majority of the peripheral nervous system, as well as the most of 
structures of the vertebrate head (Simoes-Costa and Bronner, 2015). For example, neural 
crest cells migrating within pharyngeal arches, precursors to specific skeletal, muscle, 
venous, and nervous tissues within the head (Grevellec and Tucker, 2010), rely on signals 
from EphA4 and EphB1 to facilitate their correct patterning (Smith et al., 1997). Within 
somites, sections of embryonic mesodermic cells that give rise to the cartilaginous tissues 
of the spine, rib cage, and to the majority of skeletal muscle (Barrios et al., 2003), neural 
crest cell migration is limited to the anterior portion through active EphB signalling, 
maintaining their correct positioning to ultimately become sensory neurons (Krull et al., 
1997). Eph receptors have also been implicated in the proper formation of the somites 
themselves, and in the resulting proper patterning and growth of the skeleton, including 
symmetrical fusion of the rib cage, digit formation, and craniofacial formation 
(Compagni et al., 2003; Davy et al., 2004).   
Axons are frequently bundled together along the pathway between their source and 
their target, forming either nerves in the peripheral nervous system, or neural tracts 
within the brain. In 1992 the first observations of Eph involvement in axon bundling were 
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made, where it was found that chicken EphB2 was highly expressed in the bundled, or 
fasciculated regions, of unmyleniated axons in the developing hippocampus and 
cerebellum (Pasquale et al., 1992). Shortly after further evidence for Eph involvement in 
this process was found in rats, where it was observed that ephrin-A5 and EphA5 are 
highly expressed in the brain, and that their active signalling was required for the proper 
formation of axon bundles (Winslow et al., 1995). More recently, direct evidence of 
ephrin-B1 induced EphB2 signaling promoting axon bundling was obtained, where it was 
demonstrated that ephrin-B1 induced growth cone collapse in EphB2 expressing neurons, 
and acted as a negative guidance cue as well as a promoter of axon bundling (Luxey et 
al., 2013).  Eph receptors are also important to axon defasciculation, the unbundling of 
axons that allows for their individual interaction with their correct targets (Van Vactor, 
1998), as mice lacking EphB2 and EphB3 show abnormalities in this process (Chen et al., 
2004).  
An excellent example of Eph receptor involvement in mediating axon guidance can 
be found in the developing embryonic retina-brain interface. For example, in studies 
using mice embryos it was found that retinal axons exhibit repulsive behavior when they 
come into contact with EphB receptors, either by attenuating growth in the direction of 
the Eph receptor contact, or though growth cone collapse (Birgbauer et al., 2001), and 
similar observations have been made for EphA-ephrin-A interactions (Drescher et al., 
1995). It is now understood that Eph-ephrin gradients play a crucial role in the correct 
formation of the retinal topographic map within the brain, serving to maintain spatial 
relationships between neurons of the superior colliculous and the retinal ganglion cells 
(Triplett and Feldheim, 2012). Retinal ganglion cells show an expression pattern of high 
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EphA expression in cells located temporally, in a declining gradient to low EphA 
expression in those cells located at the nasal side, coupled with high ephrin-A to low 
ephrin-A expression from the nasal to temporal side of the retina (Lambot et al., 2005). 
Likewise, EphB expression ranges from high to low along the ventral to dorsal axis, and 
the ephrin-B expression gradient is the reverse (Braisted et al., 1997). Within the neurons 
of the superior collilculous, there is a complementary expression pattern, although the 
axis shifts from vertical positioning, to a horizontal map that is rotated relative to the 
retinal positioning. During the formation of the topographic map, RGC axons grow 
towards the posterior of the superior colliculous. A well supported model for the function 
of EphAs in topographic modeling is that those RGCs with high expression of EphA 
receptors are positioned first, for as they enter the superior colliculous, and encounter the 
first neurons with ephrin-A expression (low ephrin-A), due to their high expression, have 
Eph-ephrin signaling cascades initiated in sufficient strength to cause growth cone 
collapse, and to prevent further outgrowth. As the axons move forward, they encounter 
higher ephrin concentrations, and this allows for cells with lower EphA expression to 
have their outgrowth inhibited as well, and this continues as such along the gradient of 
the anterior-posterior axis (Triplett and Feldheim, 2012). The mechanism of EphBs in 
mediating topographic mapping is less clear, but ephrin-B1 stimulation of EphB 
expressing RGCs appears to function both as an attractant and repellant, and is essential 
to correctly position cells along the lateral-medial axis, as EphB knock-out mice display 
correct anterior-posterior axonal positioning, but incorrect medial-lateral relationships 
(Harada et al., 2007; McLaughlin et al., 2003) (Figure 1.10). 
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Figure 1.10. Eph receptors are involved in formation of the retinal topographic 
map.  
Gradients of EphA and EphB receptors as well as their ligands play important roles in 
guiding axons from cell of retinal ganglion to their correct position within the superior 
colliculous. In general, neurons with high EphA expression target to areas with low 
ephrin-A expression, and those with low EphA expression target to areas with high 
ephrin-A expression along the anterior-posterior axis. RGCs with high EphB expression 
target to areas with high ephrin-B expression, and vice versa, along the medial-lateral 
axis.  Figure adapted from Pasquale (Pasquale, 2005). 
 
 
 
Eph receptors are essential signalling molecules for the correct guidance of spinal 
neuronal axons during development as well, where EphA4, in particular, has been 
demonstrated to play a regulatory role during axon development within the corticospinal  
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tract (Canty et al., 2006). In mice lacking EphA4, pronounced motor abnormalities are 
observed, including a “hopping” gait as opposed to the normal alternating limb 
movement (Kullander et al., 2003), and this was functionally observed to be the result of 
abnormal axonal crossing of the spinal chord midline (Kullander et al., 2003).     This 
effect is mediated through repellent forward signalling into EphA4 expressing cells, 
triggered by their interaction with ephrin-B3 expressed at the midline of the spinal chord 
(Kullander et al., 2001). The necessity of EphA4 forward signalling was   confirmed 
through experiments that showed a loss of ephrin-B3 or expression of a cytoplasmic 
domain deletion mutant of EphA4 resulted in the same physiological effects (Paixao et 
al., 2013; Yokoyama et al., 2001), while expression of a cytoplasmic deletion mutant of 
ephrin-B3 did not (Yokoyama et al., 2001). EphA4 has been implicated in regulating the 
correct temporal and spatial organization of axon branching within the spinal cord as well 
(Canty et al., 2006).  
Synapses, specialised signalling junctions between neurons and other cells, are also 
dependent upon Eph receptors for their proper formation. Within dendrites, the 
information “receiving” arm of a neuron, structural protrusions called dendritic spines 
form synaptic connections with the transmitting cell, and the formation of these structures 
requires active signalling by EphB receptors (Ethell et al., 2001; Penzes et al., 2003). In 
agreement, in mice lacking EphB1, EphB2, and EphB3, fewer dendritic spines are 
formed, and those present exhibit structural abnormalities (Henkemeyer et al., 2003). Eph 
receptors may also be important to axon terminal positioning and formation, as EphA4 
has been observed to localize to this region in neurons of the hippocampus (Tremblay et 
al., 2007).  
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Apart from the well established role of Eph receptors in the development of the 
nervous system, their involvement in the regulation of T-cell functionality and in thymus 
development is perhaps the most studied to date (Wu and Luo, 2005). The expression of 
several Ephs and ephrins have been detected in the thymus, and their individual 
expression levels are often localised to specific compartments. Among these include 
EphA7, ephrin-A1, and ephrin-A5 which are all expressed in the thymic cortex; EphA8, 
EphA1, EphA2, and EphA4 which are found in the medulla, and ephrin-A2 which is 
expressed throughout the thymus (Vergara-Silva et al., 2002). While less is known 
regarding the compartmental localisation of EphBs within the thymus, all EphB receptors 
and ephrins show some level of expression in this organ, with EphB6 expression being 
the most pronounced (Hafner et al., 2004). Of these, EphB2 and EphB3 are expressed on 
thymic epithelial cells (TECs) (Garcia-Ceca et al., 2009b), and EphB6 is found 
predominantly within the cortex (Hafner et al., 2004). Consistent with the ability of Eph 
receptors to mediate spatial patterning and cell motility, ephrin-B2 expression is essential 
for the proper migration of the developing thymus into the thoracic cavity during 
embryogenesis. When isolated thymus cells were treated with a soluble EphB4 fusion 
protein that blocks EphB signalling, they observed a similar inhibition of cell motility 
relative to those cells lacking ephrin-B2 expression, strongly indicating EphB-ephrin-B2 
forward signalling in this process (Foster et al., 2010).  EphB2 and EphB3 appear to be 
important to the proper structural organisation of the thymus, as morphological defects 
are observed when the expression of either is perturbed (Alfaro et al., 2011; Garcia-Ceca 
et al., 2009a). EphBs also appear to play a role in the survival of TECs, cells which are 
important to assisting in proper T-cell maturation (Takada et al., 2014), as disruption of 
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EphB signalling leads to increased apoptosis of embryonic TECs (Garcia-Ceca et al., 
2013). 
  Eph receptors are also essential signaling molecules during formation of the 
vasculature. Eph receptors and ephrins are expressed on the endothelial and mesenchymal 
cells that organize during the process of vasculogeneis (Adams et al., 1999), and in 
agreement, are essential for proper formation of the heart and angiogenesis during 
embryonic development (Shin et al., 2001; Wang et al., 1998). The EphB4 receptor, and 
its ligand, ephrin-B2, are important to guiding mural and endothelial cells during the 
formation of vasculature (Fuller et al., 2003), and Eph-ephrin interactions play an 
essential part in the formation and separation of veins and arteries (Gerety et al., 1999; 
Shin et al., 2001; Wang et al., 1998). Indeed, EphB4 and ephrin-B2 serve as markers for 
venous or arterial cell types, respectively, in the developing embryo (Wang et al., 1998), 
where they play important roles in spatial organization and vessel formation (Fuller et al., 
2003). 
 
1.3.5.2. Ephs in the adult organism 
Eph receptors continue to play a crucial part in the adult organism, able to assist in 
the maintenance of homeostasis, tissue repair, and spatial patterning (Pasquale, 2005). 
High levels of expression for multiple Eph receptors are found in the brain of the adult 
organism (Hafner et al., 2004; Hruska and Dalva, 2012), and in agreement, studies have 
demonstrated a significant role of Eph receptors in the adult brain, where they have been 
implicated in mediating synaptic plasticity, the ability of the brain to learn new things and 
adapt throughout life (Klein, 2009; Pasquale, 2010). One of the mechanisms underlying 
this process is the ability of neurons to undergo long-term potentiation (LTP). This 
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involves the formation of new synaptic connections between two neurons, as well as in 
an increase in the number of signal transmitting neural receptors, in response to high 
levels of repeated stimulus (Baudry et al., 2014). Overall, this allows for a higher signal 
to be generated in the receiving cell in the future, when the stimulus is repeated, even 
with lower levels of stimulus (Baudry et al., 2014). Two receptors involved in generating 
LTP are the N-methyl-D-aspartate receptor (NMDAR) and the α-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate (AMPA) receptor (Anwyl, 2009). Briefly, in order to 
generate LTP, AMPA receptors in the post-synaptic neuron need to be activated in a high 
enough level to allow for the subsequent activation of the NMDA receptors, and this 
facilitates NMDA initiation of LTP. EphB2 appears to play a role in regulating this, 
based on several observations. First, activation of EphB2 leads to its rapid association 
with NMDAR (Takasu et al., 2002), the interaction mediated through the extracellular 
domains of the proteins (Dalva et al., 2000), and EphB2 ligand-binding has been 
observed to cause NMDAR phosphorylation in a Src dependent manner (Takasu et al., 
2002). Additionally, EphB activation has been observed to increase the effects of 
NMDAR signalling (Takasu et al., 2002). In mice lacking EphB2, there is a significant 
reduction in NMDAR localised in post-synaptic densities compared to those with EphB2 
expression (Henderson et al., 2001), implying a role for EphB2 in recruiting NMDAR to 
this region, and importantly there is also a decrease in the observed NMDAR mediated 
LTP (Henderson et al., 2001).  Furthermore, EphB2 is also able to interact with the 
AMPA receptor through its PDZ-binding motif, and this appears to assist in clustering 
and stabilisation of the AMPA receptor at the surface of the post-synaptic density (PSD), 
ensuring proper spatial localization for efficient activation (Kayser et al., 2006). In 
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contrast to EphB2-NMDAR interactions and effects, EphB2’s effect on the AMPA 
receptor is independent of its kinase ability (Kayser et al., 2006). Thus, EphB2 is able to 
ensure correct targeting of synaptic signalling molecules to the post-synaptic density, as 
well as to enhance signaling, overall contributing to LTP and synaptic plasicity. 
Although the ability of nerves to heal following damage is limited, some attempt at 
repair is often made, and Eph receptors have been observed to play an important role in 
promoting or inhibiting this process. For example, following optic nerve damage in mice, 
EphB3 expression is increased in macrophages that are recruited to the site of injury. It 
was demonstrated that the axons of ephrin-B3 expressing RGCs are attracted to EphB3, 
suggesting that it acts as a positive guidance cue during axon repair. In mice lacking 
EphB3, reduced axon sprouting and nerve regrowth was observed, strongly implicating 
EphB3-ephrin-B3 signalling as positive mediators of axon outgrowth following nerve 
damage in the adult organism (Liu et al., 2006). In contrast to this, EphA4 acts to inhibit 
axon repair in the spinal cord in mice following injury (Fabes et al., 2006), and mice 
lacking EphA4 show improved repair and return of function relative to mice with normal 
EphA4 expression (Goldshmit et al., 2004). Furthermore, positive results have been seen 
in mice where the use of peptides that block EphA4 activation lead to improved tissue 
repair and functional recovery, strongly implicating EphA4 forward signaling in axonal 
outgrowth inhibition (Goldshmit et al., 2011). 
Eph receptors continue to function in the post-natal thymus as well, where they 
function predominantly as a component of the T-cell regulatory network.  Eph receptors 
can act as guidance cues for immature thymocytes, demonstrated by the requirement for 
EphB2 expression for the proper migration of bone marrow hematopoietic progenitor 
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cells into thymic compartments, an important physical localization that promotes correct 
cellular differentiation and maturation (Stimamiglio et al., 2010). Within the thymus Eph 
receptors may help modulate T-cell selection, as both EphB receptors (Freywald et al., 
2003), and EphA receptors (Freywald et al., 2006) are able to protect T-cells from TCR 
instigated apoptosis. The Eph-ephrin system also appears to play a role in T-cell motility, 
as ephrin-A1 stimulation of CD4+ T-cells is able to modulate their chemotaxis in 
response to various cytokines (Aasheim et al., 2005a; Sharfe et al., 2002).  
The presence of Ephs and ephrins in the cells of the circulatory system persists into 
adulthood (Shin et al., 2001), which suggests they play a role in maintaining these 
populations throughout the lifetime of the organism. Ephrin-B2 and EphB4 continue to 
serve as markers for arterial and venous vessels, respectively, in the adult organism (Gale 
et al., 2001), and changes in their expression are observed during the phenotypic shifts 
required during neovascularization in the adult organism (Kudo et al., 2007; Nunes et al., 
2011). Additionally, Eph signaling appears to play a role in initiating neovascularization, 
working together with ephrin-B2. For instance, ephrin-B2 expression is upregulated in 
response to the angiogenesis-promoting vascular endothelial growth factor (VEGF) and 
FGF, and ephrin-B2 treatment has been demonstrated to initiate venous angiogenesis 
(Hayashi et al., 2005). Complementary to these findings, it has been shown that blockage 
of EphB4 activation is able to severely inhibit neovascularization, strongly supporting 
ephrin-B2-EphB4 signaling as a necessary element for initiation of this process (Su et al., 
2013). Additionally, the human brain microvascular endothelial cell line (HBMEC) 
displayed impaired angiogenic behaviour in cell culture when EphA2 expression was 
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reduced, or a mutant of EphA2 lacking kinase activity was expressed, indicating other 
Eph receptors are also involved in regulating angiogenic progression (Zhou et al., 2011).  
Eph receptors have also been implicated in actively regulating bone homeostasis 
(Matsuo and Otaki, 2012). Osteoblasts and osteoclasts promote bone formation, and bone 
resportion, respectively, and their activities are carefully balanced to maintain bone 
integrity. EphB4, ephrin-B2 and ephrin-B1 signals promote differentiation of osteoblasts, 
while inhibiting osteoclastogenesis, from osteoclast and osteoblast precursor cells, and 
thereby direct bone formation over resorption (Cheng et al., 2012; Zhao et al., 2006). 
Complementary to this, EphA2 and ephrin-A2 signalling acts to promote 
osteoclastogenesis, and to inhibit osteoblastogenesis, thereby promoting bone resporption 
(Irie et al., 2009). Together, these findings suggest that the modulation of the expression 
of Ephs and ephrins is an essential component in regulation of bone formation and 
degradation, and bone homeostasis.  
While their function in the developing pancreas has not been explored, Eph receptors 
are expressed in this organ during embryogenesis (van Eyll et al., 2006), and continue to 
be expressed and play important roles in the pancreas of the adult organism. Here, Eph 
signalling has been observed to be involved in regulating insulin production. Cell-cell 
contact between β-cells of pancreatic islets results in constitutive forward signalling 
through EphA5, and this was found to suppress insulin production. Following exposure to 
glucose, cells rapidly dephosphorylate EphA5, leading to a shift in the balance between 
EphA5 signalling, and the signalling output from its ligand, ephrin-A5. Overall, this 
change in signaling output was observed to result in an increase in insulin production 
(Konstantinova et al., 2007). 
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1.3.5.3. Ephs in malignancies 
Eph receptors also play an important role in human malignancies, including 
breast, colorectal, prostate, brain, skin, lung, hepatocellular, and gastric cancers (Xi et al., 
2012). Their overall effect appears to be receptor and tissue type specific, as Eph 
receptors have been associated with both aggressive and non-aggressive cancers, and 
have been shown to have both pro and anti-malignant effects. In agreement with their 
role in mediating cell-cell and cell-substrate attachment and repulsion as well as motility, 
the observed impact of Eph receptors in malignancies is often related to the invasive and 
metastatic potential of the cancer (Kandouz, 2012). Invasive activity of a cancer cell is 
defined by its ability to invade the surrounding tissue, generally by altering the 
surrounding extracellular matrix, disengaging cell-matrix and cell-cell contacts at its 
point of origin, and promoting cell movement that occurs as a result of dynamic 
alterations to the actin cytoskeleton (Friedl and Alexander, 2011) (Figure 1.11). Eph 
receptors have been implicated in modifying the invasive behavior of cancer cells by 
altering the activity of enzymes involved in the degradation of the extracellular matrix, by 
inducing changes to the actin cytoskeleton associated with motility, and by altering the 
surface presence of proteins involved in cell anchorage (Campbell and Robbins, 2008; 
Gucciardo et al., 2014). In addition to having the ability to invade surrounding tissues, 
metastatic cancer cells must also have the ability to enter into either the blood or 
lymphatic system and travel to other organs in the body. For cancer cells originating from 
solid tumor types, such as those of the breast, lung, and skin, this requires that the 
metastatic cell is able to survive independent of the pro-survival signals normally 
generated  by  contact  with  the  surrounding  environment. A healthy cell will undergo a  
  O. Allonby 
 
 38 
 
 
Figure 1.11. Cancer cell invasion.  
A) Representation of a solid tumor mass and the surrounding tissue. B) An invasive 
cancer cell produces enzymes capable of degrading the extra cellular matrix, detaches 
from other cells of the tumor, as well as from its connections with the surround matrix, 
invading the surrounding tissue. C) Migrating cancer cells are able to invade the blood 
vessels by migrating between endothelial cells, breaking the connections between them as 
they do. D) Once in the blood stream, an invasive tumor can migrate to new tissues to 
form secondary tumors.  
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specialised form of apoptosis, anoikis, in  the absence  of  these  signals,  where  a  
metastatic  cancer  cell  will  not. Additionally, in order to form a secondary tumour in a 
distinct tissue from that in which the tumour initiated, a cancer cell must be able to 
invade the new tissue, adapt to the new environment, and to initiate proliferation in order 
to generate a secondary lesion (Chaffer and Weinberg, 2011). Eph receptors are able to 
modulate metastatic behaviour by facilitating changes in gene transcription that help cells 
evade anoikis, and exhibit greater plasticity allowing them to better adapt to foreign 
environments (Wang, 2011). 
In non-small cell lung cancer (NSCLC), high levels of EphA2 expression were 
correlated to an increased risk of metastasis to the brain (Kinch et al., 2003), and 
biochemical analysis of the effect of EphA2 in lung cancer cell lines found that cells 
expressing EphA2 had increased invasive behaviour and resistance to apoptosis relative 
to EphA2-null cells (Faoro et al., 2010).  Furthermore, an EphA2 mutation has been 
identified in several NSCLC patient samples, and this mutant exhibited constitutive 
kinase activity, an increased phosphorylation of EphA2 targets, including Src and 
cortactin, as well as increased cell-survival and invasive behaviour, relative to the wild-
type receptor (Faoro et al., 2010). EphB3 has also been implicated in NSCLC, where its 
high expression has been linked to increased metastatic behaviour, through mechanisms 
independent of its kinase activity (Ji et al., 2011). Interestingly, ligands of EphB3, ephrin-
B1 and ephrin-B2 are often downregulated concurrently with increased EphB3 
expression in NSCLC, and it was found that ligand-induced EphB3 signalling inhibits 
metastasis, by acting on several regulators of the actin cytoskeleton (Ji et al., 2011). 
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As Eph receptors play critical roles in brain development, and show continued 
expression in the brain in adulthood, it is unsurprising that they would be implicated in its 
malignancies as well. In glioblastoma (GBM), a cancer of the glial, or support cells, of 
the brain, altered Eph expression is frequently observed. Most consistently, significantly 
increased EphA2 expression, relative to healthy tissue, is observed in patients with GBM 
(Wykosky et al., 2005). EphA2, in the absence of ligand, was found to promote invasive 
behavior in these cells, and this effect was dependent upon EphA2 cross-talk with Akt, 
which ligand treatment was observed to disrupt (Miao et al., 2014). Similar to the 
observations made for the EphB3 receptor in lung cancer, it was found that the 
expression of the EphA2 ligand, ephrin-A1, was not increased concurrently with the 
receptor, and ephrin-A1 treatment of GBM cells with high EphA2 expression resulted in 
both reduced cancer cell survival and invasive behavior (Binda et al., 2012; Wykosky et 
al., 2005). Other Eph receptors whose increased expressions in GBM are associated with 
more aggressive cancer phenotypes include EphA3 (Day et al., 2013), EphA7 (Wang et 
al., 2008), and EphB4 (Chen et al., 2013; Tu et al., 2012), with the receptors acting to 
promote proliferation, invasive behaviours, or tumour angiogenesis.  
In contrast to high expression being linked to an unfavourable prognosis, in 
colorectal cancer, expression of several EphB receptors is associated with a less 
aggressive phenotype (Batlle et al., 2005). For instance, a high level of EphB2, which is 
expressed in normal epithelial cells of the intestine, is associated with prolonged survival 
in colorectal cancer patients (Jubb et al., 2005). A separate study found the expression 
levels of EphB2 decreased with increasing disease stage, and these reduced levels were 
associated with poorer survival and disease-free survival. Biochemical studies in 
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colorectal cancer cell lines demonstrated that induced expression of EphB2 in colorectal 
cancer cell lines resulted in reduced colony formation relative to cells lacking EphB2, and 
activation of the receptor by ephrin-B1 led to reduced cell adhesion and migration (Guo 
et al., 2006). Like EphB2, EphB1 expression is also reduced in more invasive colorectal 
cancers (Sheng et al., 2008), and studies examining the effects of EphB3 expression in 
colorectal cancer cell lines found that this receptor inhibited proliferation, anchorage-
independent growth, and promoted the less invasive epithelial cell phenotype (Chiu et al., 
2009). However, not all EphB receptors inhibit colorectal cancer cell growth and 
invasiveness, as the EphB4 receptor is upregulated in colorectal cancer, and its 
expression promotes cancer cell survival and metastatic behaviour (Kumar et al., 2009). 
Eph receptors are important to prostate development (Lisle et al., 2013), and a wide 
number of them are deregulated in and contribute to prostate cancer oncogenesis (Lisle et 
al., 2013). Of the Eph receptors examined in this disease, the effects of EphA2 are among 
the most extensively studied, and as has been observed in glioblastoma, this receptor may 
have differential effects depending upon the presences or absence of ligand. EphA2 
expression is frequently upregulated in prostate cancers, relative to normal tissue, and its 
levels of expression positively correlate to the stage of the disease (Zeng et al., 2003), 
while expression of its ligand, ephrin-A1, is decreased in aggressive prostrate cancer 
(Larkin et al., 2012).  This suggests that EphA2 in aggressive prostate cancer would not 
be in a ligand-activated state, and fits well with the observations that in contrast to the 
situation when ligand in absent, ligand-stimulated EphA2 acts in a protective fashion by 
causing a decrease in cell proliferation (Miao et al., 2001). Ligand-treated EphA2 is also 
able to reduce invasive behaviour in prostate cancer cell lines, acting at least in part 
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through phosphatases that target the Akt/mTOR (mammalian target of rapamycin) 
pathway (Miao et al., 2000; Yang et al., 2011).  However, the effects of EphA2 in 
prostate cancer are not fully clear, as a separate group found that cells expressing a 
kinase-deficient mutant of EphA2 were less invasive, and formed fewer metastatic 
lesions in mice, suggesting that EphA2 kinase activity may also be able to promote 
metastatic behavior. Nevertheless, the same group also found that stimulation of cells 
expressing wild-type (WT) EphA2 reduced their invasive behaviour, while having no 
impact on the invasive behaviour of kinase-dead or cytoplasmic domain deletion mutant 
EphA2 expressing cells (Taddei et al., 2009).  Overall, it appears that the effects of 
EphA2 on prostate cancer cells are altered depending upon the presence of ligand, and 
generally ligand-induced activation of EphA2 appears to suppress invasive tendencies. 
EphB4 expression is also frequently increased in prostate cancer relative to normal tissue 
(Lee et al., 2005), and higher expression levels have been observed in higher-grade 
prostate cancer cells (Lee et al., 2005; Xia et al., 2005). Like EphA2, EphB4 appears to 
either suppress or enhance malignant behaviour depending on the presence of its ligand, 
ephrin-B2 (Rutkowski et al., 2012). EphB4 predominantly appears to promote malignant 
activities, as its expression was found to enhance anchorage independent growth, cell 
motility, and invasive behavior (Rutkowski et al., 2012; Xia et al., 2005). While one 
group found that all of these qualities were reversed by treatment with ephrin-B2 
(Rutkowski et al., 2012), others have observed that EphB4-ephrin-B2 interaction 
promotes cell motility (Astin et al., 2010), or even acts to promote invasive behavior 
(Khan, 2009).  
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In breast cancer EphA2 contributes strongly to the malignant behavior of the tumour, 
acting to enhance angiogenesis and metastatic behavior (Brantley-Sieders et al., 2005), 
and in contrast to observations in other cancer types, ligand-induced EphA2 kinase 
activity enhances many of its pro-oncogenic effects (Fang et al., 2005).  EphB4 is also 
expressed in a high percentage of breast malignancies, where it has been implicated in 
promoting breast cancer cell survival, invasive behaviour, and potentially angiogenesis 
(Kumar et al., 2006). However, as has been observed for other Eph receptors, these 
oncogenic effects were observed in the absence of ligand, and there are studies that 
demonstrate that active EphB4 signalling may inhibit malignant behaviour (Noren et al., 
2006). In agreement, our group has shown that active EphB4 signalling, when in the 
presence of the kinase –dead EphB6 receptor, significantly reduces the invasive behavior 
of breast cancer cells, demonstrating that EphB4 signaling can be anti-malignant. 
However, the anti-invasive signaling was dependent upon EphB6 presence, and EphB4 
was found to promote invasive behavior when acting alone (Truitt et al., 2010). 
Interestingly, EphB6 has also been shown to reduce EphA2 invasive signalling (Akada et 
al., 2014). Indeed, while the expression of other Eph receptors appears to have a highly 
inconsistent influence on the invasive behaviour and prognosis between cancer types, 
EphB6 expression is consistently associated with reduced metastatic potential in almost 
all malignancies it has been characterized in (Truitt and Freywald, 2011). This 
emphasizes the significant role kinase-deficient receptors can play, and highlights the 
need for a full understanding of the mechanisms they employ for their signaling and 
regulation.  
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1.4. Kinase-Dead RTKs 
Despite being a part of the RTK family, five receptors lack a functional kinase 
domain due to various alterations of key amino acids. Among these is ErbB3, as well as 
two members of the Eph family, EphA10, and EphB6. The other two kinase-dead RTKs 
are Ryk and Protein Tyrosine Kinase 7 (PTK7, also known as colon carcinoma kinase 4, 
CCK-4) (Kroiher et al., 2001). Aside from EphA10, whose biological function has yet to 
be explored, all of these receptors are important to normal and/or cancer cell biology. For 
example, Ryk is involved in regulating cell motility, and has been observed to interact 
with Wnt signaling pathways (Green et al., 2014), as well as several Eph receptors 
(Halford et al., 2000; Kamitori et al., 2005; Trivier and Ganesan, 2002).  PTK7 also 
influences Wnt signaling, and in normal tissues has been found to be important to 
determining cell polarity (Peradziryi et al., 2012). In cancer, PTK7 appears to promote 
cell motility and metastasis (Golubkov et al., 2014), and consistent with these findings, 
PTK7 is generally regarded as an indicator of high metastatic potential in several cancer 
types (Gartner et al., 2014; Jin et al., 2014; Shin et al., 2013). However, PTK7 effects in 
cancer may be context and type dependent, as its expression has also been correlated to 
an improved prognosis (Chen et al., 2014), and it has been observed to suppress 
proliferation and invasive behavior in lung cancer (Kim et al., 2014). ErbB3 is the most 
extensively studied of the kinase-dead receptors, due to its association with the highly 
oncogenic ErbB2. ErbB3 is overexpressed in multiple malignancies (Ma et al., 2014), and 
when signaling in a heterodimeric complex with ErbB2, is a potent activator of the 
PI3K/Akt signaling pathway, which has proven to be a key element of ErbB3’s ability to 
promote drug resistance (Ma et al., 2014). In agreement, ErbB3 expression is frequently 
associated with a poor prognosis (Ledel et al., 2014; Park et al., 2014; Wu et al., 2014), 
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and as such, it is actively being studied as a drug target (Kol et al., 2014). In contrast to 
ErbB3, one of the kinase-deficient members of the Eph family, EphB6, is gaining 
increased attention as it has been found to suppress invasive and metastatic cancer in 
sever malignancies (Truitt and Freywald, 2011), and so well little is known regarding the 
other kinase-dead Eph receptor, EphA10, some light has begun to be shed on the 
functions of the EphB6 receptor. 
 
1.4.1. EphB6 
Both the EphA and EphB subclasses of Eph receptors contain an intrinsically kinase-
dead member, EphA10 and EphB6, respectively (Aasheim et al., 2005b; Gurniak and 
Berg, 1996; Matsuoka et al., 1997), and as such, it is likely that both these kinase-inactive 
players have an important role in Eph receptor signalling network. The function of 
EphA10 is largely unknown, and its expression appears to be largely restricted to the 
testis (Aasheim et al., 2005b), however, the kinase deficient member of the EphB 
subclass, EphB6, is recognized as an important mediator of several important biological 
effects in normal and cancerous tissues (Truitt and Freywald, 2011). Murine EphB6 was 
first identified in 1996 during a PCR based screen for receptor tyrosine kinases. It was 
predicted to lack intrinsic kinase activity based on alterations to several residues in the 
highly conserved tyrosine-kinase domain, and was this was functionally determined to be 
true, at least in a bacterial fusion protein containing the EphB6 kinase domain (Gurniak 
and Berg, 1996). The human ortholog was identified shortly thereafter, and six amino 
acid substitutions within the kinase domain were identified (Table 1.2). These included 
the substitution of a glutamine residue in place of an invariant lysine residue in the ATP 
(adenosine triphosphate) binding site,  as well as  a serine in place of an invariant aspartic  
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Table 1.2. AMINO-ACID SUBSTITUIONS IN EPHB6 KINASE DOMAIN. 
 
* Conserved residue numbers correspond to their locations in cyclic adenosine-
monophosphate kinase α  (Hanks et al., 1988; Matsuoka et al., 1997). 
Conserved residue EphB6 variant 
Function of conserved 
residue 
Lysine72 Cysteine687 
Interacts with ATP, 
essential for phosphoryl-
transfer. 
Aspartate166 Serine780 
Orientates and primes the 
substrate tyrosine for 
phosphorylation. 
Glutamate91 Arginine704 
Interacts with the invariant 
lysine and maintains its 
correct orientation for ATP-
interaction. 
Aspargine171 Serine785 
Positioned within the 
catalytic loop, required for 
catalysis. 
Aspartate184-
Phenylalanine185-
Glycine186 
Arginine798-Leucine799-
Glycine800 
Interacts with ATP, 
promotes its functional 
orientation. 
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acid in the phosphor-transfer site, both of which would severely limit the functional 
properties of the domain.  Like the murine receptor, fusion proteins containing the human 
EphB6 kinase domain were found to lack detectable kinase activity (Matsuoka et al., 
1997). EphB6 is ubiquitously expressed, with the highest expression levels being found 
in the brain, pancreas, and thymus (Hafner et al., 2004; Matsuoka et al., 1997). While it 
lacks intrinsic kinase activity, EphB6 is able to interact with ephrin-B1 (Freywald et al., 
2002), and ephrin-B2 (Munthe et al., 2000), and is able to generate active signalling in 
response to ligand- binding by undergoing phosphorylation in a Src- (Matsuoka et al., 
2005), EphB1- (Freywald et al., 2002), or EphB4- (Truitt et al., 2010) dependent manner. 
Furthermore, although their role in EphB6 phosphorylation has yet to be examined, 
EphB6 has also  been  shown  to  interact with EphB2, as  well  as  EphA2,  and  notably, 
to not associate with the other kinase-deficient Eph receptor, EphA10 (Fox and Kandpal, 
2011). Due to its ability to interact with a wide range of Eph receptors, and its lack of 
intrinsic kinase ability, EphB6 has been proposed to modify the signalling output of its 
kinase-active signalling partners, and indeed this has been observed in several situations 
(Fox and Kandpal, 2011; Truitt et al., 2010).  
 
1.4.2. EphB6 biological effects 
Despite its lack of kinase activity, the EphB6 receptor is implicated in a number of 
biological responses in normal physiological conditions (Freywald et al., 2003; Luo et al., 
2012; Luo et al., 2004) and in human malignancies (Fox and Kandpal, 2009; Maddigan et 
al., 2011; Tang et al., 2000; Truitt and Freywald, 2011; Truitt et al., 2010; Yu et al., 
2010). EphB receptors are involved in signalling events important to hyperalgesia, an 
increased sensitivity to pain, and in neuropathic pain (Battaglia et al., 2003; Cao et al., 
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2008; Slack et al., 2008; Song et al., 2008a; Song et al., 2008b), and EphB6 has recently 
been identified as a potential EphB receptor involved in modulating pain transmission 
signals, as it has been observed in induced colitis, a model used to study the effects of 
inflammatory pain and hyperalgesia (Laird et al., 2001), that EphB6 expression is greatly 
reduced in the spinal dorsal horn sensory neurons relative to those of healthy mice (King, 
2014). However, the mechanisms leading to reduced EphB6 expression, as well as the 
alterations to pain signalling resulting from its loss have yet to be determined.  
Another promising area where EphB6 appears to be involved is in the kidney, where 
EphB6 may be involved in regulating permeability. EphB6 is expressed in the cortex and 
outer medulla of the kidney, along with ephrin-B1, and this is in contrast to EphB2, 
which is expressed in the inner and outer medulla, but not the cortex. The specific effects 
of EphB6 signalling in this compartment have yet to be resolved, however, ephrin-B1 
treatment of kidney cells expressing EphB2 and EphB6 resulted in increased Rho activity 
and decreased Rac activity, which led to cytoskeletal rearrangements and membrane 
retraction.  The differential expression of the two receptors in distinct regions of the 
kidney suggest that they function to alternatively modulate the adhesive/permeability 
properties of these cells, and thus may contribute to the spatial organization of the 
kidney’s uptake of water and solutes (Ogawa et al., 2006).  
EphB6 has also been implicated in maintaining proper blood pressure levels. 
Vascular smooth muscle cells  (VSMCs) are specialised cells found within the walls of 
blood vessels, whose primary function is to contract or relax in response to stimuli, 
increasing or decreasing the vessel diameter, and thus affecting blood pressure (Lacolley 
et al., 2012). EphB6, and its ligands ephrin-B1 and ephrin-B2, are expressed in VSMCs, 
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and a loss of EphB6 was found to result in alterations to contractility of the cells. EphB6 
knock-out reduced arterial contractility in male mice, but increased it in females and 
castrated males, suggesting that EphB6 and testosterone work together to regulate VSMC 
contractility. Physiologically, mice exhibited increased blood pressure when lacking both 
EphB6 and testosterone, while the presence of either was able to partially compensate in 
the absence of the other, in part by regulating catecholamine production.   Thus, EphB6 
works in concert with testosterone to regulate vessel contractility to maintain normal 
blood pressure levels (Luo et al., 2012).  
Although EphB6 expression is not limited to T-cells within the hematopoietic cells of 
the immune system, the role of EphB6 in these cells is currently the best described 
(Shimoyama et al., 2000). EphB6 activity is able to modify T-cell receptor (TCR) 
activation, and has been observed to impact both signaling intensity, as well as signaling 
output, and the presence or absence of EphB6 was also found to affect T-cell 
functionality (Freywald et al., 2003; Luo et al., 2001; Luo et al., 2002). Importantly, 
EphB6 colocalises with TCRs following their activation, even in the absence of EphB6 
ligand, and this spatial localisation of the receptor may be required for the ability of 
EphB6 to influence TCR output (Luo et al., 2004; Luo et al., 2002). EphB6 is also highly 
expressed in monocytes, which may indicate that EphB6 plays a role in mediating 
chemotaxis in this cell population, however this has yet to be explored (Sakamoto et al., 
2011).  
While the role of EphB6 in normal physiology is only beginning to be fully explored, 
EphB6 has been more actively studied in malignancies, where it is becoming recognized 
for its apparent ability to suppress invasive and metastatic behaviour in several cancer 
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types (Truitt and Freywald, 2011). In agreement, EphB6 expression is frequently reduced 
in highly aggressive and metastatic cancers relative to normal tissues, or more benign 
tumors (Truitt and Freywald, 2011). Among those cancers for which reduced EphB6 
cancer appears to coincide with a more aggressive phenotype is melanoma, as EphB6 
expression is present in benign samples, reduced in cancerous lesions, and absent in 
melanoma metastases (Hafner et al., 2003). These observations were recapitulated in cell 
lines, as EphB6 was found to be present in a non-cancerous melanocyte cell line, as well 
as a poorly invasive melanoma cell line, while EphB6 expression was silenced in the 
highly invasive melanoma cell line, C8161 (Bailey et al., 2012). The loss of EphB6 
expression in aggressive melanoma may indicate the loss of this receptor allows for a 
more invasive phenotype, and to explore this possibility, a study was performed to 
determine what impact EphB6 expression has on melanocyte migration and intravasation 
abilities. The chorioallontoic membrane (CAM) of the chick embryo has been found to 
serve as a useful tool to study metastatic behaviour of cancer cells, as it is highly 
vascularised, and due to its structural constraints, tumour cells must have the ability to 
enter its vasculature in order to form metastatic lesions distant from their point of origin 
(Deryugina and Quigley, 2008).  When C8161 cells were seeded onto chick CAMs, 
ectopic expression of EphB6 was observed to significantly reduce the number of cells 
able to enter the vasculature, relative to their EphB6-null counterparts (Bailey and 
Kulesa, 2014). There was no observable difference in size of the primary tumor between 
the two groups, suggesting that EphB6 does not inhibit proliferation of melanoma cells, 
but rather their invasive and potential intravasative abilities (Bailey and Kulesa, 2014). 
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EphB6 also suppresses invasive behaviour in non-small cell lung cancer (NSCLC). In 
NSCLC cell lines, expression of wild-type EphB6 is able to strongly reduce cell 
migration and metastatic behaviour relative to cells lacking EphB6 (Bulk et al., 2012; Yu 
et al., 2010). In contrast, expression of an EphB6 mutant, identified in a patient sample of 
NSCLC, that is lacking three residues in its cytoplasmic domain (residues 915-917, 
aspartate-proline-glycine), did not produce the same anti-metastatic effects as the wild-
type receptor, indicating that a ‘functional’ cytoplasmic domain is required for proper 
EphB6 effects despite the receptor’s lack of kinase activity (Bulk et al., 2012). In 
agreement, EphB6 expression is frequently reduced in NSCLC, and this reduction is 
correlated to an increased risk of metastasis (Muller-Tidow et al., 2005; Yu et al., 2010). 
Experiments in the NSCLC cell line, A549, have provided evidence that EphB6 presence 
increases Erk2 phosphorylation, but reduces activation of one of Erk’s targets, the 
transcription factor Elk-1 (Yu et al., 2009). As a result, the expression of genes initiated 
by the MAPK signalling cascade likely differ as a consequence of EphB6 signalling, 
which may contribute to EphB6 effects. As Elk-1 activation is known to increase the 
expression of multiple genes involved with invasive and metastatic behaviour (Kasza, 
2013), and as Elk-1 is involved in active signalling cascades known to produce an 
invasive mesenchymal cellular phenotype (Hou et al., 2014), this possibility warrants 
further investigation. 
Although the current data is almost exclusively limited to expression studies, EphB6 
appears to also indicate a more favorable prognosis in neuroblastoma, as high EphB6 
expression was found to strongly correlate to a lower tumor grade and higher survival 
incidence in neuroblastoma (Tang et al., 1999; Tang et al., 2000). In agreement, a 
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neuroblastoma cell line with induced EphB6 expression exhibited poorer ability to form 
colonies, and reduced tumor growth in mice (Tang et al., 2000). 
In breast cancer, expression of EphB6 is frequently reduced relative to healthy 
surrounding tissue (Toosi et al., In Revision), and, in agreement, it has been found that 
invasive breast carcinoma cells have reduced EphB6 expression due to transcriptional 
silencing by methylation of its promoter region (Fox and Kandpal, 2006).  As Eph 
receptors often form oligomeric complexes in response to ligand binding (Lisabeth et al., 
2013), and since EphB6 has been shown to interact with both EphA and EphB receptors 
(Fox and Kandpal, 2011), EphB6 may act by modifying the signalling output of other 
Eph receptors that are implicated in invasive behaviour (Akada et al., 2014; Truitt et al., 
2010). Indeed, our group has demonstrated that induced expression of EphB6 in breast 
cancer cell lines with high endogenous EphB4 expression leads to cytoskeletal 
rearrangements, as well as reduced invasive behaviour, relative to cells lacking EphB6. 
This effect was enhanced by treatment with an EphB6 ligand, ephrin-B2, and as EphB6 is 
unable to self-phosphorylate and relies on other molecules for its ligand-induced 
phosphorylation, this implies that some other kinase was important to mediating this 
effect. Further experiments determined that EphB6 phosphorylation following ephrin-B2 
treatment was assured by the kinase- active EphB4 receptor, demonstrating a cross-talk 
between the two receptors. EphB4 was found to support invasiveness, when acting in the 
absence of EphB6, as knock-down of EphB4 in cells lacking EphB6 expression resulted 
in reduced invasive behavior. EphB4 also supported invasion when its expression was 
sufficiently high so as to overwhelm EphB6 signals, as overexpression of EphB4 in cells 
with EphB6 expression enhanced invasive behavior.  However, as it was also determined 
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to be indispensable for EphB6-induced adhesive responses, it appears that the cross-talk 
between EphB4 and EphB6 serves to dampen pro-invasive EphB4 signalling, and that 
overall cell behavior is determined by the balance between the two receptors (Figure 
1.12). Thus, while EphB4 has been reported to have both tumour suppressive (Noren et 
al., 2006) and tumour enhancing effects (Noren et al., 2004), our observations of EphB6 
co-expression suppressing  invasive  behaviour of EphB4 positive breast cancer cell lines, 
in an EphB4 dependent manner, strongly supports the idea that EphB6 cross-talk with 
other Eph receptors can alter their biological output, and explains in part the duality 
exhibited by the EphB4 receptor (Truitt et al., 2010). Moreover, EphB6 has been 
observed to interact with and modify the output of other Eph receptors as well, as Akada 
et al (Akada et al., 2014) observed that in the breast cancer cell line MCF7, EphB6 and 
EphA2 interact  with each  other  through  their  ligand-binding  domains,  in  a  ligand- 
independent manner. This interaction results in reduced phosphorylation of EphA2 on a 
serine residue, and also significantly reduces the ligand-independent interaction of 
EphA2 with ephexin4. As mentioned previously, an important characteristic needed for a 
cancer cell to exhibit invasive potential is the ability to escape anoikis, the apoptotic 
response to detachment from the cell-matrix and other cells (Frisch et al., 2013). As a 
result of EphB6 interaction with EphA2, the EphA2-ephexin4 initiated signalling cascade 
that protects cells from anoikis is significantly attenuated, and thus much higher levels of 
apoptosis were observed when EphB6 expressing cells were grown in non-adherent 
culture conditions relative to those lacking EphB6 (Akada et al., 2014). The anti-invasive 
impact of EphB6 presence in breast cancer may also be partly mediated through 
alterations in gene expression, as Kandpal has observed that ectopic expression of EphB6 
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Figure 1.12. EphB6 suppresses pro-invasive signals of EphB4.  
Active EphB4 signaling promotes invasive behavior in highly invasive breast cancer. 
Ectopic expression of EphB6 inhibits invasive behavior, by promoting cell spreading and 
attachment, through active EphB4-EphB6 signalling. Thus when EphB4 expression is 
high relative to EphB6, cells exhibit strongly invasive behavior, while EphB6 expression 
in equal or greater quantity to EphB4 results in anti-invasive signals that require EphB4 
mediated phosphorylation for their initiation. 
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in MDA-MB-231 cells causes significant alterations to the expression of a number of 
genes (Kandpal, 2010), including matrix-metalloproteinases 7 and 19, and 
metalloproteinase 2 (Fox and Kandpal, 2009). Furthermore, our group has also made 
exciting observations regarding the impact of EphB6 on expression of numerous 
molecules involved in the EMT transition, an essential requirement for solid tumour cells 
to undergo metastasis (Toosi et al., In Revision). 
In contrast to observations in solid tumour types, EphB6 has been identified as a 
possible marker for a poorer prognosis in chronic lymphocytic leukemia cells (Alonso et 
al., 2009). Complementary with these findings, our group has found that EphB6 is 
expressed in T-ALL cell lines, as well as in some patient samples, along with another 
EphB receptor, EphB3. We determined that EphB6 and EphB3 were able to act in a cyto-
protective manner in these cells, preventing Fas receptor initiated apoptotic responses by 
stimulating Akt phosphorylation (Maddigan et al., 2011). 
 
1.5. Ligand-Induced Downregulation 
1.5.1. Downregulation Basics  
The activation of receptors on the surface of the cellular membrane allows for the 
transmission of external information to the interior of the cell. In order to properly react 
to external cues, cells need to finely regulate their responses to signals they receive. The 
amplitude of a response and the duration of the signal generated by the activation of a 
receptor must reflect the environmental input for a cell to properly modulate processes 
and function as an effective component of a tissue, organ, or organism. Regulating the 
number of receptors present on the surface of a cell is one mechanism that allows for the 
control of signal intensity (Goh and Sorkin, 2013), and termination of the signals 
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propagated by activated receptors must take place in order to facilitate real-time 
responses to external stimuli. Often, this is achieved through ligand-induced receptor 
downregulation.  Numerous receptor types employ this overall mechanic, including G-
protein coupled receptors (von Zastrow, 2003), hormone receptors (Bouley et al., 2013), 
as well as RTKs (Lu and Hunter, 2009; Roepstorff et al., 2008), highlighting its 
effectiveness at addressing an essential process.  
Following interaction with their ligands, activated receptors recruit signaling 
molecules within a cell to propagate the signal, and also to terminate their own signaling. 
Often, for cell surface receptors, the first phase in attenuating a signal is the 
internalisation of the activated receptor, frequently in a complex with the bound ligand. 
This is a dual-purpose step, as it not only acts as the first move towards receptor 
degradation, but can also bring the activated receptor into proximity with key molecules 
required for efficient signal transduction (Miaczynska et al., 2004b; Platta and Stenmark, 
2011; Sorkin and von Zastrow, 2009), or alter the signals it generates relative to those 
initiated at the cell membrane (Sorkin and von Zastrow, 2009). Following internalisation, 
cessation of signaling can be achieved in one of two ways: the ligand-receptor complex 
can be dissociated, and any ligand-induced modifications of the receptor, such as 
phosphorylation, can be removed so that the receptor may be recycled back to the cell 
surface, ready to undergo another round of activation, or, alternatively, the receptor can 
be degraded. In the event that the ligand-receptor complex remains intact, the internalised 
receptor continues signaling from inside the cell, and may even generate a stronger 
response, as has been observed for EGFR (Taub et al., 2007; Vieira et al., 1996). In this 
situation, the receptor-ligand complex is eventually targeted for degradation, terminating 
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the signal (Sorkin and von Zastrow, 2009). Recycling of the receptor allows for rapid and 
frequent cycles of receptor activation, allowing a cell to respond to the same type of 
stimulus repeatedly in a short amount of time, degradation of the receptor, on the other 
hand, can leave a cell less able to respond to repeated stimuli of the same type until the 
cell-surface pool of the receptor has been replenished. 
For some receptors, internalisation may not be necessary, and degradation can be 
initiated at the cell surface, where ligand binding induces cleavage of the activated 
receptor.  This cleavage may serve to facilitate more than just removal of the cell-surface 
receptor, as is demonstrated by Notch signalling, where the proteolysis of the receptor 
itself is a means of signal transduction (Andersson et al., 2011). 
 
1.5.2. Clathrin-coated Pits  
As mentioned, in addition to the recruitment of molecules that are required for 
intracellular signal propagation, activated receptors also recruit the machinery required 
for their own signal attenuation, and frequently for RTKs this involves recruitment of 
clathrin and its associated machinery (Goh and Sorkin, 2013). First described in 1964 
(Roth and Porter, 1964), clathrin-coated pits (CCP) have become the most widely 
explored mechanism of receptor internalisation. Clathrin is a protein heterohexamer 
found in the cytosol, composed of three heavy-chains and their three associated light 
chains. Together these peptides connect to form a structure called a triskelion, whose 
appearance looks much like the name suggests, consisting of a central connection point, 
and three bent arms (Young, 2007). Clathrin triskelions assemble together to form soccer 
ball like structures, with both five- and six-sided ring arrangements (Kirchhausen et al., 
2014) (Figure 1.13).  
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Figure 1.13. Clathrin triskelions.  
Clathrin is made up of a trimer of pairs of light and heavy chains that connect to form a 
triskelion. Triskelions arrange to form five and six sided soccer ball like structures that 
help induce an inward curvature of the cell membrane. Image adapted from Harrison and 
Kirchhausen (Harrison and Kirchhausen, 2010).  
 
 
While clathrin can spontaneously arrange into a polyhedral lattice in vitro under low 
pH conditions (Brodsky, 1988), in living cells, the proper formation of clathrin-coated 
pits in response to receptor activation requires the association of adaptor proteins 
(Kirchhausen et al., 2014). Adaptor proteins bind to membrane components, including 
activated  receptors,  and to clathrin,  and thus  are  able to help both with the targeting of  
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cargo for internalisation, and in the recruitment of clathrin to the cell membrane 
(Kirchhausen et al., 2014). Perhaps the most important of these is the adaptor protein AP-
2 (adaptor protein 2), that binds to phosphatidylinositol-4,5-bis-phosphate (PIP2), a 
component  of  the cell  membrane, and  also to  clathrin, target  cargo (such as activated 
RTKs), and to numerous other proteins (accessory proteins) that promote CCP formation 
(Boucrot et al., 2010). In this way, AP-2 is able to assist in maintaining clathrin at the 
inner membrane, in cargo selection, and in promoting the further assembly of the clathrin 
lattice, and as such it is unsurprising that AP-2 is one of the most common proteins 
associated with clathrin-mediated endocytosis (Boucrot et al., 2010). However, while 
studies in AP-2 depleted cells show a significant reduction in overall levels of clathrin-
mediated endocytosis, and while the endocytosis of some clathrin-targeted RTKs may be 
completely blocked, for others it remains unchanged, suggesting that despite its wide use, 
certain cargo are selected in AP-2 independent manners (Motley et al., 2003).  
Following activation, numerous RTKs are ubiquitinated by E3 ligases, including 
EGFR (Piper and Lehner, 2011), and this modification may assist in their targeting for 
internalisation through CCPs by promoting their interaction with proteins involved in pit 
formation (Piper et al., 2014; Piper and Lehner, 2011). This is observed in the classical 
EGFR downregulation pathway, where the ubiquitination of the activated receptor is 
performed by the E3-ligase, c-Cbl (Waterman et al., 1999). Here, following receptor 
activation, c-Cbl interacts with the phosphorylated receptor with its tyrosine kinase-
binding (TKB) domain (Thien and Langdon, 1997), and this promotes the 
phosphorylation and activation of c-Cbl by the receptor (Kassenbrock and Anderson, 
2004). c-Cbl is then able to interact with a ubiquitin-carrying E2 enzyme, and mediates 
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the transfer and attachment of ubiquitin to a lysine residue of the receptor (Thien and 
Langdon, 2005). Several proteins involved in clathrin-pit formation have been shown to 
bind to ubiquitinated RTKs, as will be discussed below. 
Accessory proteins are cytosolic proteins that interact with AP-2, or other adaptors, 
and help to provide additional cargo specificity, as well as to enhance lattice formation. 
For example, the AP-2 interacting protein Eps15 (Benmerah et al., 1998), is essential to 
proper assembly of the clathrin-coated pit (Benmerah et al., 1999; Tebar et al., 1996), and 
is also involved in the selection of cargo for internalisation. Eps15 is able to specifically 
bind to ubiquitinated RTKs through its UIM (ubiquitin interacting motif) (Polo et al., 
2002), and in this way helps target them to CCPs for internalisation (Polo et al., 2002). 
Other major accessory proteins frequently involved in CCP formation, include FCHo1 
and FCHo2 (F-BAR domain-containing Fer/Cip4 homology domain-only proteins 1 and 
2) (Henne et al., 2010) (Umasankar et al., 2012), and the epsins (Eps 15 interacting 
proteins) (Horvath et al., 2007). The epsin family contains four members, epsin1, 
epsin2a, epsin2b, and epsin3, and except for epsin3, whose expression is restricted to 
motile keratinocytes, all of them are ubiquitously expressed (Horvath et al., 2007). 
Epsins, as their name suggests, were first identified due to their interaction with Eps15, 
and have since been shown to interact with AP-2 and clathrin as well. They appear to 
play a role in promoting membrane curvature during the formation of the growing pit 
(Ford et al., 2002), and as they also possess a UIM domain, they likely assist in 
ubiquitinated cargo selection as well (Hofmann and Falquet, 2001). FCHo1 and FCHo2 
were initially believed to involved in the nucleation of CCPs (Henne et al., 2010), 
however more recent studies suggest that their predominant role is in assuring the 
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sustained growth of the clathrin-lattice following the initiation of its assembly 
(Umasankar et al., 2012). There are an immense number of other AP-2 accessory 
proteins, however their roles are more specific to certain receptors and cell-types, and 
thus are out of the scope of this review (Rodemer and Haucke, 2008).  
The general mechanism of CCP mediated internalization for many RTKs is often 
prompted by activation of the receptor by ligand-binding. Following activation, the 
phosphorylated RTK recruits adaptor proteins such as AP-2, and accessory proteins such 
as Eps15, to the cell surface, and thus initiates the process of CCP formation. For the 
successful nucleation of a clathrin-coated pit at least two AP-2 molecules need to be 
bound to the inner membrane and to one clathrin triskelion (Cocucci et al., 2012). Eps15, 
epsins, and FCHo1/2 then work together to stabilize the forming clathrin structure, 
promote membrane curvature, and concentrate cargo, such as RTKs, in the growing pit 
(Cocucci et al., 2012), and are essential to promoting the growth of the CCP (Benmerah 
et al., 1999; Cocucci et al., 2012; Horvath et al., 2007). Following initiation, clathrin 
triskelions from the cytosolic pool are recruited to the growing pit at a constant rate 
(Ehrlich et al., 2004), and the continued assembly of clathrin along the inner membrane 
causes the membrane to curve inward, forming a round pit. Observations using confocal 
microscopy suggest that in CCPs containing RTKs, the pit diameter reaches a maximum 
of about 100 nm, and contains about 60 triskelions (Ehrlich et al., 2004). Once the 
clathrin lattice has fully assembled, a ball like invagination of the cell membrane is 
present, with a narrow opening at the outer periphery (Figure 1.14). 
The large GTPase, dynamin (Ferguson and De Camilli, 2012), facilitates the 
separation  of the  CCP  vesicle  from  the  membrane  (Ramachandran, 2011).  The exact  
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Figure 1.14. Structure of a clathrin-coated pit. 
Following receptor activation, Clathrin is recruited to the inner membrane by interactions 
with numerous adaptor proteins. The assembly of the clathrin-lattice induces membrane 
curvature and pit formation. Ultimately, a vesicle is formed from the Clathrin-coated by 
pinching off of the membrane by the large GTPase, Dynamin.  
 
 
mechanism underlying the ability of dynamin to promote membrane scission and release 
of the vesicle has yet to be fully elucidated, however, it involves the formation of a 
helical structure encircling the narrow opening of the pit, composed of multiple 
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connected units of dynamin (Ford et al., 2011). Dynamin hydrolysis of GTP (guanine 
triphosphate) induces a conformational change allowing for the constriction of the 
dynamin helix, and the  membrane  it  is  bound  to  (Ramachandran, 2011; Sweitzer and 
Hinshaw, 1998). Through this, and potentially other mechanical forces, the vesicle 
separates from the cell membrane. In order to facilitate fusion with other compartments 
of the endocytic pathway, the newly formed vesicle sheds its clathrin coat in an auxilin 
and Hsc70 dependent manner (Prasad et al., 1993; Ungewickell et al., 1995), and is 
subsequently targeted to the appropriate intracellular compartment. Generally, the cargo 
contained in the newly endocytosed vesicle will dictate how it will be trafficked, and 
many RTKs contain signaling motifs in their cytoplasmic domains which direct their 
sorting following endocytosis (Acconcia et al., 2009). 
 
1.5.3. The Early Endosome 
Following internalisation, many RTKs are targeted to the early endosome (Goh and 
Sorkin, 2013), a membranous structure characterized by the presence of markers such as 
the early endosomal antigen 1 (EEA1) (Mu et al., 1995) and Rab-5 (Bucci et al., 1992). 
The early endosome is highly dynamic, with tubule like protrusions, and several 
compartments of distinct lipid and protein composition within its limiting membrane 
(Jovic et al., 2010). Among these compartments are areas of high membrane activity, 
with regions where vesicles form and bud off from the early endosome, as well as areas 
of intraluminal vesicle formation and internalisation (Jovic et al., 2010). The pH of the 
early endosome is between 6.8-5.9, which is slightly lower than that of the surrounding 
cytoplasm (Maxfield and Yamashiro, 1987). This reduction in pH may help to facilitate 
the dissociation of ligand from receptor to enable the recycling of receptors back to the 
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cell surface, however, oftentimes, receptors continue signalling from this compartment 
(Miaczynska et al., 2004b).  
For several RTKs, including EGFR, The GTPase Rab5, and its effectors, EEA1 
(Simonsen et al., 1998), and rabenosyn-5 (Nielsen et al., 2000) help to initiate the fusion 
of the endocytotic vesicle with the early endosome (Nielsen et al., 2000). This dynamic 
process involves soluble NSF (N-ethylmaleimide sensitive factor) attachment protein 
receptor (SNARE) proteins, including syntaxin-6 and syntaxin-13 (Brandhorst et al., 
2006), and the Sec1/Munc18-like (SM) protein, Vps45 (vacuolar protein sorting 45) 
(Nielsen et al., 2000), that are present on both the target and donor membranes. 
Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) is actively enriched on the surface of 
early endosomes by several proteins, including PI3K isoforms and phosphatases (Zoncu 
et al., 2009), and this helps to assure the correct recruitment of effectors that bind to PIP3 
such as EEA1 and rabenosyn-5 (Mills et al., 1998; Nielsen et al., 2000). By binding to the 
SNARE proteins syntaxin-6 and syntaxin-13, and to Vps45, EEA1 and rabenosyn-5 
facilitate the formation of a large component of the fusion complex on the surface of the 
early endosome and vesicle (Nielsen et al., 2000). Vesicle fusion is initiated when Rab-5, 
which is associated with a newly endocytosed vesicle, interacts with EEA1, rabenosyn-5, 
and other components of the tethering complex present on the early endosome, and 
concurrently Rab-5 on the early endosome interacts with components on the newly 
endocytosed vesicle. These interactions work together to stabilize the vesicle in close 
proximity to the early endosome (Barbieri et al., 1998; McBride et al., 1999; Mills et al., 
1998; Mu et al., 1995; Nielsen et al., 2000; Stenmark, 2009), in a process commonly 
called tethering (Kummel and Ungermann, 2014). The SNARE proteins, which are 
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present on both the surface of the vesicle and the endosome, are then able bind to each 
other (Kummel and Ungermann, 2014). The N- to C-terminal “zippering” of the SNARE 
proteins to each other brings the two membranes in close proximity, destabilises them, 
and promotes vesicular fusion (Chen and Scheller, 2001) (Figure 1.15).  
Following the fusion of the internalised vesicle with the early endosome, RTKs are 
sorted  within  its  membrane,  localising  to  compartments  that  facilitate  their  correct 
subsequent trafficking. At this point key sequences in their cytoplasmic domains, or 
structural modifications such as ubiquitination, play important roles in determining how 
cargo are sorted (Raiborg et al., 2003), and internalised receptors will begin to associate 
with proteins reflective of their ultimate fate (Seaman, 2008). For example, effectors such 
as Tsg101 are able to interact with ubiquitinated cargo, and target such proteins for late 
endosomes/ multi-vesicular bodies (MVBs) (Raiborg et al., 2003). Additionally, 
receptors destined for degradation may also localise to compartments with Rab-7 (Girard 
et al., 2014). For receptors which are to be recycled, there is an increased association with 
Rab4, and its effectors Rab coupling protein (RCP) (Lindsay et al., 2002) and rabaptin-4 
(Deneka et al., 2003). Over time, some enriched compartments are able to bud from the 
early endosome, such as those bearing receptors to be recycled, while other receptors and 
proteins accumulate resulting in a refinement of cargo and endosome composition 
(Huotari and Helenius, 2011). Eventually, following fusion with multiple vesicles, and 
the targeting of cargo to correct compartments, the early endosome matures through the 
simultaneous loss of markers and characteristics of the early endosome such as Rab-5, 
and the  acquisition  of proteins such as Rab-11, the formation of intraluminal vesicles, a 
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Figure 1.15. Endocytosed vesicles fuse with the early endosome.  
Following their internalization, many vesicles containing RTKs are targeted to the early 
endosome, a sorting station for a variety of subcellular components. Fusion with the early 
endosome requires the tethering of the vesicle to the early endosome by Rab5 GTPase, 
and EEA1, as well as the activity of SNARE proteins for membrane fusion. 
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reduction in pH, and morphological changes including the loss of the tubular arms, to 
become the late endosome (Huotari and Helenius, 2011). 
 
1.5.4. The Lysosomal Pathway 
Those receptors destined for degradation are often sorted towards the lysosomal 
compartment, as is the case for the most studied instance of RTK downregulation, EGFR  
(Duan et al., 2003). Receptors, such as EGFR, when fated for degradation, accumulate 
within early endosomes, and there is a concurrent shift from lipids and proteins 
associated with the early endosome, to those associated with late endosomes, a process 
termed endosome maturation (Huotari and Helenius, 2011).  
Ubiquitination is not only important for receptor interactions with proteins 
involved with internalisation (Piper et al., 2014), it is also essential for targeting of the 
many receptors to the degradative pathway (Eden et al., 2012). This modification 
facilitates EGFR interaction with Tsg101, Hrs, and other members of the endosomal-
sorting complex required for transport (ESCRT) machinery, which are able to recognise 
and bind to ubiquitinated proteins through their UIM domains (Urbe et al., 2003). There 
are five ESCRT complexes that make up the ESCRT machinery, and receptors are 
trafficked through them in a sequential manner (Schmidt and Teis, 2012). ESCRT 0, 
which associates with endosomes through its interaction with PIP2, is composed of Hrs 
and STAM (signal-transducing adaptor molecule), both of which are able to bind to 
ubiquitinated proteins, and help to concentrate ubiquitinated cargo within the endosomal 
membrane (Mayers et al., 2011). ESCRT I, in turn, is recruited to the endosome through 
its interaction with ESCRT 0. ESCRT I is a tetramer containing Tsg101, Vps28, Vps37, 
and ubiquitin-associated protein 1 (UBAP-1).  Tsg101 interacts with both ESCRT 0 as 
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well as the ubiquitinated proteins associated with it, and UBAP-1, as the name suggests, 
also interacts with the ubiquitinated cargo; these interactions are believed to help locally 
concentrate ubiquitinated proteins. The Vps28 subunit of ESCRT I acts to recruit the 
ESCRT II complex (Gill et al., 2007). ESCRT II is composed of Vps22, Vps25, and 
Vps36 (Babst et al., 2002b). ESCRT II also interacts with ubiquitinated cargo through the 
Vps36 subunit, and is believed to be responsible for nucleating the formation of the 
ESCRT III complex through the interaction between Vsp25 of ESCRT II and Vps20 of 
ESCRT III (Im et al., 2009). The ESCRT III complex, Vps2, Vps20, Vps24, and 
Snf7 (Babst et al., 2002a), together with ESCRT II, acts to initiate the formation of 
intraluminal vesicles. Unlike other ESCRT complexes, which are recruited to endosomal 
membranes as pre-formed complexes, ESCRT III components do not form stable 
complexes within the cytosol (Williams and Urbe, 2007), and the nucleation of ESCRT 
III assembly at the endosomal membrane requires the interaction between Vps20 and 
Vsp25 (Teis et al., 2008). The Vps20-Vps35 interaction promotes the subsequent 
recruitment of Snf7, and the formation of a multiple-Snf7 oligomeric filament that 
convexly distorts the membrane, assisting in the formation of the intraluminal vesicle 
(Teis et al., 2010). The elongation of the Snf7 filament is terminated when the final two 
components of the ESCRT III complex, Vps24 and Vps2, bind to its end, capping it 
(Saksena et al., 2009). Vps20, Snf7, and Vps24 are responsible for membrane budding 
and scission, while Vps2 acts to recruit the fifth and final component of the ESCRT 
machinery, Vps4, which disassembles the ESCRT III complex and allows it to be 
recycled for further rounds of vesicle formation (Babst et al., 1998; Saksena et al., 2009; 
Wollert et al., 2009). Thus, the ESCRT complexes 0, I, II, and III interact and mediate the 
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formation of intraluminal vesicles containing activated EGFR receptors, and other RTKs 
destined for degradation in lysosomes (Schmidt and Teis, 2012) (Figure 1.16). Once an 
accumulation of intraluminal vesicles has taken place, including those containing EGFR, 
the MVB, or late endosome, continues to acquire characteristics and proteins required for 
its fusion with lysosomes. The maturation of the MVB involves the loss of Rab-5, 
accumulation of Rab-7 (Rink et al., 2005), and a continued reduction in pH (reaching a 
pH of 6.0-4.8) (Maxfield and Yamashiro, 1987). 
 
1.5.5. Mechanisms of Degradation 
Late endosomes ultimately fuse with lysosomes to form endolysosomes (Kummel 
and Ungermann, 2014). Where Rab5 and EEA1 play key roles in tethering endocytic 
vesicles to the early endosome, the HOPS (homotypic fusion and vacuole protein sorting) 
complex is required for late endosome/lysosome fusion (Luzio et al., 2010).  
Endolysosomes are a major compartment for macromolecular degradation, and 
RTKs that are contained in the intraluminal vesicles, as well as the membranes of the 
intraluminal vesicles themselves, are proteolytically cleaved by the acid hydrolases stored 
in the lysosomal compartment (Bonten et al., 2014; Katzmann et al., 2002) (Figure 1.17). 
Lysosomes contain up to 50 distinct hydrolases (Castino and Isidoro, 2008), and these 
enzymes are able to form complexes within the endolysosome to efficiently degrade a 
wide range of targets (Bonten et al., 2014). Due to their requirement for a low pH to 
function, with many exhibiting optimal activity at a pH close to 5, hydrolase activity is 
limited to the lysosomal compartment, which maintains an acidic state through the active 
function of proton pumps (DiCiccio and Steinberg, 2011). The degradation of a wide 
number  of RTKs has  been reported to  take  place  in  a  lysosomal  dependent manner,  
  O. Allonby 
 
 70 
 
 
Figure 1.16. Formation of the multivesicular body. 
 Endocytosed receptors present in the early endosome can interact with several 
components of the ESCRT machinery, especially ESCRT 0 and ESCRT I, which serve to 
concentrate ubiquitinated cargo for internalization into intraluminal vesicles through 
ESCRT III activity. Figure adapted from Huotari and Helenius (Huotari and Helenius, 
2011). 
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Figure 1.17. Formation of the endolysosome.  
Late endosomes/multivesicular bodies fuse with lysosomes to form endolysosomes, a 
major compoenent of cellular degradative machinery. Following fusion internalized 
receptors and intraluminal vesicles are destroyed by hyrdrolases that were contained in 
the lysosome. Figure adapted from Huotari and Helenius (Huotari and Helenius, 2011). 
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including EGFR (Futter et al., 1996), and members of the PDGFR (Joly et al., 1995), 
FGFR (Wong et al., 2002), and VEGFR families (Han et al., 2014). While the lysosomal 
compartment is a major component of the degradative machinery of a cell, some 
activated receptors rely on extra-lysosomal proteasomal complexes for their degradation. 
The HGF (hepatocyte growth factor) receptor, Met, for example, can be poly-
ubiquitinated following ligand stimulation, and its subsequent degradation can be blocked 
through the use of the proteasomal inhibitor, lactacystin (Jeffers et al., 1997), and similar  
observations  have  also  made  for  the PDGFR (Mori et al., 1995). Additionally, rather 
than undergoing endocytosis, the ErbB4 receptor can be cleaved at the cell membrane by 
a metalloprotease, and the resulting ErbB4 C-terminal fragment is ubiquitinated and 
degraded by proteasomal complexes (Vecchi and Carpenter, 1997). 
 
1.5.6. Alternative Mechanisms of Internalisation 
1.5.6.1. Caveolae 
Caveolae are flask shaped invaginations of the cell membrane that are rich in 
cholesterol and sphingolipids, and have been observed to internalize several RTKs 
following their activation (Di Guglielmo et al., 2003; Salani et al., 2010; Sigismund et al., 
2005; Stan, 2005). The formation of these invaginations is dependent upon both the 
enrichment of these lipids, as well as on the presence of cavins, and caveolins (Hansen 
and Nichols, 2010) (Figure 1.18). There are three caveolin proteins identified to date, 
and while caveolin-1 and caveolin-2 are ubiquitously expressed, caveolin-3 is only 
expressed in muscle cells (Williams and Lisanti, 2004). Caveolin-1 is an integral 
membrane  protein, and  interacts  with  proteins,  sphingolipids  and  cholesterol  directly  
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Figure 1.18. Structure of caveolae. 
 Caveolae are flask-like invaginations of the cell membrane formed in areas the cell 
membrane with high cholesterol content. Caveolin-1 and cavins induce and promote 
membrane curvature, and caveolar vesicles are separated from the cell membrane through 
dynamin activity.  
 
 
(Fra et al., 1995; Murata et al., 1995). As such, it is likely that oligomers of caveolin-1 
help to concentrate specific lipids and signalling molecules in rafts within the cell 
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membrane (Sargiacomo et al., 1995). Caveolin-1 is responsible for the recruitment of 
caveolin-2 to caveolae, and also appears to regulate the size of caveolar vesicles (Li et al., 
1998). Overall, caveolin-1 is essential for the formation of caveolar flasks (Drab et al., 
2001; Li et al., 1998), while caveolin-2 appears to play a stronger role in signalling than 
in caveolae formation (Razani et al., 2002; Sowa, 2011). In contrast to caveolins, cavins 
are cytosolic proteins, and appear to function as accessory proteins, stabilising the 
caveolar structure (Hayer et al., 2010).  
While caveolae have been strongly implicated in facilitating the endocytosis of 
receptors such  as   the   EGFR   (Sigismund et al., 2005),  the  β-1-adrenergic  receptor 
(Rapacciuolo et al., 2003), and the insulin receptor (Fagerholm et al., 2009), in response 
to their stimulation, it has also come into question if these structures truly undergo fission 
from the cell surface. Images acquired by electron microscopy show that when sliced 
parallel to the membrane, caveolae appear to form vesicles, however, samples that are 
prepared by perpendicular slicing show long tubule formations that are not separate from 
the peripheral membrane (Parton et al., 2002).  This suggests the possibility that caveolae 
act predominantly as signalling structures, grouping components together, and facilitating 
efficient activation of certain pathways by ensuring their spatial organization (Harvey and 
Calaghan, 2012), and only play a minor role in endocytosis. Indeed, proper signalling of 
several receptors, including EphB1 (Vihanto et al., 2006) and EphB4 (Muto et al., 2011), 
has been found to be dependent upon their association with caveolin-1, verifying the 
important role caveolae play in signal regulation. However, the proper trafficking and 
degradation of the TGF-β (transforming growth factor-β) receptor  (Di Guglielmo et al., 
2003) and of IGF-1R (Fagerholm et al., 2009; Salani et al., 2010) is impaired when 
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caveolae-mediated internalisation is blocked, and other receptors have also been shown to 
internalize in a caveolin-dependent and clathrin-independent manner (Sigismund et al., 
2005), strongly indicating that at least for some receptors, caveolae mediated 
internalisation is important as well. 
Caveolar mediated internalisation is initiated when the activation of the RTK 
promotes its association with caveolin-1, localising it to caveolae. This may also result in 
the phosphorylation of caveolin-1, as is the case following IGF-IR activation by IGF, 
however the importance of this to internalization has not yet been fully explored 
(Fagerholm et al., 2009; Salani et al., 2010). As with CCP mediatied internalisation, there 
is strong evidence implicating dynamin in mediating caveolar vesicle scission from the 
membrane (Oh et al., 1998). Following their formation, and separation from the cell 
membrane, caveolar vesicle trafficking is dependent upon both actin and microtubules 
(Mundy et al., 2002).  
Thus, while the importance of caveolae-mediated active internalisation of cell-
surface receptors remains controversial, there is compelling evidence that caveolae play 
an important role in endocytosis for at least a few proteins, including EGFR (Sigismund 
et al., 2005), and like clathrin mediated internalisation, dynamin mediated pinching-off at 
the cell membrane has been implicated in their activity (Oh et al., 1998). 
 
1.5.6.2. Lipid Rafts/ CLIC-GEEC 
The Clathrin-Independent Carriers (CLICs), and GPI-Enriched Endocytic 
Compartments (GEECs) pathway is predominantly associated with the internalization of 
GPI-anchored proteins, however it has been linked to RTK endocytosis as well (Jahn et 
al., 2002; Vaidyanath et al., 2011). CLICs are cholesterol rich lipid-raft microdomains, 
  O. Allonby 
 
 76 
distinct from caveolae, that undergo endocytosis (Kirkham and Parton, 2005). CLIC 
mediated internalization can be initiated through active cellular signalling, and is 
dependent upon the action of members of the Rho family of GTPases (Doherty and 
Lundmark, 2009). CLICs are concentrated at the leading edge of cells, and are important 
to ensuring proper cell migration (Howes et al., 2010). Unlike the pit formed during 
clathrin mediated endocytosis, or the characteristic flask shape of caveolae, the CLIC 
mediated internalisation pathway involves the formation of long tubule like invaginations 
from the cell surface (Kirkham and Parton, 2005) (Figure 1.19). The separation of the 
vesicle from the cell membrane may not be dynamin dependent, as overexpression of a 
dominant negative dynamin mutant had no observable impact on the overall rate of 
endocytosis through this pathway (Sabharanjak et al., 2002). However, as a separate 
group found that lipid-raft endocytosis was dependent upon dynamin (Lundmark et al., 
2008), its role in these structures is not yet clear. A Rho-GAP-domain-containing protein, 
GRAF1 (GTPase regulator associated with focal adhesion kinase-1), has been 
demonstrated to play an important role in regulating this pathway (Lundmark et al., 
2008), as has the Rho family member, Cdc42 (Chadda et al., 2007; Sabharanjak et al., 
2002).  GRAF1 may play a dual role, both by acting as a Rho-GAP protein, thus affecting 
the actin cytoskeleton, and by enhancing membrane curvature through its 
Bin/Amphiphysin/Rvs (BAR) domain (Doherty and Lundmark, 2009). BAR domains are 
believed to be recruited to areas of positive  membrane  curvature  (Galic et al., 2012),  
and   to  strongly   enhance   further  curvature  through  physical  interactions  with  the 
membrane, thus facilitating pit formation (Mim and Unger, 2012). As expected from the 
observations that Rho family members are involved in mediating CLIC endocytosis, actin 
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Figure 1.19. Structure of CLIC/GEEC membrane invagination.  
Lipid-rich regions of membrane form long, tubule like invaginations, which are promoted 
both by structural rearrangements of the actin cytoskeleton, but also by the BAR domain 
containing GRAF-1, which also plays a role in membrane scission.  
 
 
polymerisation is essential for CLIC mediated internalisation (Chadda et al., 2007). 
Similar to caveolae, CLIC endocytosis also requires membranous cholesterol (Chadda et 
  O. Allonby 
 
 78 
al., 2007). While it is not yet fully clear if all cargo internalized through CLICs end up in 
GEECs (Xu et al., 2013), CLIC internalized vesicles can be targeted to the early 
endosome as association with typical markers such as Rab5 and EEA1 has been observed 
(Kalia et al., 2006). ErbB2 was observed to be internalised in a clathrin-independent 
manner in response to Hsp90 inhibition (Barr et al., 2008), and it has been proposed that 
the CLIC/GEEC pathway may be responsible (Vaidyanath et al., 2011).  Additionally, the 
RTK Ret is actively transported to GPI-enriched lipid rafts following its activation by 
ligand treatment, as is c-Kit, suggesting they too may be internalized through this 
compartment (Jahn et al., 2007; Jahn et al., 2002; Tansey et al., 2000). 
 
1.5.6.3. Macropinocytosis 
Macropinocytosis is a process that involves the internalisation of a large area of the cell 
membrane and extracellular fluids. While it is not normally associated to ligand-induced 
receptor internalisation, it has been implicated in bulk receptor removal (Kerr and 
Teasdale, 2009), and macropinocytosis is often initiated through RTK activation 
(Hamasaki et al., 2004; Lanzetti et al., 2004). The process of macropinocytosis involves 
the initiation of actin polymerization through the activation of the Rho family of GTPases 
(Egami et al., 2014) and phosphorylation of PIP2 by PI3K (Hoeller et al., 2013).  In turn, 
members of the Wiskott–Aldrich Syndrome protein  (WASp) family and WASp family 
Verprolin-homologous (WAVE) proteins are activated and promote the Arp2/3 
dependent nucleation of a new actin filament branch points (Kerr and Teasdale, 2009; 
Veltman et al., 2014). Additionally, PAK1 (p21 protein (Cdc42/Rac)-activated kinase 1) 
has been found to be essential for the initiation of this process (Dharmawardhane et al., 
2000). The localized growth of the actin skeleton promotes protrusions of the cell 
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membrane, which eventually branch to form pockets, and fuse back to the cell membrane 
(Swanson, 2008) (Figure 1.20). Macropinocytosis is a dynamin- independent mechanism 
(Liberali et al., 2008). Interestingly, following vesicle formation, macropinosomes can 
follow routes common to canonical clathrin-mediated receptor endocytosis. For example, 
Rab5, a key protein in vesicular trafficking following clathrin-mediated endocytosis, 
appears to be important to macropinosome formation (Lanzetti et al., 2004; Schnatwinkel 
et al., 2004), and macropinosomes are consistently found to associate with markers of the 
classical clathrin-mediated internalization pathway such as EEA1 (Kerr et al., 2006). 
Furthermore, macropinosomes have been shown to mature, much like canonical vesicles 
of internalisation, and instead, membrane fission has been observed to be assured by C-
terminal-binding protein-1/brefeldinA-ADP ribosylated substrate (CtBP1/BARS) (Kerr et 
al., 2006) and target to lysosomes (Racoosin and Swanson, 1993). In addition to CCP and 
caveolar mediated internalisation, EGFR has been observed to be internalised in a 
specialised form of macropinocytosis involving the formation of circular dorsal ruffles. 
These wave like structures are rich in F-actin and form  in  response  to  growth  factor  
stimulation  on  the  migratory  surface of epithelial and mesenchymal cells (Krueger et 
al., 2003). Following stimulation with EGF, activated, EGF-bound EGFR phosphorylates 
PI3K at the cell and membrane, leading to an increase in PIP3, and initiates 
WAVE/WASp   and   Arp2/3  mediated  dorsal  ruffle  formation.  EGFR  and  PIP3  are 
concentrated in the dorsal ruffles, and are subsequently internalised (Orth et al., 2006). 
However, unlike  some  instances  of  macropinocytosis,  dorsal  ruffle  mediated EGFR 
internalization appears to require dynamin, where it may function to promote membrane 
curvature (Orth et al., 2006). 
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Figure 1.20. Formation of a macropinocytotic vesicle.  
Following receptor activation, Rho family GTPases promote growth of the actin 
cytoskeleton at the leading edge of the cell. WAVE and WASp proteins work with 
Arp2/3 complexes to promote branching of the actin cytoskeleton, resulting in stable 
outgrowths of the cell membrane that ultimately fuse to engulf extracellular material and 
areas of cell membrane. 
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The RTK Met can also utilise circular dorsal ruffles for its internalisation, and 
will subsequently colocalise with components of the classical endosomal pathway 
including Rab5, EEA1, and components of the ESCRT machinery, including Hrs (Abella 
et al., 2010), further demonstrating that this process is not only able to internalise 
receptors, but can also act as the initial step in ligand-induced receptor downregulation. 
The RTK, TrkA, which is involved in neurotrophic signalling, is also endocytosed 
through macropinocytosis in response to activation, and this was observed to contribute 
to proper downstream signalling (Shao et al., 2002). 
 
1.5.6.4. Endophilin-mediated internalization 
One of the most recently described mechanisms of non-clathrin mediated 
endocytosis involves the BAR-domain containing protein, endophilin. While endophilin 
has been observed to associate with CCPs, its presence is dispensable for the formation 
and internalization of these structures (Taylor et al., 2011), and in agreement, it is only 
found in a fraction of CCPs (Taylor et al., 2011). Stimulation of EGFR with high levels 
of EGF was found to rapidly promote the formation of endophilin and EGFR positive 
vesicles, and knock-down of endophilin led to an accumulation of EGFR at the cell 
surface. Importantly, knock-down of clathrin did not affect the formation of endophilin 
positive vesicles in response to EGF. Like CCP mediated internalisation, endophilin 
mediated internalization requires dynamin activity (Boucrot et al., 2015). The same group 
also found that interleukin-2β receptor (IL-2Rβ) could also be internalized in an 
endophilin dependent manner, confirming observations made by separate team same who 
found that the IL-2Rβ appears to undergo endocytosis in a mechanism distinct from 
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clathrin, caveloae, or the CLIC/GLEEC pathway (Grassart et al., 2008). Furthermore, 
both studies found that this mechanism of internalization requires the activity of 
dynamin, Rac1, PAK1, and actin (Boucrot et al., 2015; Grassart et al., 2008).  
 
1.6. Downregulation and Signaling 
Internalisation of an activated receptor does not necessarily signify a termination of 
RTK signalling. Indeed, the opposite is often found to be true, where increased activation 
of target pathways can be achieved in the endosomal compartment (Sorkin and von 
Zastrow, 2009). For example, several studies have indicated that the full activation of the 
Ras/MAPK pathway following EGFR activation requires the internalisation of the 
receptor (Sigismund et al., 2008; Vieira et al., 1996), and in agreement, several proteins 
which complex with EGFR to initiate this signalling cascade, including SHC (Src 
Homology 2 Domain-Containing) and Grb2, were found to associate with EGFR at 
endosomes (Di Guglielmo et al., 1994). Furthermore, several studies have clearly 
demonstrated that EGFR is able to efficiently activate Ras from endosomes (Haugh et al., 
1999a; Wang et al., 2002). These observations are not specific to EGFR, as the RTK also 
TrkA interacts with signalling effectors from endosomes (Grimes et al., 1996), and 
effectively leads to the activation of downstream targets (Howe et al., 2001), as does 
PDGFR (Wang et al., 2004). 
 While internalization does not indicate an end of signaling, it can signify a change in 
the signals that are generated. For example, while EGFR demonstrates a continued ability 
to activate the Ras/MAPK cascade following internalisation, endocytosis inhibits its 
ability to activate the phospholipase-C pathway, providing evidence that the signals 
generated by a receptor can be controlled by its spatial organisation (Haugh et al., 
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1999b). Similar observations of VEGF receptor signalling further support this, as the cell-
surface receptor can only poorly activate the Ras/MAPK pathway, whereas the 
internalised receptor exhibits efficient signalling leading to cell proliferation 
(Lampugnani et al., 2006).  Additionally, the c-Met receptor also relies on endocytosis to 
guarantee efficient downstream effects are achieved, although in this instance it is the 
phosphorylation and nuclear translocation of STAT3 (Signal transducer and activator of 
transcription 3) following c-Met activation that requires receptor internalisation 
(Kermorgant and Parker, 2008). However, it should be noted that as some reports suggest 
that signalling is indeed terminated following internalisation, the impact of internalisation 
for signal activation is likely be cell-type, pathway, or situation dependent (Galperin and 
Sorkin, 2008; Johannessen et al., 2000). 
In some cases, internalisation of receptors to the endosomal compartment appears to 
allow for their better association with scaffolding proteins that serve to bring together 
components of signalling pathways. For example, p-18, a MAPK scaffolding protein, is 
only observed in endosomes, and is absent from the peripheral cell membrane (Nada et 
al., 2009). P-18 acts by anchoring components of the MAPK signalling pathway to the 
RTK bearing membrane promoting their efficient activaiton (Nada et al., 2009). P-18, 
and other endosome specific scaffolds are necessary for proper activation of RTK 
downstream signals, as loss of their expression results in reduced signalling efficiency 
(Nada et al., 2009; Teis et al., 2002).  
Some endosome-associated proteins are not only important to facilitating the 
formation of receptor signalling complexes, but also play a direct role signal transduction. 
Two such proteins are represented by the Rab-5 effectors, adaptor protein, 
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phosphotyrosine interacting, PH (Pleckstrin homology) domain, and leucine zipper-
containing-1 (APPL-1) and APPL-2 (Urbanska et al., 2011). Rab-5, APPL-1, and APPL-
2 positive vesicles are considered to be specialised signalling endosomes, and, likely due 
to the ability of APPL-1 and 2 to bind to both PI3K and Akt, show enhanced PI3K/Akt 
signalling relative to EEA1 positive endosomes (Schenck et al., 2008; Zoncu et al., 
2009).  In neuronal cells, APPL-1 has been observed to be required for proper TrkA 
signalling and activation of multiple pathways, including the PI3K/Akt pathway and 
Ras/MAPK pathway (Lin et al., 2006; Varsano et al., 2006). EGFR also associates with 
APPL-positive endosomes (Zoncu et al., 2009), and in agreement, a portion of its ligand, 
EGF, was found to rapidly internalise and colocalise with APPL-1 and APPL-2 
(Miaczynska et al., 2004a). Interestingly, the authors found that the presence of EGF in 
APPL endosomes initiated the translocation of APPL-1 and APPL-2 to the cell nucleus, 
where they were observed to interact with components of a complex of proteins involved 
in chromatin remodeling, and that knock-down of APPL-1 or APPL-2 resulted in reduced 
proliferation. This suggests that APPLs may also directly transfer signals to the nucleus, 
and that this may be important to proliferative signaling initiated by some RTKs 
(Miaczynska et al., 2004a). Several observations have been made that suggest that APPL-
positive endosomes “mature” to form more canonical early endosomes (Miaczynska et 
al., 2004a; Zoncu et al., 2009),  including the finding that that EGF association with 
EEA1-positive endosomes increases as APPL-1 and APPL-2 translocate to the nucleus 
(Miaczynska et al., 2004a). Mechanistically, it has been suggested that APPL proteins 
compete with EEA-1 for binding to Rab-5, and it was demonstrated that as the endosome 
becomes enriched with PIP3, possibly as a result of receptor driven-PI3K activation, 
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EEA-1 is consequently accumulated. This could allow EEA1 to potentially outcompete 
the APPL proteins for Rab5 interaction, mediating the conversion to the canonical early 
endosome (Zoncu et al., 2009).  As APPL-positive endosomes have been shown to 
enhance signalling by EGFR (Zoncu et al., 2009), TrkA (Lin et al., 2006), and other non-
RTKs (Hu et al., 2003; Mao et al., 2006), especially through the PI3K/Akt pathway, this 
method of receptor-initiated conversion from a highly active signalling endosome, to one 
with relatively reduced PI3K/Akt signalling potential could represent a second level of 
regulation of signalling ouput, allowing for a controlled short-term burst of high level, 
self-limiting receptor signalling. Importantly, the method of internalization appears to 
impact targeting to APPL-positive endosomes, as it was found that EGF channeled to 
these compartments was internalised in a dynamin independent manner. Therefore, the 
subset of EGFR receptors that are targeted to APPL-positive endosomes undergo 
endocytosis in a manner distinct from the canonical pathway, and thus the mechanism of 
internalization too is important to downstream signaling effects (Miaczynska et al., 
2004a).  
As suggested by the dynamin independent internalisation of EGF that targets to APPL-
positive endosomes, the mechanism of receptor internalisation can alter the availability 
and potential signalling output of RTKs. For example, EGFR can be internalised in CCP-
dependent and independent manners, and recent observations suggest that this results in 
its targeting for either recycling or degradation (Sigismund et al., 2008). EGFR has been 
found to be endocytosed through CCPs when stimulated with low levels of EGF 
(Sigismund et al., 2005), however, it utilises alternate mechanisms of internalisation 
when in the presence of high EGF (Sigismund et al., 2008; Sigismund et al., 2005). 
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According to observations by one group, when internalised through CCPs, EGFR is 
preferentially sorted for recycling, and thus is able to be activated again rapidly. In 
contrast, when a high concentration of ligand is present, EGFR is endocytosed in a CCP 
independent manner, and is efficiently targeted to MVBs and degraded (Sigismund et al., 
2008) (Figure 1.21). Furthermore, it was found that EGFR recycling led to sustained 
signaling in comparison to that observed for the lysosomal-targeted receptor (Sigismund 
et al., 2008). While it should be noted that there are several other reports of CCP 
mediated EGFR internalization leading to receptor downregulation (Grovdal et al., 2004; 
Madshus and Stang, 2009), and as such these observations may be context specific, the 
ability of ligand concentration to alter receptor endocytosis, resulting in differential 
receptor sorting and signaling output is an excellent example of the impact trafficking has 
on RTK activity.  Furthermore, as this model represents a useful mechanism to finely 
regulate cell surface RTK levels in response to ligand concentration in a very rapid 
manner, and it may be important to other RTKs as well. Thus, while it was initially 
believed that signalling ended upon endocytosis and entry into the endosomal pathway, it 
is now recognised that internalisation is integrally linked to signalling, and that there even 
exist  specialized  proteins  and  compartments  within  this  pathway  specifically  for the 
production of  efficient  signaling  responses.   Ultimately, until the receptor is sorted into 
intraluminal vesicles, it has the opportunity to interact with a variety of downstream 
targets, many of which may be represented in higher concentrations at endsomes than at 
the cell membrane, and so receptor internalisation and trafficking represents an important 
component of active signalling. 
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Figure 1.21. Example of the impact of trafficking on signaling output.  
EGFR has been shown to be preferentially sorted to the recycling endosome following 
internalization through clathirin-coated pits. In contrast, EGFR that is internalized in a 
clathrin-independent manner has been observed to initiate increased signaling output 
through the MAPK pathway. Non-clathrin endocytosis has also been observed to be the 
primary mechanism of internalization for activated EGFR that is destined for 
degradation.  
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1.7. Downregulation and Malignancy 
A striking example of the power of naturally inefficient RTK downregulation is 
presented by a member of the EGFR group (also referred to as the ErbB group), ErbB2. 
The high potency of ErbB2 receptor action is in part, assured by its ineffective 
internalisation and degradation, and by its ability to slow down ligand-induced 
downregulation of other ErbB receptors in heterodimers (Haslekas et al., 2005; Lenferink 
et al., 1998; Wang et al., 1999; Worthylake et al., 1999). This results in highly active and 
robust signalling, which in pathological situations, drives malignant cell behaviour in a 
variety of tumours, including those of breast, ovarian, gastric, and lung origins (Baselga 
and Swain, 2009; Parachoniak and Park, 2012). The oncogenic potential that stems from 
inefficient ErbB2 downregulation, and from its ability to modify the internalisation and 
degradation of its signalling partners gives a strong indication of the biological 
importance of modulating the balance in these processes.  
Thus, disruption of Met receptor degradation, following activation by its ligand, 
HGF, leads to a sustained activation of the Ras-MAPK pathway and oncogenic 
transformation in non-small-cell lung cancer (Abella et al., 2005). Colony-stimulating 
factor-1 receptor mutations, which impair its internalisation and degradation, have been 
linked to myelodysplasia and acute myeloid leukemia (Ridge et al., 1990), and the 
mitogenic capacity of c-Kit receptor signalling is greatly enhanced in a mutant lacking a 
docking site for c-Cbl, a well-described regulator of receptor downregulation (Herbst et 
al., 1995).  
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Receptor downregulation can be impaired due to mutations of the receptor itself, as is 
the case for c-Kit, or, alternatively, can result from aberrations within the downregulation 
machinery. Cortactin is a protein that is involved in actin polymerisation at the cell 
periphery (Schafer et al., 2002), and has been linked to a regulatory role in both CCP 
dependent and independent endocytosis (Cao et al., 2003; Sauvonnet et al., 2005). 
Overexpression of cortactin has been observed in several cancer types, including invasive 
melanoma (Xu et al., 2010), breast cancer (Buday and Downward, 2007), head and neck 
squamous cell carcinomas (HNSCC) (Akervall et al., 1995), as well as colorectal cancer 
(Hirakawa et al., 2009), and is linked to increased metastatic behaviour (MacGrath and 
Koleske, 2012). This appears to be at least in part due to alterations to endocytosis of 
RTKs, as HNSCC cell lines with high expressions of cortactin exhibited reduced rates 
ligand-induced downregulation of EGFR compared to those with lower cortactin 
expression. Furthermore, when siRNA was used to reduce the levels of cortactin 
expression, the rate of EGFR downregulation correspondingly increased (Timpson et al., 
2005).  
Vps37, otherwise known as HCRP1 (hepatocellular carcinoma related protein 1), is a 
component of the ESCRT I machinery, and is required for EGFR degradation (Bache et 
al., 2004). In hepatocellular carcinoma the expression levels of Vps37 are significantly 
reduced relative to healthy tissue, and knock-down of Vps37 expression resulted in 
increased cancer cell proliferation (Xu et al., 2003). In agreement, reduced Vps37 
expression is associated with a poorer prognosis in breast (Xu et al., 2014), oral, and 
oropharyngeal cancer (Perisanidis et al., 2013). Furthermore, in ovarian cancer high 
EGFR or ErbB2 coupled with low Vps37 was found to have a strong negative impact on 
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overall patient survival, while patients with high levels of Vps37 were found to have a 
significantly better prognosis regardless of EGFR and ErbB2 expression levels, 
suggesting that Vps37 induced degradation of these receptors is important to attenuating 
their oncogenic signalling (Wittinger et al., 2011). This is supported by the observations 
that knock-down of Vps37 directly inhibits EGFR degradation following its activation, 
leading to an increase Erk1/2 phosphorylation in ovarian cancer cell lines (Wittinger et 
al., 2011).  
Point mutations of c-Cbl have been detected in samples from acute myeloid leukemia 
(AML) patients, and these mutants were found to be unable to bind to and ubiquitinate 
one of the known RTK drivers of this disease, FLT3 (FMS-like tyrosine kinase-3) (Abbas 
et al., 2008; Caligiuri et al., 2007; Sargin et al., 2007). The loss of c-Cbl mediated 
ubiquitination of FLT3 following its activation results in its impaired endocytosis as well 
as an increased duration of FLT3 signalling, and promoting cellular transformation 
(Sargin et al., 2007). 
 
1.8. Current Knowledge of Eph Receptor Downregulation 
As mentioned above, stimulation-induced receptor downregulation through 
internalization and subsequent targeted degradation play an important role in controlling 
cellular responses by both enhancing and suppressing cytoplasmic signaling (Platta and 
Stenmark, 2011). While these processes are well described for some receptor groups 
(Andersson, 2012; Parachoniak and Park, 2012; Platta and Stenmark, 2011; Sorkin and 
Goh, 2009), much less is understood about downregulation of Eph receptors. Currently, 
the available data on Eph receptor downregulation are not systematic, and imply that 
different Ephs may use very distinct mechanisms. As such, little can currently be 
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assumed regarding the downregulation of one receptor based upon observations made for 
a separate receptor, and any generalizations would likely be inaccurate. For example, 
ligand-induced downregulation of the EphA2 receptor is assured by its degradation in the 
lysosomal compartment (Boissier et al., 2013), while in contrast, EphA3 is internalised 
following its activation, but is not transported to lysosomes (Nievergall et al., 2012), and 
instead is degraded by proteasomal complexes (Sharfe et al., 2003).  While EphA2 can be 
internalised through macropinocytosis (Ha et al., 2014), activation with ephrin-A1 
increases its association with clathrin and dynamin, both of which are likely to be 
important to mediating ligand-induced receptor internalisation (Greene et al., 2014).  
Furthermore, EphA2 internalisation also appears to utilise members of the Rho family, as 
knock-down of the Rho family GEF, Tiam-1, leads to a reduction in EphA2 endocytosis 
(Boissier et al., 2013). EphA8 is ubiquitinated and internalised in response to ligand 
stimulation, and this appears to be regulated by interactions with the Rab5 GEF, RINL 
(Ras and Rab interactor-like), and the Anks family protein, Odin (Kajiho et al., 2012; 
Kim et al., 2010; Shin et al., 2007). EphA4 (Bouvier et al., 2010), EphA8 (Yoo et al., 
2010) and EphB1 (Parker et al., 2004) are endocytosed through CCPs following ligand 
stimulation, and internalized EphB1 and EphA8 appear to be degraded in the lysosomal 
compartment inside the cell (Fasen et al., 2008; Kajiho et al., 2012). In contrast, EphB2 
can be cleaved at the cell membrane by matrix-metalloproteases (Lin et al., 2008), and 
potentially other proteases, such as BACE (β-secretase) (Litterst et al., 2007). The C-
terminal fragment of cleaved EphB2 is subsequently processed by the presenilin 
dependent γ-secretase complex (Lin et al., 2008; Litterst et al., 2007), overall highlighting 
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the vastly different mechanisms Eph receptors are able to utilise to mediate receptor 
internalisation and degradation following ligand stimulation (Table 1.3).  
 
Table 1.3. KNOWN MEDIATORS OF EPH RECEPTOR DOWNREGULATION. 
Receptor Molecule Effect Source 
EphA2 c-Cbl, proteasome 
Interacts with EphA2 
following activation. 
Acts as an E3-ligase, 
facilitating 
ubiquitination of 
EphA2, leading to 
EphA2  proteasomal 
degradation. 
(Walker-Daniels et al., 
2003; Walker-Daniels 
et al., 2002) 
EphA4 
 Clathrin 
Forms vesicles in 
response to EphA4 
activation facilitating 
EphA4 internalisation. 
(Bouvier et al., 2010) 
EphA4 
Rab5 and Rin1 
Promote EphA4 
internalisation 
following its 
activation. 
(Deininger et al., 
2008) 
γ-secretase Cleaves EphA4 at the cell membrane. (Inoue et al., 2009) 
EphA8 
 
Rac-1, Tiam-1, and 
Clathrin 
Assist in the 
endocytosis of EphA8 
following ephrinA 
interaction. 
(Yoo et al., 2010) 
c-Cbl 
Ubiquitinates EphA8 
following ligand-
binding, inducing its 
internalization and 
degradation 
(Kim et al., 2010) 
Rab-5 and RINL 
RINL acts as a GEF for 
Rab-5. Involved in 
facilitating EphA8 
internalisation. 
(Kajiho et al., 2012) 
EphB1 Caveolin-1 
EphB1 associates with 
caveolin-1 following 
activation and 
localizes to caveolae. 
(Vihanto et al., 2006) 
EphB1 c-Cbl and lysosomal compartment 
c-Cbl ubiquitinates 
EphB1 following 
ligand activation, 
targeting EphB1 for 
lysosomal 
degradation. 
(Fasen et al., 2008) 
EphB2 
γ-secretase 
Cleaves EphB2 in 
response to ligand 
stimulation 
(Litterst et al., 2007) 
Proteasome 
Mediates EphB2 
degradation following 
ligand-induced 
internalisaiton. 
(Mann et al., 2003) 
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Receptor Molecule Effect Source 
EphB2 BACE 
Cleaves EphB2 in 
response to ligand-
stimualtion 
(Litterst et al., 2007) 
EphB4 
Ena/Vasp 
Proteins that are 
involved in regulating 
the actin cytoskeleton, 
implicated in EphB4 
internalisation. 
(Evans et al., 2007) 
Rac Required for receptor internalization. (Marston et al., 2003) 
 
 
In this situation, it is not a surprise that despite the recent accumulation of data that 
highlight an important role for one of Eph receptors, EphB6, in both normal physiology 
and in malignancy (Fox and Kandpal, 2009; Freywald et al., 2003; Luo et al., 2012; Luo 
et al., 2004; Maddigan et al., 2011; Tang et al., 2000; Truitt and Freywald, 2011; Truitt et 
al., 2010; Yu et al., 2010), the molecular mechanism of its downregulation has never 
been investigated. Such an investigation is especially interesting in light of the unusual 
nature of this protein, which is kinase-inactive, despite its association with the Eph group 
of RTKs (Matsuoka et al., 1997), and due to the lack of available information on the 
ligand-induced downregulation of kinase dead receptors in general.  Until now, 
downregulation of only one other kinase-deficient RTK, the ErbB3 receptor, has been 
dissected and yet even this remains not well understood, as multiple reports suggest that 
ErbB3 is internalisation- and downregulation- deficient, while some recent observations 
show that ErbB3 undergoes ubiquitination and is efficiently downregulated in response to 
ligand stimulation (Baulida et al., 1996; Cao et al., 2007; Chen et al., 1996; Daly et al., 
1997; Sak et al., 2013; Waterman et al., 1998).  
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1.9. Ligand Induced Downregulation of Kinase-Dead RTKs 
Initial studies into the downregulation of ErbB3 utilised a chimeric protein, 
composed of the EGFR extracellular domain fused to the intracellular domain of ErbB3. 
While it was found that the addition of EGF was able to rapidly induce phosphorylation 
of the ErbB3 chimera, a very low level of internalisation was observed relative to EGFR, 
and there was no significant alteration to the apparent rate of receptor degradation 
(Baulida et al., 1996). Additionally, experiments in breast cancer cells with endogenous 
ErbB3 expression consistently demonstrated a slower rate of ligand internalisation and 
reduced levels of cell-surface receptor removal for ligand-treated ErbB3, relative to 
EGFR (Baulida and Carpenter, 1997). Two other groups observed similar effects, where 
ligand treatment of ErbB3 resulted in its association with ErbB2 and phosphorylation, but 
failed to reduce overall ErbB3 protein levels (Chen et al., 1996; Daly et al., 1997). A 
more in depth study also found that ligand-induced ErbB3 endocytosis was relatively 
slow compared to EGFR, and that ErB3 was recycled back to the cell-surface following 
its internalisation, whereas EGFR was targeted for lysosomal degradation. The 
examination of ligand-binding affinities suggested that the ErbB3-ligand complex was 
more transient than that between EGF and EGFR, and thus rapid ligand dissociation 
following receptor internalisation was proposed to promote ErbB3 receptor recycling 
over degradation (Waterman et al., 1998). Additionally, it was also found that ligands of 
EGFR and ErbB3 were degraded by different mechanisms, where EGF appeared to rely 
on lysosomes for its degradation, while ErbB3 ligands did not (Waterman et al., 1998). In 
agreement, ErbB3 degradation following ubiquitination by Ndrp1 was shown to occur 
preferentially in proteasomal complexes rather than lysosomes (Qiu and Goldberg, 2002). 
However, more recent studies of ligand-induced ErbB3 degradation found that it in 
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contrast to previous observations, the receptor is indeed efficiently downregulated in 
response to ligand treatment, and that its degradation requires lysosomal activity (Cao et 
al., 2007). Further evidence for ligand-induced downregulation of ErbB3 was obtained by 
a separate group, who found that while ErbB3 is constitutively endocytosed in a clathrin-
dependent manner at a relatively high rate compared to EGFR (Sak et al., 2012), ligand 
treatment significantly increased its internalisation, as well as its degradation (Sak et al., 
2013). Interestingly, their observations suggest that while ErbB3 is downregulated 
efficiently in response to ligand, its interaction with ErbB2 has a potential to inhibit its 
ligand-induced downregulation (Sak et al., 2013), which may explain some of the 
discrepancies described for the ErbB3 receptor. Thus, while the ligand-induced 
downregulation of ErbB3 has been actively explored, the details are still unclear, and 
since the ligand-induced downregulation of any other RTK with an intrinsic deficiency in 
kinase activity has not been assessed, it is impossible to determine if these observations 
are relevant to other kinase-dead RTKs, or are unique to ErbB3.  
As two of the five known kinase-deficient RTKs, EphA10 and EphB6, belong to the 
Eph group of receptors (Aasheim et al., 2005b; Gurniak and Berg, 1996; Matsuoka et al., 
1997), it strongly suggests that they are likely to play important roles in modulating Eph 
receptor effects. Eph receptors play an essential role in a wide variety of biological 
functions, including embryo development and angiogenesis (Pitulescu and Adams, 2010), 
and have also been implicated in both positive and negative effects in malignancies (Xi et 
al., 2012). At present, little is known regarding the functions of EphA10, however, 
EphB6 is rapidly emerging as an important member of the Eph receptor group, 
influencing both normal biology and malignant behaviour in cancer cells (Truitt and 
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Freywald, 2011). Despite the important role that ligand-induced trafficking can play in 
receptor signalling, nothing is yet known about the downregulation of the kinase dead 
Eph receptors, EphA10, and EphB6. As EphB6 is known to be important to numerous 
processes, the mechanism of its ligand-induced downregulation is of particular interest, 
as this may be pivotal to EphB6 effects. Furthermore, an understanding of EphB6 
downregulation will give a better general understanding of the ligand-induced 
downregulation of kinase-dead RTKs in general, as the current knowledge is limited to 
but one receptor, and the observations are frequently inconsistent. 
 
1.10. Conclusion 
Ligand-induced internalisation is an essential mechanism utilised by cells to attenuate 
signals generated following ligand activation, acting as a gateway to receptor 
degradation, and also as a means to target receptors to the correct compartments for their 
proper interaction with downstream effectors and targets. Despite Eph receptors being the 
largest known family of RTKs, playing essential roles in both normal and cancer biology, 
the mechanisms of their ligand-induced downregulation have yet to be fully described, 
and based upon current knowledge, there appears to be important distinctions between 
receptors. Of note, the Eph family contains two kinase dead members, EphA10 and 
EphB6, and of these, EphB6 has been demonstrated to be important to several biological 
functions, including T-cell and thymus biology, blood pressure regulation, potential roles 
in pain signaling and osmotic regulation, and also in cancer, where it appears to act as a 
metastasis suppressor. Ligand-induced downregulation has only been described for one 
other kinase-deficient receptor, ErbB3, however the observations are inconsistent, and it 
is unclear if other kinase-deficient receptors will share any commonalities in these 
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mechanisms. Therefore, knowledge of the ligand-induced downregulation of EphB6 will 
expand understanding of the mechanisms utilized by kinase-deficient receptors in general 
for this process. Furthermore, as the pathways and mechanisms utilised by RTKs for their 
downregulation have been shown to have a profound influence on their overall signalling 
output, knowledge of the factors involved in this process for EphB6 will provide 
important insights into how the activity of this receptor is controlled, and as EphB6 
signaling is strongly anti-metastatic, could potentially offer opportunities for therapeutic 
interventions.  
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CHAPTER 2 
HYPOTHESIS AND OBJECTIVES 
Hypothesis 
1. The only kinase-dead receptor for which ligand-induced downregulation is 
currently described is ErbB3, and it is internalised and degraded following ligand 
stimulation. Furthermore, EphB6 is phosphorylated by kinase-active signalling 
partners in response to ligand stimulation, thus enabling it to interact with 
downstream signalling effectors, and therefore potentially also with components 
of the downregulation machinery. Based on all this, I hypothesized that EphB6 is 
actively downregulated in response to ligand stimulation.  
 
Objectives 
1. To determine if EphB6 is actively downregulated in response to ligand-
stimulation. 
 
2. If EphB6 is actively downregulated, to explore the mechanisms and pathways 
used by EphB6 during ligand-induced downregulation, and to compare ligand 
induced downregulation of kinase-deficient EphB6 to that of its kinase active 
signaling partner, EphB4. If EphB6 is not actively downregulated, to fully 
examine the impact it has on the mechanisms and pathways of downregulation 
utilised by its kinase-active signaling partners. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Antibodies 
Antibodies for Myc, Erk2, b-Tubulin, EphB4, Clathrin heavy-chain, EphB4, and 
Eps15 were from Santa Cruz Biotechnology, goat anti-human Fc (anti-hFc) was from 
Pierce Biotechnology, anti-EphB6 were from Santa Cruz, R&D Systems, and Sigma-
Aldrich, anti-Hsp90 was from StressGen, and Goat F(ab')2 Anti-Human IgG (Fc) FITC 
was from Beckman Coulter. Ephrin-B2-Fc and fluorescein labelled anti-sheep IgG were 
purchased from R&D Systems. Secondary antibodies linked to IR-dyes for Western 
blotting (anti-goat, anti-rabbit, anti-rat and anti-mouse) were purchased from Mandel 
Scientific. Anti-rat Alexafluor 594 was purchased from Cell Signalling. 
 
Table 3.1 LIST OF CHEMICALS AND SUPPLIERS 
Chemical Name Source 
Acrylamide Fisher 
Agarose Fermentas 
Ammonium persulfate Sigma 
Bleach Lavo 
Bromophenol blue Sigma 
DMSO Fisher 
EDTA Fisher 
Ethanol Fisher 
Formaldehyde Polysciences 
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Chemical Name Source 
Glacial Acetic acid EMD 
Glycerol Fisher 
Glycine Fisher 
HEPES Sigma 
Hydrogen chloride Fisher 
Igepal Sigma 
Isopropyl Alcohol Fisher 
LB Agar Sigma 
LB Broth Sigma 
Methanol Sigma 
Phenylmethanesulfonyl fluoride Sigma 
Phosphate Buffered Saline Fisher 
Ponceau Sigma 
Potassium phosphate EMD 
Saponin Sigma 
Sodium Azide Fluka 
Sodium chloride Fisher 
Sodium Dodecyl Sulfate Sigma 
Sodium hydroxide Fisher 
Sodium Orthovanadate Fisher 
Sodium phosphate dibasic anhydrous Fisher 
Trizma base Sigma 
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Chemical Name Source 
Triton-X Sigma 
Tween Sigma 
β-Mercaptoethanol Sigma 
 
 
3.2 Expression Constructs and shRNA 
The wild-type EphB6 receptor and EGFP (enhanced green fluorescent protein)-
tagged EphB6 constructs were kindly provided by Dr. C.M. Roifman (Sick Children’s 
Hospital, Toronto, ON). EphB4 and EphB4-EGFP constructs were purchased from 
OriGene Technologies, Inc. Myc-tagged EphB4 was generated by polymerase chain 
reaction (PCR) utilising the forward primer 5’-cgcggatcccgccatggagctccgggtgctgctctg-3’ 
and the reverse primer 5’-
ccggaattcttattaattcagatcctcttctgagatgagtttttgttcgtactgcggggccggtcctcctg-3’. Myc-tagged 
EphB6 and an EphB6 mutant, lacking the cytoplasmic domain (ΔEphB6) and a tyrosine 
to phenylalanine substitution mutant of EphB6 (EphB6 Y->F) were described previously 
(Freywald et al., 2003; Freywald et al., 2002; Truitt et al., 2010). Clathrin heavy chain 
(CHC) shRNA (short hairpin ribonucleic acid) lentiviral particles and control non-
silencing shRNA were purchased from Santa Cruz. Dr. Anderson from the University of 
Saskatchewan provided HA-tagged Rab5 S34N. An Eps15 mutant, DIII, as well as a 
corresponding control peptide, were provided by Dr. Benmerah from the Institut Imagine, 
Paris, France.  
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3.3 Cell Culture and Generation of Stable Cell Lines 
3.3.1 Electroporation 
Stable cell lines of HEK-293 (human embryonic kidney-293) cells [American Type 
Culture Collection (ATCC)], expressing either Myc-tagged EphB4 (HEK-B4-M), EphB6 
(HEK-B6), ΔEphB6 (HEK-ΔEphB6), EphB6(Y->F) (HEK-EphB6(Y->F)), EGFP-tagged 
EphB4 (HEK-B4-EGFP), or Myc-tagged EphB6 (HEK-B6-M) were generated by 
electroporation using 20 mg of DNA (70 ms, 140 V, ECM 830 electroporator; Harvard 
Apparatus Inc.). Cells were allowed to rest overnight and were then subjected to G418 
(1mg/ml) (Calbiochem) selection for 30 days. Cells were lysed and screened for Eph 
receptor expression by Western blotting.  
 
3.3.2 Cell Culture 
All HEK-293 based cell lines were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, HyClone), 10% fetal bovine serum (FBS, Gibco), and 1 mM sodium pyruvate 
(SP, HyClone). MDA-MB-231 (ATCC) were cultured as HEK-293 with the addition of 
1% Pen Strep (Gibco). Hcc-70 (ATCC) were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 (HyClone) medium with 10% FBS and 0.5% Pen Strep. Cells were grown 
to 80-90% confluence prior to re-plating. Cells were kept at 37oC and 5% CO2 for 
expansion and during stimulations. 
 
3.3.3 Lentiviral Transducdtion 
Stable cell lines with CHC knock-down were generated based on the HEK-B6 or 
HEK-B4-M cell lines, using CHC shRNA lentiviral particles (Santa Cruz Biotechnology) 
according to the manufacturer’s instructions.  Briefly: cells at 50% confluence were 
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incubated with 10 MOI (multiplicity of infection) of lentiviral particles in the presence of 
2 mg/ml Polybrene (Sigma) for 11 h. Cells were grown for an additional 24 h in normal 
growth media prior to selection with 5 mg/ml puromycin (VWR, Mississauga, ON). 
 
3.3.4 Transient Transfections 
Transient transfections of cells were performed using 3.7 ml of Metafectene Pro 
purchased from BionTex (San Diego, CA), and 3 mg of construct DNA for 
approximately 1 x 106 cells. Cells were incubated at 37oC , 5% CO2 for 5 h in the 
presence of the construct, Metafectene Pro and 400 ml OptiMEM  (Invitrogen), and then 
returned to normal growth conditions. 
  
3.4 Cell Stimulations 
In all experiments involving stimulation, cells were treated with 1 µg/ml soluble 
ephrin-B2-Fc precomplexed with 1.5µg/ml anti-human-Fc in serum free media. 
Precomplexed human IgG (Sigma) was used as a specificity control for the Fc portion of 
the ephrin-B2-Fc (eB2) fusion protein. In some experiments, cells were preincubated at 
37oC with 80 µM dynasore (Santa Cruz) for 1 h (Garcia Lopez et al., 2009), 100 nM 
chloroquine for 2 h (Litterst et al., 2007), or 25 mM NH4Cl for 1 h  (Jia et al., 2009),  as 
indicated in figure legends. Inhibitor presence was maintained throughout treatment with 
ephrin-B2. Geldanamycin (10 µM, Santa Cruz) was used with no prior incubation 
(Whitesell et al., 1994). Matching solvents were used as controls. 
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3.5 Flow Cytometry 
3.5.1 Cell-Surface Expression  
 
 To confirm cell surface expression of EphB6 mutants, cells were collected with 2 
mM EDTA, washed in serum free media, and incubated with anti-EphB6 or matching 
IgG control (R&D Systems) for 40 min on ice. Labelled cells were washed twice with 
serum free media, and incubated with FITC (Fluorescein isothiocyanate) conjugated 
secondary antibody for 30 min on ice in the dark, washed twice with serum free media, 
and suspended in PBS (phosphate buffered saline) for analysis.  
 
3.5.2 Ligand Internalisation Assay 
 
For the ligand internalisation assay cells were stimulated for 30 min with 1 µg/ml 
eB2, washed with acidic PBS (0.2 M Acetic acid, pH 3.0) for 5 min 3 times, collected 
with 2 mM EDTA (Ethylenediaminetetraacetic acid), and fixed with 1% formaldehyde in 
PBS, or fixed and permeabilised with 0.1% Triton-X-100 (Sigma). Cells were stained 
with anti-human IgG (Fc)-FITC.  
 In all experiments, staining was monitored by flow-cytometry using a Coulter 
Epics XL or a MACSQuant VYB  (Miltenyi Biotec) Flow Cytometer. Results were 
analysed with the FlowJo software.  
 
3.6 Cell Lysis, Immunoprecipitation and Western Blotting 
3.6.1 Cell Lysis 
Following stimulation cells were washed once in serum free media and once with 
PBS to remove excess ligand and ions. Cells were detached from the surface of the plate 
in the lysis buffer (0.1 M EDTA, 0.3 M Tris, 0.1 M NaCl, 6 mM PMSF 
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(phenylmethylsulfonyl fluoride) and 3 mM sodium ortho-vanadate), and transferred to a 
1.5 ml tube.  Following a 20 min incubation period on ice, cell lysates were centrifuged at 
9500 x g for 15 min to remove the nuclear fraction and debris. The resulting supernatant 
was transferred to a fresh 1.5 ml tube and mixed with 2x loading buffer (0.5 M Tris, 0.5% 
SDS, 0.1% 2-mercaptoethanol). 
 
3.6.2 Immunoprecipitation 
For immunoprecipitation, cell lysates were prepared as described above, omitting the 
addition of the 2x loading buffer. Instead, 20 µl of Protein G Sepharose beads (GE 
Healthcare) and 3 µg of the required antibody were added, and samples were rotated at 
4oC overnight. Beads were washed three times in lysis buffer, and resuspended in 35 µl 
of 2x loading buffer.  
 
3.6.3 Western Blotting 
Samples were resolved by SDS-PAGE (sodium dodecyl sulfate- polyacrylamide gel 
electrophoresis), and transferred to a nitrocellulose membrane (Amersham) for Western 
blotting. The membrane was blocked with 7% non-fat dried milk (Bio-Rad; Mississauga, 
ON) and incubated with gentle agitation in primary antibodies overnight. Membranes 
were washed 3 times in PBS with 0.1% Tween (Sigma-Aldrich) and incubated with 
secondary antibodies in PBS with 5% milk and 0.1% Tween, with gentle agitation, for 1 
h. Excess secondary antibody was removed by washing with PBS, and images were 
acquired using the LI-COR Odyssey imaging system. Densitometry analysis was 
performed using Carestream software (Carestream Health). 
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3.7 Confocal Microscopy 
3.7.1 Live Cell Imaging 
HEK-293 cells were plated on glass bottom culture dishes (MatTek) at low density 
(~10%), and allowed to adhere for 24 h. Seeded cells were transfected with EphB6-EGFP 
or EphB4-EGFP cDNAs (complementary DNA) and cultured 72 h to facilitate optimal 
expression of the constructs (Rice et al., 1991). To examine lysosomal colocalisation, 
transfected cells were stained for 30 min with 60 nM LysoTracker Red DND-99 
(Invitrogen) in serum-free DMEM, and washed twice with DMEM prior to ephrin-B2 
stimulation. To reduce background fluorescence, cells were imaged in phenol-red free 
DMEM (Fisher), and media pH was buffered with 25 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) (Sigma). Cells were visualized using an Olympus FV1000 
confocal microscope, and live cells were imaged at 40X magnification. Experiments took 
place in a heated imaging chamber maintained at 37oC, with images collected prior to, 
and every 1 or 2 min for 20 min following the addition of ephrin-B2. 
 
3.7.2 Immunofluorescence Staining 
To monitor Hsp90 association, HEK-293 cells were seeded at low density on glass 
coverslips (Fisher) pre-coated with poly-L-lysine (Trevigen), transfected with EphB6-
EGFP or EphB4-EGFP construct, and stimulated 72 h post transfection. Cells were 
treated with ligand or hIgG for 20 min and fixed in 4% formaldehyde/PBS on ice for 20 
min. To facilitate staining and reduce background, fixed cells were permeabilised and 
blocked for 1h at room temperature in blocking buffer (PBS containing 5% normal horse 
serum (Sigma), 1% bovine serum albumin (Sigma), and 0.1% saponin (Sigma)), and 
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incubated with an antibody of interest in blocking buffer for 48-72 h with gentle agitation 
at 4oC. Incubation for 1 h with matching Alexafluor-conjugated antibodies was used for 
detection, and excess antibody was removed by washing 3 times with blocking buffer. 
ProLong Gold antifade reagent with DAPI (4',6-diamidino-2-phenylindole) (Invitrogen) 
was used as a mounting medium and provided nuclear staining. Cells were visualized 
using an Olympus FV1000 confocal microscope. Fixed cells were imaged using a 60X 
oil-immersion lens.  
 
3.7.3 Image Processing 
All images have been subjected to deconvolution using Auto-Deblur (AutoQuant X3, 
Media Cybernetics).  Images were processed using the Image J software (McMaster 
Biophotonics) and Adobe Photoshop CS6 (Adobe Systems Inc.). 3D-reconstruction was 
performed using the IMARIS 7.4.2 software (Bitplane). Pearson’s correlation coefficients 
were determined using FIJI software (2012). 
 
3.8 Statistical Analysis 
 All experiments were performed at minimum three times. For experiments 
involving Western blotting, bands were quantified by densitometry, the average and 
standard deviation between all replicates was determined. For experiments involving 
confocal microscopy, colocalisation was assessed using Pearson’s correlation coefficient, 
as this method is widely employed as means to measure the level of colocalisation 
between two fluorophores (Dunn et al., 2011). Pearson’s correlation coefficient was 
determined using Image J software, and the values from at least 50 randomly selected 
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cells representing at least three independent experiments were averaged.  P-values were 
calculated using the students t. test in GraphPad Prism software. 
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CHAPTER 4 
RESULTS 
4.1. The EphB6 Receptor is Actively Downregulated in Response to Ligand Stimulation 
To assess the ligand-induced downregulation of the kinase-deficient EphB6 receptor, we 
compared it with the downregulation of its kinase-active signalling partner, EphB4 (Truitt et al., 
2010). To do this, we generated cell lines with stable expression of EphB6 (HEK-B6) or EphB4 
(HEK-B4-M) by transfecting human embryonic kidney cells, HEK-293, a cell line that is 
commonly used as a model for this type of investigation, and contains all necessary cellular 
machinery to evaluate downregulation (Cui et al., 2009; Gironacci et al., 2011; Stautz et al., 
2012; Thompson and Whistler, 2011; Yancoski et al., 2012).  A Myc-tagged version of EphB4 
was used in these experiments to overcome a relatively low sensitivity of available anti-EphB4 
antibodies at the onset of the study (Fig. 4.1 A&B). Cells were stimulated for up to 3 hours with 
a common ligand of the EphB6 and EphB4 receptors, ephrin-B2. As an ephrin-B2-Fc fusion 
protein was used for the stimulation, human IgG (hIgG) was applied as a specificity control for 
the human-Fc portion of this chimera. Following previously reported models related to other Eph 
receptors, all stimulations were performed at 1 µg/ml of ephrin-B2 (Fasen et al., 2008; Vihanto 
et al., 2006). Receptor downregulation was monitored by Western blotting.  These experiments 
showed that kinase-dead EphB6 and kinase-active EphB4 are efficiently downregulated, with 
both receptors being degraded following their activation (Fig. 4.2 A&B). EphB6 downregulation 
was also monitored in MDA-MB-231 breast cancer cells with restored EphB6 expression, MDA-
B6-M, which express Myc-tagged EphB6 (described in our previous work (Truitt et al., 2010)), 
and in a breast cancer cell line, HCC-70, that expresses this receptor endogenously  (Fig. 4.3 
A&B).   These   results   indicate   that    our  initial    observations    were    not    restricted     to  
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Figure 4.1. Expression of EphB6 and EphB4 in HEK-293 cells. 
 A and B) Human embryonic kidney cells (HEK-293), were electroporated with the pcDNA3 
expression vector encoding EphB6 (HEK-B6) (A), or Myc-tagged EphB4 (HEK-B4-M) (B). 
Cells were cultured in G418 (1 mg/ml) selection medium for 30 days and receptor expression 
was analyzed by Western blotting with anti-EphB6 or anti-Myc. Cells mock-transfected with the 
empty pcDNA3 expression vector (HEK-pc3) were used as a specificity control. HEK-293 cells 
transiently transfected with EphB6 or Myc-tagged EphB4 cDNAs were used as a positive control 
(P.C.). Western blotting of different slices of the same membranes with anti-Erk2 was used as 
loading control. 
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Figure 4.2. EphB6 and EphB4 are downregulated in response to ligand stimulation. 
 A) HEK-B6 cells were stimulated for the indicated time periods at 37oC with 1 µg/ml of ephrin-
B2-Fc (eB2). EphB6 downregulation was assessed by Western blotting with anti-EphB6 and gel 
loading was monitored by Western blotting with anti-Erk2. In all receptor downregulation 
experiments, unstimulated cells (-) were treated with human IgG (hIgG) for time periods 
matching the longest eB2 stimulation, as a specificity control for the Fc portion of the eB2 fusion 
protein. The results of Western blotting were quantitated by densitometry.  EphB6 
quantifications were normalized on matching Erk2 loading controls and plotted as a percentage 
relative to the unstimulated control (%EphB6/hIgG). B) HEK-B4-M cells were treated as in (A). 
EphB4 presence was monitored by Western blotting with anti-Myc and receptor downregulation 
was assessed and presented as in (A). All Western blot panels in this figure represent one of at 
least three independent experiments. Each graph summarises the analysis of at least three 
independent experiments, bars, SD. *, P < 0.05, Student's t test, for indicated points and 
corresponding controls as shown. 
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Figure 4.3. EphB6 is actively downregulated in response to ligand stimulation in breast 
cancer cells.  
A) MDA-MB-231 cells with induced EphB6 expression (MDA-B6-M) (Truitt et al., 2010) were 
stimulated with eB2 and EphB6 downregulation was monitored and assessed as in (Fig. 4.2 A). 
B) HCC-70 breast cancer cells were treated with eB2 and EphB6 downregulation was monitored 
as in (Fig. 4.2 A). All Western blot panels represent one of at least three independent 
experiments. Each graph in this figure summarizes the analysis of three independent 
experiments, bars, SD. *, P < 0.05, Student's t test, for indicated points and corresponding 
controls. In all downregulation experiments, unstimulated cells were treated with hIgG as a 
specificity control. 
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HEK-293, and are relevant to the mechanism acting in other cell types, including human breast 
cancer cells.  
One of the means by which the ErbB2 receptor imparts its biological effects is through a 
negative impact on the downregulation of its signalling partners (Haslekas et al., 2005; Lenferink 
et al., 1998; Wang et al., 1999; Worthylake et al., 1999). To determine if EphB6 also relies on 
this mode of action, we examined if EphB6 modulates EphB4 downregulation, as this receptor 
specifically has been observed to show altered responses in the presence of EphB6 (Truitt et al., 
2010). EphB6 was transiently co-expressed in HEK-B4-M cells and ephrin-B2-induced EphB4 
downregulation was monitored (Fig. 4.4) However, no consistent inhibition of EphB4 removal 
was observed, suggesting that EphB6 does not act by reducing the efficiency of downregulation 
of its signalling partners. Interestingly, we consistently could not observe downregulation of the 
EphB6 receptor in these experiments, most likely due to the extremely high level of continuous 
EphB6 production in the transient expression model. Overall, these data demonstrate that the 
kinase-dead EphB6 receptor is efficiently downregulated in response to ligand stimulation in 
multiple cell types, and indicate that it is unlikely to function by suppressing downregulation of 
its kinase-active relatives.  
 
4.2. EphB6 Receptor Downregulation Depends on the Functional Properties of its 
Cytoplasmic Domain 
 As EphB4 acts as EphB6 partner and assures initiation of ligand-induced cytoplasmic 
signalling by this kinase-dead receptor (Truitt et al., 2010), we transiently transfected HEK-B6 
cells with EphB4-encoding cDNA to examine if EphB4 presence would increase the rate of 
EphB6 downregulation.  Surprisingly, no enhancement in ligand-initiated EphB6 elimination 
was observed   in HEK-B6 cells co-expressing the EphB4 receptor  (Fig. 4.5).  
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Figure 4.4. EphB6 does not alter the rate of EphB4 downregulation.  
HEK-B4-M cells were transiently transfected with EphB6 or mock-transfected with the pcDNA3 
expression vector and EphB4 downregulation was examined as in (Fig. 4.2 A). EphB6 
expression was confirmed by Western blotting with anti-EphB6. The Western blot panels 
represent one of three independent experiments. The graph in this figure summarises the analysis 
of three independent experiments, bars, SD. *, P < 0.05, Student's t test, for indicated points and 
corresponding controls. Statistical analysis revealed no significant difference in the rates of eB2-
induced EphB4 removal between pcDNA3- or EphB6- transfected cells at any time point 
monitored. Unstimulated cells were treated with hIgG as a specificity control. 
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Figure 4.5. EphB4 presence does not alter the rate of EphB6 removal in response to ligand 
stimulation.   
 HEK-B6 cells were transfected with EphB4-encoding pcDNA3 or mock-transfected as indicated 
and EphB6 downregulation was analyzed as in (Fig. 4.2 A). EphB4 expression was confirmed 
with anti-EphB4. All Western blot panels in this figure represent one of three independent 
experiments. The graph summarises the analysis of three independent experiments, bars, SD. *, P 
< 0.05, Student's t test, for indicated points and corresponding controls as shown. Statistical 
analysis revealed no significant difference in the rates of eB2-induced EphB6 removal between 
pcDNA3- or EphB4- transfected cells at any time point monitored. Unstimulated cells were 
treated with hIgG as a specificity control. 
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Figure 4.6. EphB6 mutants, ΔEphB6 and EphB6 (Y->F) are expressed on the cell surface. 
A and B) HEK-293 cells with stable expression of an EphB6 mutant lacking the cytoplasmic 
domain (A) (HEK-ΔEphB6) or a tyrosine-deficient EphB6 mutant with all cytoplasmic tyrosine 
residues mutated to phenylalanine (B) (HEK-EphB6 (Y->F)) were generated as in (Fig. 4.1 A). 
HEK-ΔEphB6 and HEK-EphB6 (Y->F) cells were stained with anti-EphB6 and FITC-
conjugated secondary antibodies. Staining with a matching IgG control and staining of mock-
transfected HEK-pc3 cells were used as specificity controls in each experiment. Cell debris were 
gated out and cell staining was analysed by flow cytometry. Panels represent one of three 
independent experiments. 
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Figure 4.7. EphB6 downregulation depends on its functional cytoplasmic domain. 
A) HEK-B6 and HEK-ΔEphB6 cells were stimulated with eB2 for the indicated time periods and 
receptor downregulation was monitored and assessed as in (Fig. 4.2 A). B) HEK-EphB6 (Y->F) 
downregulation was analyzed as in (Fig. 4.2 A). HEK-B6 cells were used as a control. Each 
graph summarises the analysis of three independent experiments, bars, SD. *, P < 0.05, Student's 
t test, for indicated points and corresponding controls, as shown. All Western blot panels in this 
figure represent one of three independent experiments. In all downregulation experiments, 
unstimulated cells were treated with hIgG as a specificity control. 
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This observation prompted us to examine the necessity of EphB6 interactions with 
cytoplasmic signalling molecules for its downregulation. To exclude the possibility that ligand-
induced complexing of the EphB6 receptor on the cell membrane could be sufficient to trigger its 
removal, we took advantage of a previously described cytoplasmic domain deletion mutant of 
EphB6, ΔEphB6 (Truitt et al., 2010), which completely lacks the cytoplasmic portion. Although 
our flow cytometry analysis revealed that ΔEphB6 is successfully delivered to the cell membrane 
(Fig. 4.6), this mutation completely abolished EphB6 downregulation (Fig. 4.7 A), indicating 
that interactions with cytoplasmic molecules are likely to play a crucial role in EphB6 ligand-
induced elimination. This observation is conceptually interesting, as a cytoplasmic domain 
deletion mutant of the kinase-dead ErbB3 receptor has been shown to undergo ligand-induced 
internalisation (Waterman et al., 1998).  
To further clarify the importance of the fully-functional cytoplasmic domain for EphB6 
downregulation, a previously generated EphB6 mutant with all tyrosine residues in its 
cytoplasmic domain substituted for phenylalanines (EphB6 Y->F) (Truitt et al., 2010), was 
expressed in HEK-293 cells (Fig. 4.6). Interestingly, no downregulation of this mutant was 
observed (Fig. 4.7 B), confirming that intact cytoplasmic signaling motifs are required for 
EphB6 downregulation.  
 
4.3. EphB6 and EphB4 Downregulation is Preceded by Their Internalisation Through 
Clathrin-Coated Pits 
To further follow the route leading to EphB6 and EphB4 downregulation, we examined if 
EphB6 and EphB4 are internalised prior to their degradation. HEK-B6 or HEK-B4-M cells were 
treated with ephrin-B2-Fc, washed with acidic PBS to remove receptor-bound ligand from the  
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cell surface (as previously described (Olwill et al., 2013)), fixed with formaldehyde, or fixed and 
permeabilised with Triton-X-100. To detect ligand co-internalized with the receptors, cells were 
stained with anti-Fc-FITC and analyzed by flow cytometry. A stronger staining was consistently 
observed in permeabilised cells, indicating that receptor-ligand complexes were efficiently 
internalised (Fig. 4.8 A, B &C). No internalisation-related staining could be observed in control 
mock-transfected cells (HEK-pc3), confirming that the observed response was specific to EphB6 
and EphB4 receptors. 
The final step of internalisation culminates in pinching off the endocytic vesicle from the 
cell membrane, and this step is frequently controlled by a large GTPase, dynamin (Ferguson and 
De Camilli, 2012). The requirement for dynamin action for EphB6 and EphB4 internalisation 
was assessed by using a dynamin inhibitor, dynasore, that blocks the GTPase activity of 
dynamin, that plays a crucial role in membrane scission (Macia et al., 2006; Thompson and 
McNiven, 2006). Indeed, degradation of both EphB6 and EphB4 was reduced when they were 
stimulated with ephrin-B2 in the presence of dynasore (Fig. 4.9 A&B), further confirming the 
importance of internalisation for the downregulation of these receptors. In some experiments, 
increased EphB6 receptor levels could be observed in the presence of dynasore, indicating that 
dynamin is also involved in mediating basal, ligand-independent EphB6 degradation.  
In response to ligand stimulation, RTKs are often internalised through clathrin-coated pits 
(CCPs), structures formed on the inner surface of the cell membrane by a complex of proteins, 
including clathrin (Doherty and McMahon, 2009). However some Eph receptors, including 
EphB1 and EphA2, have been shown to interact with caveolin-1, a protein associated with 
another endocytic membrane structure, caveolae (Sainz-Jaspeado et al., 2013; Vihanto et al., 
2006) . To examine if EphB6 and EphB4 preferentially use the CCP-mediated gateway, we took 
 O. Allonby 
 
 120 
 
 
 
 
 
Figure 4.8. EphB6 and EphB4 are internalised in response to ligand stimulation. 
A) HEK-pc3, B)HEK-B6 or C) HEK-B4-M cells were stimulated for 30 min with 1 µg/ml of 
eB2, washed with acidic PBS (pH 3.0) for 5 min 3 times, collected with 2 mM EDTA, and fixed 
with 1% formaldehyde in PBS (red) or fixed and permeabilized with 0.1% Triton-X-100 (blue). 
Cells were stained with FITC-labelled anti-human Fc antibody, and the ligand-receptor complex 
was detected by flow cytometry. Results were analyzed with the FlowJo software. All panels in 
this figure represent one of at least three independent experiments.  
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Figure 4.9. EphB6 and EphB4 ligand-induced downregulation depends on dynamin-
activity.  
A) HEK-B6 cells were pre-treated with 80 µM of a dynamin inhibitor, dynasore, or a matching 
volume of DMSO as a solvent control, for 1 h and stimulated with eB2 for the indicated time 
periods. EphB6 downregulation was assessed and presented as in (Fig. 4.2 A). B) HEK-B4-M 
cells were treated as in (A) and EphB4 downregulation was monitored as in (Fig. 4.2 A). All 
Western blot panels in this figure represent one of at least three independent experiments. Each 
graph summarises the analysis of at least three independent experiments, bars, SD. *, P < 0.05, 
Student's t test, for indicated points and corresponding controls, as shown. In all downregulation 
experiments, unstimulated cells were treated with hIgG as a specificity control. 
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advantage of a previously described dominant-negative mutant of the Eps15 adaptor protein, 
DIII, (Benmerah et al., 1998), as Eps15 is actively involved in CCP-dependent endocytosis 
(Benmerah et al., 1998; Benmerah et al., 2000; Parachoniak and Park, 2009). This mutant lacks 
all Eps homology (EH) domains that target it to CCPs and represents only the DIII domain 
responsible for binding to the clathrin adaptor protein, AP-2.  DIII prevents wild-type Eps15 
from interacting with AP-2, which is required for receptor internalisation through CCPs, and has 
been shown to block CCP formation (Benmerah et al., 1998; Benmerah et al., 2000). In 
agreement, the stimulation-initiated downregulation was strongly reduced for both EphB4 and 
EphB6, when this mutant was expressed (Fig. 4.10 A-D), strongly implicating CCP in the 
internalisation and subsequent downregulation of these receptors. In these experiments, the 
extent of DIII effects matched well the efficiency of its action reported by other groups 
(Benmerah et al., 1999). To further verify the role of CCP-mediated internalisation in EphB4 and 
EphB6 downregulation, we partially silenced the expression of the clathrin heavy chain (CHC) in 
HEK-B6 and HEK-B4-M cells with CHC-targeting shRNA, and as expected, this decrease in 
CHC expression greatly reduced ligand-triggered receptor removal (Fig. 4.11 A-D). Overall, 
these data imply that both EphB4 and EphB6 are internalized following ligand treatment, and 
rely on CCP-dependent internalisation for their downregulation.   
 
4.4. Both EphB6 and EphB4 are Degraded in the Lysosomal Compartment 
Following activation and internalisation, a significant portion of receptor molecules are destined 
for degradation, which is often performed in the lysosomal compartment (Clague and Urbe, 
2010). We  monitored EphB6 and EphB4 ligand-induced re-localisation  into these organelles in 
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Figure 4.10. A dominant-negative mutant of Eps15 impairs EphB6 and EphB4 
downregulation.  
A) HEK-B6 cells were transfected with a dominant-negative mutant of Eps15 (DIII) or an 
irrelevant cDNA as a control and stimulated for the indicated time periods with eB2. EphB6 
downregulation was monitored and assessed as in (Fig. 4.2 A). B) DIII expression in samples 
from (A) was examined by Western blotting with anti-Eps15; Western blotting with anti-Erk2 
was used as a loading control. C) HEK-B4-M cells were transfected and treated as in (A), and 
EphB4 downregulation was analyzed and presented as in (Fig. 4.2 A). D) DIII expression in 
samples from panel (C) was assessed as in (B). Each graph summarises the analysis of at least 
three independent experiments, bars, SD. *, P < 0.05, Student's t test, for indicated points and 
corresponding controls as shown. In all downregulation experiments, unstimulated cells were 
treated with hIgG as a specificity control. 
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Figure 4.11. EphB6 and EphB4 downregulation is clathrin-dependent.  
A) HEK-B6 cells were transduced with shRNA targeting clathrin heavy-chain (CHC shRNA), or 
non-silencing shRNA (ns shRNA) in the presence of 5 µg/ml of Polybrene overnight, and placed 
on puromycin selection (2 µg/ml) for 3 days. Selected cells were stimulated with eB2 for the 
indicated time periods and EphB6 downregulation was examined as in (Fig. 4.2 A). B) CHC 
expression in samples from panel (A) was monitored with anti-CHC. C) HEK-B4-M cells were 
transfected and treated as in (A) and EphB4 downregulation was assessed as in (Fig. 4.2 A). D) 
CHC levels for panel (C) were monitored as in (B). All Western blot panels in this figure 
represent one of at least three independent experiments. Each graph summarises the analysis of 
at least three independent experiments, bars, SD. *, P < 0.05, Student's t test, for indicated points 
and corresponding controls as shown. In all downregulation experiments, unstimulated cells 
were treated with hIgG as a specificity control. 
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cells stained with the lysosomal-specific dye, LysoTracker Red (Chazotte, 2011) (Fig. 4.12 
A&B, Fig. 4.13 & 4.14). Interestingly, a strong increase in the localisation of EphB6 and EphB4 
in lysosomes was observed following ephrin-B2 treatment, suggesting that ligand-induced 
receptor degradation likely happened in the lysosomal compartment. To assess this possibility, 
HEK-B6 and HEK-B4-M were treated with the lysosomal inhibitors,  chloroquine and 
ammonium chloride (Amenta and Brocher, 1980; Poole et al., 1977). These chemicals prevent 
acidification of the lysosomes, and therefore, interfere with proper functioning of enzymes 
contained there (Wibo and Poole, 1974). The ligand-induced degradation of both EphB6 and 
EphB4 was strongly suppressed by these inhibitors, thereby confirming a central role for the 
lysosomal compartment in their downregulation (Fig. 4.15 A-D). 
Trafficking of internalised receptors from the plasma membrane to lysosomes is in part, 
mediated by early endosomes that are actively regulated by the Rab5 GTPase (Huotari and 
Helenius, 2011).  In agreement, EphB6 and EphB4 downregulation was greatly impaired in the 
presence of a Rab5 dominant-negative mutant, Rab5 S34N (Volpicelli et al., 2001) (Fig. 4.16 
A&B), suggesting that the endosomal route is involved in targeting EphB6 and EphB4 for 
degradation.  
In sum, our observations show that the kinase-deficient EphB6, and kinase-active EphB4 
receptors are efficiently downregulated in response to ligand stimulation.  Both receptors follow 
the same pathway in their ligand-induced internalisation, trafficking and degradation, relying on 
CCPs for internalisation, dynamin for membrane scission and on Rab5 for cytoplasmic 
trafficking, whereas their degradation is carried out in the lysosomal compartment. 
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Figure 4.12. In response to ligand stimulation, EphB6 and EphB4 colocalise with the 
lysosomal compartment.  
A) HEK-293 cells were seeded onto glass-bottomed plates, transfected with cDNA encoding an 
EphB6-EGFP fusion protein, and cultured for 72 h. Cells were stained with 60 nM LysoTracker 
Red DND99 for 30 min, washed twice with phenol red-free media, and stimulated at 37oC for the 
indicated time periods. Cells were visualized at 40X magnification with an Olympus FV 1000 
confocal microscope prior to, and at each minute following the addition of eB2 (1 µg/ml) for a 
total of 20 min. Images were deconvoluted using AutoQuant X3. Scale bar is equal to 10 µm. B) 
HEK-293 cells  expressing EphB4-EGFP (HEK-B4-EGFP) were seeded, stained, treated, and 
visualized as in (A). In both A and B, graphs represent quantifications of colocalisation of 
LysoTracker Red with EphB6 or EphB4 using Pearson’s correlation coefficient. Pearson’s 
coefficient was determined using FIJI software, and values shown represent values obtained 
from at least 50 cells selected from 3 independent experiments for each receptor. ***, P < 2 X 
10-6.   
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Figure 4.13. EphB6 colocalises with the lysosomal compartment following ephrin-B2 
treatment. 
HEK-293 cells were seeded onto glass-bottomed plates, transfected with cDNA encoding an 
EphB6-EGFP fusion protein, and cultured for 72 h. Cells were stained with 60 nM LysoTracker 
Red DND99 for 30 min, washed twice with phenol red-free media, and stimulated at 37oC for the 
indicated time periods. Cells were visualized at 40X magnification with an Olympus FV 1000 
confocal microscope prior to, and at each minute following the addition of eB2 (1mg/ml) for a 
total of 20 min. Images were deconvoluted using AutoQuant X3. Images represent one of three 
independent experiments. 
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Figure 4.14. Ephrin-B2 promotes EphB4 colocalisation with the lysosomal compartment. 
 HEK-B4-EGFP cells were seeded onto glass-bottomed plates, and cultured for 72 h. Cells were 
stained with 60 nM LysoTracker Red DND99 for 30 min, washed twice with phenol red-free 
media, and stimulated at 37oC for the indicated time periods. Cells were treated and visualized as 
in (Fig 4.12 A). Images were deconvoluted using AutoQuant X3. Images represent one of three 
independent experiments. 
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Figure 4.15. EphB6 and EphB4 are degraded in the lysosomal compartment in response to 
ligand stimulation. 
 A) HEK-B6 cells were pre-treated with 100 nM of a lysosome inhibitor, chloroquine (CQ), for 2 
h and stimulated with eB2 for the indicated time periods. Receptor degradation was analyzed and 
presented as in (Fig. 4.2 A). B) HEK-B4-M cells were treated as in (A), and EphB4 degradation 
was monitored as in (Fig. 4.2 A). C) HEK-B6 cells were pre-treated with 25 mM of NH4Cl for 1 
h and stimulated with eB2. EphB6 degradation was monitored and presented as in (Fig. 4.2 A). 
D) HEK-B4-M cells were treated as in (C) and EphB4 degradation assessed as in (Fig. 4.2 A). 
All Western blot images in this figure represent one of at least three independent experiments. 
Each graph summarises the analysis of at least three independent experiments, bars, SD. *, P < 
0.05, Student's t test, for indicated points and corresponding controls, as shown. In all 
downregulation experiments, unstimulated cells were treated with hIgG as a specificity control. 
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Figure 4.16. Rab5 is required for trafficking of EphB6 and EphB4 for degradation. 
 A) HEK-B6 cells were transfected with an HA-tagged dominant-negative mutant of Rab5, Rab5 
S34N, or mock-transfected with pcDNA3 as a control and stimulated for the indicated time 
periods with eB2. EphB6 downregulation was monitored and assessed as in (Fig. 2 A). 
Expression of the mutant Rab5 was confirmed by Western blotting with anti-HA. B) HEK-B4-M 
cells were transfected and treated as in (A), and EphB4 degradation was assessed as in (Fig. 2 
A). All Western blot panels in this figure represent one of at least three independent experiments. 
Each graph summarises the analysis of at least three independent experiments, bars, SD. *, P < 
0.05, Student's t test, for indicated points and corresponding controls, as shown. In all 
downregulation experiments, unstimulated cells were treated with hIgG as a specificity control. 
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4.5. EphB6 stability is Supported by the Stimulation-Sensitive Interaction with Hsp90 
Hsp90 (heat shock protein 90) is a well-documented chaperone responsible for the proper 
folding, stability, and turnover of a wide range of proteins (Saibil, 2013). In addition to its role in 
protein stability, Hsp90 has also been implicated in assisting in the maintenance of proteins at the 
cell surface and in ensuring the availability of receptors for ligand-binding (Sidera et al., 2008; 
Wayne et al., 2011; Xu et al., 2001; Xu et al., 2007). Our co-immunoprecipitation experiments 
showed that EphB6 also interacts with Hsp90, and that this interaction was rapidly disrupted by 
treatment with ephrin-B2. The effect could be readily observed after five minutes of stimulation 
(Fig. 4.17 A). Similar experiments were performed with the EphB4 receptor; however, we were 
unable to consistently detect the EphB4-Hsp90 interaction. To determine the localisation of the 
EphB6-Hsp90 complexes affected by ephrin-B2 stimulation, EphB6-EGFP-expressing HEK-293 
cells were stimulated with ephrin-B2 for 20 minutes and stained with anti-Hsp90. Interestingly, a 
strong colocalisation of EphB6 with Hsp90 was observed at the cell membrane in unstimulated 
cells and this co-localisation was very significantly reduced upon ephrin-B2 treatment. While 
some minimal presence of cytoplasmic complexes was also observed, there was no major change 
in cytoplasmic EphB6-Hsp90 colocalisation in response to ephrin-B2 treatment (Fig. 4.17 B, 
Fig. 4.18). These novel observations suggest that Hsp90 and EphB6 interact mostly at the cell 
membrane and to a lesser degree inside the cell, and that the interaction at the membrane is 
terminated following activation of EphB6 by its ligand.  
To examine if the absence of Hsp90 support was sufficient to initiate EphB6 degradation, we 
treated HEK-B6 cells with the Hsp90 inhibitor, geldanamycin (GA) (Miyata, 2005). This 
treatment triggered EphB6  downregulation at a rate that was similar to the rate of its ephrin-B2- 
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Figure 4.17: Ligand-treatment induces rapid EphB6-Hsp90 dissociation. 
  A) HEK-B6 cells were treated with eB2 for the indicated time periods, and EphB6 was 
immunoprecipitated with anti-EphB6. Precipitates were analyzed for Hsp90 presence by 
Western-blotting with anti-Hsp90. EphB6 immunoprecipitation was confirmed by re-blotting 
with anti-EphB6. B) HEK-293 cells were plated on glass coverslips and transfected with EphB6-
EGFP cDNA. Cells were cultured for 72 h and stimulated with eB2 for 20 min. Stimulated cells 
were fixed in 4% formaldehyde, permeabilized with 0.1% saponin, and stained with anti-Hsp90 
and anti-rat Alexafluor-594 (red) labelled antibodies. Stained cells were visualized with an 
Olympus FV-1000 confocal microscope at 60X magnification. Images were deconvoluted using 
AutoQuant X3. Scale bar, 10 µm. The graph represents quantifications of colocalisation of 
EphB6 with Hsp90 using Pearson’s correlation coefficient. Values were obtained from 3 
independent experiments. ***, P < 2 X 10-6. All Western blot and confocal microscopy images 
represent one of at least three independent experiments. 
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Figure 4.18. EphB6-Hsp90 colocalisation is abolished by ephrin-B2 treatment. 
 A) HEK-293 cells were plated on glass coverslips and transfected with EphB6-EGFP cDNA. 
Cells were cultured for 72 h and stimulated with eB2 for 20 min. Stimulated cells were fixed in 
4% formaldehyde, permeabilized with 0.1% saponin, and stained with anti-Hsp90 and anti-rat 
Alexafluor-594 (red) labelled antibodies. Stained cells were visualized with an Olympus FV-
1000 confocal microscope at 60X magnification. Images were deconvoluted using AutoQuant 
X3. Scale bar, 10 mm. Images represent one of three independent experiments. 
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initiated removal (Fig. 4.19). While GA application on its own resulted in strong EphB6 
degradation, no consistent or statistically significant increase in the efficiency of ligand-induced 
receptor downregulation could be observed in response to simultaneous co-treatment with 
ephrin-B2 and GA (Fig. 4.20 A&B). This lack of a significant enhancing effect indicates that 
stimulation-induced EphB6 downregulation and GA-initiated degradation may rely on an 
overlapping molecular mechanism. Overall, these observations suggest an entirely new model, 
where the rapid disruption of the EphB6-Hsp90 complex in response to ligand treatment may 
represent a key event in the initiation of EphB6 stimulation-induced downregulation. 
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Figure 4.19. Treatment with an Hsp90 inhibitor induces EphB6 downregulation.  
HEK-B6 cells were treated with 10 µg/ml of Hsp90 inhibitor, geldanamycin (GA) or the 
matching volume of solvent control (S.C.) for the indicated time periods. EphB6 levels were 
monitored by Western blotting with anti-EphB6. Results of Western blot quantification in GA-
treated cells were normalized on Erk2 levels and presented in a graph as a percentage relative to 
matching solvent controls. All Western blot images represent one of at least three independent 
experiments.The graph in this figure summarises the analysis of three independent experiments, 
bars, SD. *, P < 0.05, Student's t test, between stimulated and control treated cells for the 
indicated time points.  
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Figure 4.20. Hsp90 inhibition and ligand treatment induce EphB6 downregulation through 
overlapping pathways. 
HEK-B6 cells were treated with eB2 in the presence of the solvent control, or eB2 with GA, or 
with the solvent control alone, for the indicated time periods, and EphB6 levels were monitored 
by Western blotting. EphB6 levels in eB2-stimulated cells were normalized as in (Fig. 4.19). 
Numbers representing this normalization are shown below Western blot images. Each graph in 
this figure summarises the analysis of three independent experiments, bars, SD. *, P < 0.05, 
Student's t test, between stimulated and control treated cells for the indicated time points. No 
statistically significant difference was observed between the rates of EphB6 downregulation in 
eB2 treated cells or GA treated cells, and cells co-treated with eB2 and GA at any time point 
measured. In all experiments involving eB2 stimulation, unstimulated cells were treated with 
hIgG as a specificity control. All Western blot and confocal microscopy images represent one of 
at least three independent experiments. 
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Chapter 5 
DISCUSSION AND CONCLUSIONS 
Stimulation-induced receptor downregulation through internalisation and subsequent 
targeted degradation play an important role in controlling cellular responses by both 
enhancing and suppressing cytoplasmic signalling (Platta and Stenmark, 2011). While 
these processes are well described for the EGFR receptor (Sorkin and Goh, 2009), much 
less is understood about downregulation of Eph receptors.  Available data are not 
systematic and imply that different Ephs may use very distinct mechanisms. For example, 
ligand-induced downregulation of the EphA2 receptor relies on its degradation in the 
lysosomal compartment (Boissier et al., 2013), while in contrast, stimulation-initiated 
EphA3 elimination is mediated by proteasomal complexes (Sharfe et al., 2003) .  Both 
EphA8 (Yoo et al., 2010) and EphB1 (Parker et al., 2004) are endocytosed through CCPs 
following ligand stimulation, and internalised EphB1 is degraded in the lysosomal 
compartment inside the cell (Fasen et al., 2008). Unlike these examples, EphB2 
proteolysis in response to ligand stimulation is performed by the γ-secretase complex and 
is triggered by the initial ligand-induced cleavage of EphB2 by metalloproteases at the 
cell membrane (Litterst et al., 2007). In this situation, it is not a surprise that despite the 
recent accumulation of data that highlight an important role for one of Eph receptors, 
EphB6, in both normal physiology and in malignancy (Fox and Kandpal, 2009; Freywald 
et al., 2003; Luo et al., 2012; Luo et al., 2004; Maddigan et al., 2011; Tang et al., 2000; 
Truitt and Freywald, 2011; Truitt et al., 2010; Yu et al., 2010), the molecular mechanism 
of its downregulation has never been investigated. Such an investigation appears 
especially attractive in light of an unusual nature of this protein, which is kinase-inactive, 
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despite its association with the Eph group of RTKs (Matsuoka et al., 1997).  Until now, 
downregulation of only one other kinase-deficient RTK, the ErbB3 receptor, has been 
dissected and yet, even this remains not well understood, as multiple reports suggest that 
ErbB3 is internalisation- and downregulation- deficient, while some recent observations 
show that ErbB3 undergoes ubiquitination and is efficiently downregulated in response to 
ligand stimulation (Baulida et al., 1996; Cao et al., 2007; Chen et al., 1996; Daly et al., 
1997; Sak et al., 2013; Waterman et al., 1998).  
The work presented within this thesis, attempts to systematically analyse the 
mechanism of ligand-induced downregulation of the kinase-dead EphB6 receptor, while 
comparing it with the downregulation of its kinase-active relative and signaling partner, 
EphB4 (Truitt et al., 2010), which also has not been fully assessed.   It shows that 
similarly to the EphB4 receptor, EphB6 is actively downregulated in response to ligand 
stimulation and does not suppress EphB4 downregulation. Furthermore, despite the lack 
of intrinsic kinase ability, EphB6 removal occurs at a rate that closely resembles what is 
observed for EphB4. Likewise, following treatment with their common ligand, ephrin-
B2, both receptors are internalised through clathrin-coated pits and both are eventually, 
targeted towards their degradation in the lysosomal compartment in a Rab5-dependent 
manner. Efficient receptor internalisation requires separation of the endocytic vesicles 
from the cell membrane into the cytoplasm and the dynamin GTPase is often responsible 
for this process (Ferguson and De Camilli, 2012). Matching our other observations, 
ligand-induced downregulation of both EphB6 and EphB4 proved to require dynamin 
activity. 
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Perhaps the most intriguing finding of these studies is the apparent role of Hsp90 in 
EphB6 downregulation. In the absence of stimulation, EphB6 consistently interacts with 
the Hsp90 chaperone that is known to bind to and stabilize few other RTKs, including 
EGFR and ErbB2 (Ahsan et al., 2012; Xu et al., 2001). According to our confocal 
microscopy data, Hsp90 stabilizes the EphB6 receptor predominantly at the cell surface, 
as the EphB6-Hsp90 interaction is compartmentalized mostly in this area. These 
observations are similar to what has been described for the ErbB2 receptor, as Hsp90 has 
also been shown to associate with this protein and to protect it from degradation 
(Chavany et al., 1996). Intriguingly, the membrane-associated EphB6-Hsp90 complex is 
rapidly disrupted following ligand application and this response precedes EphB6 
degradation, implying that EphB6 downregulation could be triggered by modifications 
caused by ligand-induced Hsp90 dissociation. This possibility is strongly supported by 
our data, showing that inhibition of Hsp90 activity results in EphB6 elimination at a rate 
that closely resembles the rate of its ephrin-B2-triggered downregulation. Moreover, 
Hsp90 inhibition does not produce any consistent significant increase in ligand-induced 
EphB6 removal, suggesting that in both cases, receptor downregulation may be executed 
by the same molecular mechanism that is most likely initiated by the lack of Hsp90 
activity. This is in contrast to EGFR behaviour, which has been reported to be 
downregulated much more efficiently when simultaneously treated with its ligand, EGF, 
and GA in comparison to each individual treatment alone (Pedersen et al., 2009). 
This mode of action has not been reported previously in relation to ligand-induced 
receptor degradation, and it remains to be seen if it represents a frequent approach to 
downregulation of Eph receptors or RTKs in general, or if it is EphB6-specific. 
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Interestingly, the Eph group contains one more kinase-deficient member, the EphA10 
receptor (Aasheim et al., 2005b). Its functional properties are still enigmatic and it would 
be curious to see if its downregulation is also governed by Hsp90.  
At this stage, Hsp90 inhibitors are being tested in clinical trials for treating ErbB2-
overexpressing breast cancer (Garcia-Carbonero et al., 2013). As previous observations 
indicate that the EphB6 receptor acts to suppress breast cancer aggressiveness (Fox and 
Kandpal, 2009; Truitt et al., 2010), our current data, showing that Hsp90 inhibition 
reduces EphB6 presence, suggest that this approach should be applied with caution to 
EphB6-expressing breast cancer tumours.  
Overall, our work provides the first description of the route of ligand-induced 
downregulation of an intrinsically kinase-deficient member of the Eph group of RTKs, 
EphB6, and shows that EphB6 is removed in a manner that is very similar to the mode of 
downregulation of its kinase-active relative, the EphB4 receptor. Perhaps more 
importantly, our observations present the first example of Eph receptor interaction with 
the Hsp90 chaperone and reveal that stimulation-dependent EphB6 degradation is 
preceded by the disruption of its association with Hsp90, which likely acts as 
downregulation trigger (Figure 5.1). To our knowledge, this model has not been 
previously discussed and this mechanism may potentially represent a frequently used 
stage in ligand-induced RTK downregulation, shared by multiple family members on 
their way to lysosomal degradation. 
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Figure 5.1. Proposed pathway of EphB6 ligand-induced downregulation.  
Prior to ligand binding, EphB6 is associated with Hsp90 at the cell membrane. Ligand-
binding initiates EphB6 receptor clustering and Hsp90 dissociation. EphB6 is recruited 
into CCPs and endosomal vesicle formation is finalized by pinching off at the cell 
membrane by dynamin. Internalised EphB6 receptors are trafficked within Rab5-positive 
early endosomes, and are eventually targeted to the lysosomal compartment for 
degradation. 
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Chapter 6 
FUTURE WORK 
6.1 Receptor recycling 
Following internalization many receptors undergo recycling back to the cell surface as 
opposed to degradation. For example, EGFR, Met, and PDGFR have all been observed to 
undergo recycling following ligand-induced internalization (Hellberg et al., 2009; Parachoniak et 
al., 2011; Sigismund et al., 2008; Sigismund et al., 2005). It is likely that some internalized 
EphB6 molecules also undergo recycling, and this may play a role in the signalling output 
generated in response to activation. To determine if EphB6 undergoes recycling, cells can be 
simultaneously treated with ligand and labeled with anti-EphB6 at 37oC, and the receptor 
allowed to internalize, or at 4oC to prevent internalization as a control. An acidic wash at 4oC can 
then be used to remove the antibody from remaining cell surface EphB6, and cells returned to 
normal growth conditions to allow any internalized receptor to recycle back to the surface. 
Fixation and staining with a fluorescently tagged secondary antibody targeting the EphB6 
antibody and analysis by flow cytometry or confocal microscopy will then allow for the 
identification of recycled receptors (Fraile-Ramos et al., 2001; Mitchell et al., 2004).  
Alternatively, cell surface proteins, including EphB6, can be biotinylated, and cells subsequently 
treated with ephrin-B2 and receptors allowed to internalize. Remaining cell surface biotin can be 
stripped from the cell in reducing conditions at 4oC, the cells returned to 37oC to allow recycling, 
and a second round of biotin stripping performed. Biotinylated proteins can then be recovered 
using avadin beads. A comparison, through Western blot analysis, of the of the amount of 
biotinylated EphB6 found in cells that have undergone a second round of stripping following the 
recycling period, to those that have not, will give a general ratio of the amount of receptor that is 
being recycled (Hammond et al., 2003; Parachoniak et al., 2011). If EphB6 does undergo 
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recycling, fewer biotinylated EphB6 should be recovered and observed by Western blot analysis 
when cells undergo a second round of stripping.  
Should it become apparent that EphB6 does indeed undergo recycling, the effects of this 
trafficking on EphB6 removal from the cell surface and downregulation could be assessed 
through the use of inhibitors of the recycling pathway, such as monensin, as well mutants of Rab 
GTPases involved in receptor recycling, such as Rab4 and Rab11. Recycling of EphB6 back to 
the cell surface should be greatly decreased upon use of recycling inhibitors, or the expression of 
the Rab mutants. It is possible that EphB6 that fails to recycle will remain in the early endosome, 
as has been observed for FGFR4 (Haugsten et al., 2014), or alternatively, EphB6 that is 
prevented from recycling may be rapidly targeted for degradation, in which case a significant 
increase in the observed rate of ligand-induced downregulation would be observed. To 
distinguish between these possibilities, EphB6 subcellular localization can be examined by the 
use of EGFP-EphB6 in conjunction with early endosome specific antibodies, such as anti-EEA1, 
as well as markers for later compartments, such as LysoTracker, and through Western blotting to 
examine total protein levels of the receptor, to clarify how EphB6 is trafficked when recycling is 
inhibited.  
There are two distinct pathways of receptor recycling currently described, rapid recycling 
which takes place from the early endosome and is mediated largely by Rab4, as well as a slower-
rate recycling which is observed from late endosomes/MVBs that relies on Rab11 (Grant and 
Donaldson, 2009; Sheff et al., 1999). The use of shRNAs specific to Rab4 or Rab11, and 
monitoring receptor recycling through the assay described above, as well as the analysis of 
receptor localization/degradation following Rab4 or Rab11 silencing will give a strong indication 
of which recycling pathway EphB6 predominantly utilizes. Additionally, stimulation and fixation 
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of EGFP-EphB6 expressing cells, and staining with antibodies for Rab4 or Rab11, and analysis 
by confocal microscopy would allow for the visualization of EphB6 colocalisation with specific 
recycling pathways. 
For PDGFR-β, PKC has been observed to be important to mediating receptor recycling 
through the Rab4 recycling pathway, as PKC activation is able to significantly increase PDGFR-
β recycling, and knock-down of PKC inhibits recycling and promotes degradation of this 
receptor (Hellberg et al., 2009). The involvement of PKC in EphB6 recycling could be examined 
through the use of shRNA to knock-down PKC expression, and the subsequent analysis of 
receptor recycling in response to ligand-stimulation using the recycling assay described above. 
Should PKC be important to mediating EphB6 recycling, its knock-down should result in a 
decrease in its cell surface levels. Furthermore, as receptor recycling can impact the level of 
observed downregulation/degradation, an examination of the overall rate and degree of EphB6 
downregulation in response to ligand treatment in PKC-deficient cells would give further insight 
into the importance of PKC in mediating the balance between EphB6 recycling/degradation in 
response to ligand treatment.  Here, Western blot analysis would be sufficient to determine total 
EphB6 protein levels following ligand-treatment, and should PKC be important to mediating 
EphB6 recycling, its knock down should result in an increase in the observed rate, and 
potentially the level, of EphB6 receptor degradation.  
Met receptor recycling was shown to require the activity of GGA3 (Golgi-localized 
gamma-ear containing Arf-binding protein 3). It was found that GGA3 rapidly associates with 
Met following ligand stimulation, and promotes its localization to Rab4 positive endosomes. 
Moreover, knock-down of GGA3 resulted in a significant loss of receptor recycling and reduced 
surface levels (Parachoniak et al., 2011). Examination of EphB6 interaction with GGA3 through 
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co-immunoprecipitation and Western blot analysis, with and without ligand stimulation, would 
give some indication if GGA3 is also involved in EphB6 recycling. Staining of ligand treated 
EGFP-EphB6 expressing cells for GGA3 and analysis by confocal microscopy would further 
allow for the determination of whether or not EphB6 also associates with GGA3 following 
ligand-treatment, and give some indication where this association takes place. The use of shRNA 
for GGA3 would allow for the analysis of the impact of knock-down GGA3 on EphB6 
trafficking, which could be assessed using experimental approaches relying on receptor 
biotinylation. If GGA3 is indeed involved in EphB6 recycling, its knock-down should cause a 
reduction in EphB6 recycling and potentially an increase in overall levels of EphB6 
downregulation.  
 
6.2 How Hsp90-dissociation induces EphB6 downregulation 
The association of EphB6 with Hsp90 is perhaps one of the most important observations 
acquired through the course of my work. There are numerous reports in recent years suggesting a 
role for Hsp90 in either membrane stability of receptors, receptor activation, or both 
(Mahalingam et al., 2009), however, this is the first report linking Hsp90 behaviour to ligand-
induced downregulation. At this stage it is unclear if these observations are EphB6-specific or 
not, and the potential involvement of Hsp90 dissociation in the downregulation of other Eph 
receptors is an interesting prospect which warrants further investigation. Furthermore, many Eph 
receptors have an unfavourable impact on the prognosis for several cancer types (Kandouz, 
2012), so establishing whether or not targeting Hsp90 would also effectively induce their 
downregulation could lead to effective cancer treatments aimed at reducing overall Eph receptor 
levels in tumors. Co-immunoprecipitation of Hsp90 with other Eph receptors could be performed 
to determine if any other members of this RTK family interact with this chaperone. Analysis of 
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observed interactions following ligand stimulation would determine whether receptor activation 
induces Hps90 dissociation, as was observed for EphB6.  The subcellular localisation of Eph-
Hsp90 interaction, examined by confocal microscopy, will determine if it predominantly takes 
places at the cell surface or in intracellular compartments. Should the Eph-Hsp90 colocalisation 
occur at the cell surface, as was observed for EphB6, monitoring receptor downregulation 
following treatment with Hsp90 inhibitors using Western blot analysis will indicate whether or 
not other Eph receptors also utilize Hsp90 dissociation as a key step in their downregulation.  
Our experiments strongly suggest that ephrin-B2 and GA induced downregulation of 
EphB6 both promote receptor downregulation through the same pathway; however, it is not yet 
fully clear how Hsp90 dissociation is initiating this process. Therefore, some investigation into 
the effectors underlying ligand-induced and Hsp90 inhibition-promoted downregulation is 
required. The E3 ligase CHIP (C-terminus of Hsc70 Interacting Protein) and Hsp70 are 
important to mediating ErbB2 downregulation induced through Hsp90 inhibition (Xu et al., 
2002). Here, the induction of Hsp90 dissociation from ErbB2 promotes a concurrent increase in 
ErbB2 association with another molecular chaperone, Hsp70 and CHIP. The formation of the 
CHIP/Hsp70/ErbB2 complex results in CHIP-mediated ubiquitination of the receptor, leading to 
ErbB2 degradation (Xu et al., 2002; Zhou et al., 2003).  Examining the role of CHIP and Hsp70 
in ligand-induced and GA-triggered downregulation of EphB6 would determine if these proteins 
also mediate Hsp90 effects for other RTKs, and clarify how Hsp90 dissociation induces EphB6  
downregulation. As mentioned, following inhibition of Hsp90, Hsp70 forms a complex with 
CHIP and ErbB2, and therefore, Hsp70 presence is likely required for targeting of the receptor 
for degradation, as has been observed for numerous other proteins that undergo CHIP mediated 
ubiquitination (Gao et al., 2010; Luo et al., 2010; Meacham et al., 2001). Co-
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immunoprecipitation experiments examining the association of Hsp70 with EphB6 with, and 
without ligand stimulation, as well as in the presence or absence of GA, would indicate whether 
Hsp70 is also involved in the EphB6 degradation pathway. Should Hsp70 be involved, there will 
be an increase in Hsp70 immuoprecipitation with the receptor following ligand or GA treatment. 
Knock-down of Hsp70 levels by using shRNA would then cause a decrease in ligand- and GA-
induced receptor downregulation, which can be assessed through Western blot analysis. Co-
immunoprecipitation experiments of EphB6 with CHIP, as well as examining the effect of CHIP 
knock-down on EphB6 downregulation would indicate whether or not CHIP is involved in this 
process. In the co-immunoprecipitation experiments, an increase in association with EphB6 
following ligand stimulation or GA treatment should be observed if it is indeed involved in 
EphB6 downregulation, and the knock-down of CHIP expression using shRNA should reduce 
the observed GA- and ephrin-B2-induced EphB6 downregulation. Furthermore, experiments 
monitoring EphB6 ubiquitination following ligand stimulation or GA treatment in cells with 
reduced and unmanipulated levels of CHIP expression would give evidence of whether or not 
CHIP is responsible for EphB6 ubiquitination in these situations. Here, cells with normal or 
reduced CHIP expression should be treated with ligand or GA, EphB6 immunoprecipitated, and 
analysed for ubiquitination by Western blotting. Should CHIP ubiquitinate EphB6, there should 
be a reduction in observed ubiquitination of the receptor following either ligand or GA treatment 
in cells with CHIP expression knocked down relative to cells with normal CHIP expression.  
 
6.3 Negative impacts of Hsp90 inhibition 
Finally, as indicated in the discussion, several inhibitors of Hsp90 are under active 
investigation for the treatment of ErbB2 positive breast cancers, however, as this treatment 
would concurrently reduce surface EphB6 levels, it could lead to an increase in the metastatic 
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potential of the cells. To clarify this, potential unfavorable aspects of Hsp90 inhibition should be 
analyzed in animal models of EphB6-positive breast cancer. This would involve the injection of 
breast cancer cells with high EphB6 expression into the mammary fat pads of immune-deficient 
mice, and monitoring the number of metastatic lesions that form in the presence or absence of 
treatment with Hsp90 inhibitor. By transfecting the EphB6-positive cancer cells with a 
luciferase-expressing vector, tumor growth and metastasis can be monitored in live mice by 
injecting them with D-luciferin and visualization of the resulting fluorescent areas with a 
bioluminescence imager. Metastases can be confirmed at the end of the experimental period by 
collection of organs and examination for tumor presence. If Hsp90-inhibition induced EphB6 
removal does increase the invasive activities of the cancer cells, a higher number of metastatic 
lesions will be observed in the Hsp90 inhibitor treated mice. Should this prove to be the case, 
Hsp90 inhibition should be used with caution when EphB6 is known to be expressed by the 
tumor.  
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